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ABSTRACT 
           In the pharmaceutical industry, recombinant monoclonal antibodies (mAbs) have become 
a major focus of therapeutic drug development due to their broad applications in many disease 
areas. During manufacturing and storage of mAb drug products, metal-catalyzed carbonylation, a 
post-translational modification referring to the formation of carbonyls (aldehydes and ketones) 
on proteins after metal-catalyzed oxidation, is a relevant product variant of mAbs, which may 
impact mAb safety and/or efficacy. However, to date, very little is known about the occurrence 
of metal-catalyzed carbonylation during mAb manufacturing and storage or the effects of metal-
catalyzed carbonylation on chemical and physical stability of mAbs. To answer those questions, 
this dissertation first focused on developing a new protein carbonylation assay with improved 
assay precision and robustness over the conventional assays. Using the new protein 
carbonylation assay, a study was performed to investigate various cell culture and formulation 
factors, which revealed that iron ion, hydrogen peroxide, and polysorbate 20 can critically impact 
mAb carbonylation during manufacturing or storage. This study also revealed that metal-
catalyzed carbonylation positively correlated with increased acidic charge heterogeneity and 
aggregation propensity of mAbs. To elucidate the increased acidic charge heterogeneity, the 
acidic fraction of a model IgG1 mAb after metal-catalyzed oxidation was collected and 
characterized, which showed that metal-catalyzed carbonylation products (primarily threonine 
carbonylation products) directly contributed to the increased acidic charge heterogeneity. Several 
additional oxidation products, such as carboxylic acids (from further oxidation of aldehydes) and 
pyroglutamate (from oxidation of proline residues in the hinge region), were identified for the 
first time in mAbs, which provides further explanation to the increased acidic charge 
heterogeneity. To elucidate the increased aggregation propensity, this dissertation used a model 
iv 
stress system and anions from the Hofmeister series to investigate the effects of metal-catalyzed 
carbonylation on physical stability of the model IgG1 mAb. In particular, the investigation 
applied a site-specific carbonylation analysis, which revealed for the first time that mAb 
aggregation can be affected by carbonylation location, carbonylation type, and buffer type. These 
findings showed that effects of metal-catalyzed carbonylation on physical instability of mAbs 
can be much more complex than what have been previously proposed/suggested in the literature. 
Finally, this dissertation investigated formation of Schiff base crosslinks as a potential route of 
chemical instability of the metal-catalyzed carbonylation products. To facilitate the investigation, 
a new analytical methodology was developed to characterize crosslinked peptides. This new 
methodology addressed several key analytical challenges for crosslink analysis and successfully 
identified bissulfosuccinimidyl suberate (BS3)-crosslinked peptides in a BS3-treated mAb 
sample. Using the new analytical methodology, this study showed that Schiff base formation is a 
not major degradation pathway of mAbs even under a harsh condition by copper-catalyzed 
oxidation. In summary, this dissertation provided a comprehensive understanding of the 
chemical and physical instability of mAbs induced by metal-catalyzed carbonylation, which can 
help improve mAb stability against metal-catalyzed carbonylation in the future.    
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Metal-Catalyzed Antibody Carbonylation  
              Recombinant monoclonal antibodies (mAbs) are an important class of therapeutics for 
the treatment of many diseases.
1-2
 Compared to small molecule drugs, mAbs are much more 
complex due to their heterogeneous nature.
3
 A major source of the mAb heterogeneity are post 
translational modifications (PTMs) introduced to mAbs during manufacturing and/or storage.
4
 
Among the various PTMs, metal-catalyzed oxidation is a highly relevant degradation pathway of 
mAbs since mAbs are in contact with metal or metal ions during the manufacturing or the 
storage processes. For example, during cell culture production, iron ions at concentrations of 0.1-
0.5 mM are used in the cell culture media to increase mAb production titers.
5
 During purification 
or storage, stainless steel is a common surface contact material.
6
 The iron ions present in the cell 
culture media or leached from the stainless steel can cause methionine
7-8
 and histidine oxidation
8
 
in the Fc region. Other than methionine and histidine oxidation, metal-catalyzed protein 
carbonylation, referring to the formation of aldehyde/ketone groups, primarily on Arg, Lys, Pro, 
and Thr,
9-10
 is a major degradation pathway caused by metal-catalyzed oxidation reactions.
9
 
From various studies, the levels of metal-catalyzed carbonylation products were found to be 
several orders of magnitude greater than those of other oxidation products.
11-12
 Metal-catalyzed 
carbonylation is also widely accepted as a biomarker for oxidative stress,
13-14
 because the metal-
catalyzed carbonylation is an irreversible and unrepairable PTM in biological systems. 
Interestingly, in the pharmaceutical industry, the knowledge on metal-catalyzed carbonylation as 
a degradation product of mAbs is limited. In one study, Bee et al. showed that a significant 
amount of protein carbonylation, at approximately 0.8 mole of carbonyl per mole of mAb, but no 
methionine oxidation, was found in the mAbs absorbed to the stainless steel surface,
15
 which 
suggests that metal-catalyzed carbonylation may increase mAb aggregation propensity and thus 
3 
can potentially affect mAb product quality and stability. In another study, Purdie et al. showed 
that cell culture medium composition affected the extent of mAb carbonylation, and also 
reported a positive correlation between mAb carbonylation and mAb aggregation.
16
 However, 
there is a lack of a comprehensive study on various factors that impact mAb carbonylation and 
on how mAb carbonylation impacts the physical and chemical stability of mAbs.   
Analytical Methods for Quantifying Protein Carbonylation  
            Many different carbonylation assays have been developed for studying protein 
carbonylation.
17
 Historically, quantitation of protein carbonyls is usually based on the unique 
characteristics of the hydrazines and the corresponding hydrazones after the derivatization.  For 
example, a widely used spectrophotometric carbonylation assay measures the absorbance of a 
derived sample at 375 nm, where the derivatization reagent, 2,4-dinitrophenylhydrazine (DNPH), 
and the resulting hydrazone, strongly absorb.
18
 A fluorometric carbonylation assay measures the 
fluorescence with excitation at 485 nm and emission at 535 nm of a derived sample after the 
derivatization with fluorescein thiosemicarbazide.
19
 An ELISA carbonylation assay uses anti-
DNPH antibody for quantification after the derivatization of a sample with DNPH.
20
 While 
different hydrazine/hydrazide reagents have been employed for the derivatization and the 
quantitation purposes, a common procedure in these protein carbonylation assays is the removal 
of the unreacted hydrazine/hydrazide after the derivatization step to prevent over-quantification 
of the carbonylation levels.
21
 Typically, the unreacted hydrazine/hydrazide is removed through 
protein precipitation and washing, which is a labor-intensive process and constitutes a major 
source of experimental variability.
21
 In fact, a study by Matthijssens et al. demonstrated that two 
additional washing steps during sample preparation reduced the carbonylation result by 15% 
when using the DNPH spectrophotometric carbonylation assay.
22
 The poor assay precision and  
4 
labor-intensive nature associated with the sample precipitation and washing steps can make it 
difficult to broadly apply these carbonylation assays to measure mAb carbonylation for product 
characterization, development, and quality control. While improved ELISA
23
 and DNPH
24
 
assays have been recently reported, to the best of our knowledge, there has not been a study that 
comprehensively addresses various assay performance issues inherent to protein carbonylation 
measurement, particularly issues related to assay robustness. 
Factors Influencing the Extent and Specificity of Protein Carbonylation  
                Based on the mechanism proposed by Stadtman for metal-catalyzed carbonylation,
9
 
protein carbonylation involves a site-specific Fenton-like reaction, where the hydroxyl radical 
attacks the side chain of the residue adjacent to a metal binding site to form the carbonyl group. 
Presumably, metal ions, oxidants (such as hydrogen peroxide), and protein 
structure/conformation may all affect the extent and specificity of carbonylation. However, from 
the protein formulation perspective, how various formulation factors, such as buffer species, 
formulation excipients, and surfactants, affect protein carbonylation is still not well understood. 
In a study by Arai et al., the effects of bicarbonate and phosphate buffers on metal-catalyzed 
oxidation of low-density lipoprotein (LDL) were studied
25
. Under the same stress condition, a 
greater extent of protein carbonylation of LDL was observed in the bicarbonate buffer than in the 
phosphate buffer, for which the authors suggested that a complex interaction between 
bicarbonate and iron ions may be responsible and that intermediary formation of a carbonate 
radical may result in much more selective oxidation reactions. In recent studies by Rao et al.
23, 26
, 
several narrowly specified stress conditions were tested for their effects on the extent of protein 
carbonylation of β-glucosidase, rabbit IgG, and transferrin. These experiments suggest that the 
extent of carbonylation is Fe
2+
 concentration dependent; however, the effects of other factors, 
5 
such as the protein type and the addition of mannitol, were found to vary from case to case.
23
 
Clearly, more studies are needed to understand how the various factors affect the extent and 
specificity of carbonylation of mAbs, particularly under the relevant manufacturing and storage 
conditions, which can help us develop better manufacturing processes and stable protein 
formulations against oxidative carbonylation.  
              For the site specificity of oxidative carbonylation, our previous work showed that the 
common carbonylation sites on three different mAbs were solvent-exposed.
27
 However, not all 
solvent-exposed lysine, arginine, proline, and threonine residues are prone to oxidative 
carbonylation. Apparently, the occurrence and distribution of oxidative carbonylation sites on 
proteins are not random. One observation is that the protein carbonylation sites tend to “cluster 
together”.
28
 This observation suggests an autoxidation type of mechanism, i.e. self-propagation 
of carbonylation sites.
28
 Another theory suggested that protein sequence regions that are enriched 
with Arg, Lys, Pro, and Thr residues are oxidative carbonylation hot spots.
29
 However, it is 
unclear if we can use these empirical observations to predict carbonylation hot spots on mAbs. In 
this work, we will identify carbonylation hot spots on mAbs by characterizing highly 
carbonylated mAb samples, and understand if there are any sequence motifs that dictate site-
specific antibody carbonylation.  
Effects of Metal-Catalyzed Carbonylation on Protein Stability 
              As the result of the oxidative carbonylation, the positive charge on lysine and arginine 
side chains and the steric constrains from proline residues are lost. Those changes could lead to 
increased protein aggregation propensity. Based on molecular dynamics simulation results, 
Petrov and Zagrovic proposed that the carbonylation of lysine and arginine residues are 
equivalent to introducing charge-neutral and hydrophobic mutations.
30
 However, this theoretical 
6 
model does not provide a comprehensive picture of how various carbonylation species impact 
the physical stability of mAbs. For example, it is not known if lysine and arginine carbonylation 
products play a more dominant role than proline and threonine carbonylation products in driving 
the formation of aggregates. To elucidate the detailed effects and mechanisms at the site-specific 
level, we will apply stress conditions to carbonylated mAbs and characterize the induced 
aggregation/precipitation to investigate if certain carbonylation species are preferentially 
enriched in the aggregates.  
             From the chemical stability perspective, the aldehyde products (amino-adipic 
semialdehyde and glutamic semialdehyde) from the carbonylation of lysine, arginine, and proline 
residues may undergo further reactions. One of the reactions is the oxidation of the aldehydes to 
the respective carboxylic acids (2-aminoadipic acid and glutamic acid), which leads to a 
decreased isoelectric point of proteins. This mechanism has been hypothesized by Stadtman to 
explain the formation of more acidic forms, observed on the isoelectric focusing gel images of E. 
Coli. glutamine synthetase after metal-catalyzed oxidation.
9, 31
 However, to the best of our 
knowledge, to date, no report has directly investigated these potential carboxylic acid species to 
understand the acidic charge variants induced by metal-catalyzed oxidation. Therefore, it will be 
interesting to investigate if these carboxylic acid products constitute a significant degradation 
pathway for the induced acidic charge variants on mAbs. Another reaction is the formation of a 
Schiff base between an aldehydes and a primary amine, which generates intra- or inter-peptide 
crosslinks, which could contribute to the formation of aggregates.
32
 For mAbs, formation of 
these potential crosslink products has not been well studied, particularly after metal-catalyzed 
oxidation.  
Significance 
7 
              In the pharmaceutical industry, metal-catalyzed carbonylation represents a relatively 
new product variant of mAbs. Recently, this product variant is gaining more interest from both 
the pharmaceutical industry and the FDA, since metal-catalyzed carbonylation may pose safety, 
immunogenicity, or efficacy concerns about protein therapeutics. For example, using transgenic 
mouse models, Filipe et al. showed that mAbs stressed with metal-catalyzed oxidation were 
more immunogenic than mAbs stressed with other conditions.
33
 This finding suggests that 
carbonylation, a major degradation product of metal-catalyzed oxidation, may critically impact 
the immunogenicity of mAbs. However, to date, very little is known about the mechanisms for 
the occurrence of metal-catalyzed carbonylation or the effect of this type of PTM on therapeutic 
mAb products. This thesis seeks to establish analytical methods to characterize carbonylation 
and related degradation products on mAbs and to obtain in-depth understandings of how various 
factors during mAb manufacturing and storage may impact mAb carbonylation. This knowledge 
will be valuable for the industry to develop manufacturing processes or formulations to control 
mAb carbonylation. In addition, this thesis seeks to elucidate the impact of oxidative 
carbonylation on the physical and chemical stability of mAbs, which will be useful for designing 
mAbs with improved stability against metal-catalyzed carbonylation in the future.     
Specific Aim 1: to develop an improved analytical method for quantifying protein 
carbonylation (Chapter 2).  
         The existing assays for quantifying protein carbonylation suffer from rather crude 
performance issues,
21
 which have been attributed to protein precipitation and washing used in the 
sample preparation procedures. Given that the performance issues with current assays may 
hinder progress on our study of mAb carbonylation, this work developed an improved analytical 
method to address the analytical challenges/drawbacks with the conventional protein 
8 
carbonylation assays. This work first focused on identifying a new reagent for the derivatization 
and quantitation of protein carbonyls that does not require protein precipitation or washing. This 
work then developed the derivatization and sample preparation conditions to achieve optimal 
assay performance. Finally, an extensive set of experiments to evaluate the performance of the 
new method was performed, which showed that the new protein carbonylation assay has 
excellent assay precision, linearity, reproducibility, and robustness for quantifying total protein 
carbonylation of mAbs. These assessments demonstrated that the new assay represents a 
significant improvement over the commonly used assays.  
Specific Aim 2: to understand bioprocessing and formulation factors that critically impact 
mAb carbonylation during manufacturing and storage (Chapter 2). 
          From the mAb bioprocessing prospective, the level of iron ions in cell culture media may 
play a critical role in generating mAb carbonylation. This study will perform cell culture 
experiments with various levels of iron ions to understand the effect of iron on mAb 
carbonylation during cell culture production. From the formulation perspective, this study will 
investigate how the presence of iron ions and polysorbate 20 in the formulations impact mAb 
carbonylation under long term storage, which can help identify critical formulation factors for 
mAb carbonylation and the related mAb instability during storage. Additionally, this study will 
evaluate relative effects of iron (II) and hydrogen peroxide on mAb carbonylation to explain the 
findings from the cell culture and the storage experiments. Finally, this study will investigate the 
relationship between carbonylation and mAb product quality, such as size and charge 
heterogeneity, from all the experiments, to gain an initial understanding of the effects of mAb 
carbonylation on physical and chemical instability of mAbs.    
9 
Specific Aim 3: to elucidate the effect of oxidative carbonylation on acidic charge 
heterogeneity of mAbs after metal-catalyzed oxidation (Chapter 3).  
          The findings from Chapter 2 revealed a positive correlation between metal-catalyzed 
carbonylation and formation of acidic charge heterogeneity in mAbs. This chapter describes a 
study on the mechanism and the related degradation products to explain the observed correlation 
between mAb carbonylation and the induced acidic charge variants after metal-catalyzed 
oxidation. This study will induce the formation of acidic charge variants on a model IgG1 mAb 
by iron (II) and hydrogen peroxide, and then fraction collect the acidic and the main peak regions 
from an ion exchange chromatography column. Subsequently, an extended characterization of 
mAb carbonylation products will be performed to address the following questions: 1) are 
carbonylation products enriched in the acidic fraction? 2) what types of carbonylation products 
are enriched in the acidic region? 3) is there any further oxidation of aldehydes (to carboxylic 
acid), and if so, are these products a major component in the acidic fraction? 4) does mAb 
conformation play a critical factor in the induced acidic charge variants? To facilitate these 
investigations, the study will also optimize the site-specific carbonylation analysis method for 
relative quantitation of site-specific carbonylation products by LC-MS/MS analysis.     
Specific Aim 4: to elucidate the effect of oxidative carbonylation on physical stability of 
mAbs (Chapter 4).  
          The findings from Chapter 2 suggested that metal-catalyzed carbonylation may contribute 
to mAb aggregation. To elucidate the effect of oxidative carbonylation on physical stability of 
mAbs, this chapter will compare the aggregation/precipitation of oxidized and unstressed mAb 
samples under a commonly used stir stress condition.
8, 34
 This comparison will help differentiate 
the effects of oxidation products (including oxidative carbonylation) from those of intrinsic mAb 
10 
aggregation factors. This chapter will then describe an investigation aimed at determining if there 
is any preferential enrichment of carbonylation products in the aggregates or in the supernatants. 
In particular, from a site-specific perspective, it will be interesting to understand if carbonylation 
type or location plays a role in the aggregation/precipitation of the tested mAb samples, and if 
there are any carbonylation hotspots that drive mAb aggregation/precipitation. In addition, the 
chapter will probe the effect of oxidative carbonylation on the physical stability of mAbs by 
studying the aggregation/precipitation behaviors in buffers that contains various Hofmeister 
anions. This will aid in determining if the effect of oxidative carbonylation may be influenced by 
specific interactions with the anions. The knowledge gained from these studies will be useful for 
designing mAbs with improved stability against metal-catalyzed carbonylation in the future.     
Specific Aim 5: to develop a new analytical method to investigate formation of Schiff base 
and other crosslinks in mAbs after metal-catalyzed carbonylation (Chapter 5).  
             Formation of Schiff base crosslinks between aldehydes (as generated from carbonylation 
of Arg, Lys, and Pro residues) and primary amines (such as N-terminus and lysine side chain) 
could represent a mechanism for the increase of acidic charge variants and aggregates in mAbs 
after metal-catalyzed oxidation. To investigate this potential mechanism for the induced 
chemical and physical instability of mAbs after metal-catalyzed oxidation, this chapter describes 
the development of a new analytical method using Strong cation exchange Enrichment and 
Enzymatic MS
2
 (SEEMS
2
) to enrich and identify crosslinked peptides. The main goal for 
developing this new method is to reduce the difficulty and complexity with crosslink analysis. 
Specifically, crosslinked peptides are often in low abundance;
35
 and the MS
2
 spectra of 
crosslinked peptides are often very complex to interpret.
36
 To demonstrate the feasibility of the 
new method, this work will include characterization of crosslinked peptides in a BS3-crosslinked 
11 
model mAb sample. Subsequently, this method will be applied to investigate mAb crosslinks 
after copper-catalyzed oxidation. The rationale for selecting copper-catalyzed oxidation instead 
of iron-catalyzed oxidation is threefold. First, copper-catalyzed oxidation is more effective than 
iron-catalyzed oxidation in generating carbonylation on mAbs and other proteins.
26, 37
 Potential 
Schiff base crosslink products are, therefore, expected to be more abundant in mAbs after 
copper-catalyzed oxidation than after iron-catalyzed oxidation, which would be beneficial to the 
investigation. Second, copper-catalyzed oxidation was found to be more effective than iron-
catalyzed oxidation in generating dityrosine crosslinks in lens proteins.
38
 It will be interesting to 
understand if any dityrosine crosslink products in mAbs can be identified after copper-catalyzed 
oxidation. Third, after stressed by copper-catalyzed oxidation, mAbs were found to induce 
immunogenicity in transgenic mice.
33
 It will be interesting to identify oxidation-induced mAb 
crosslink products, which may help elucidate the observed immunogenicity. By applying the 
SEEMS
2
 method to investigate potential crosslink products in a model mAb after copper-
catalyzed oxidation, this study seeks to determine if formation of Schiff base crosslinks is a 
major degradation pathway related to oxidative carbonylation, and if the Schiff base crosslinks 
are a major factor for the chemical and physical instability of mAbs induced after metal-
catalyzed oxidation. Additionally, this study seeks to identify other types of crosslinks, such as 
di-tyrosine crosslinks, which can help better understand the nature of chemical and physical 
instability of mAbs induced after metal-catalyzed oxidation.         
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Chapter 2 
Investigation of Metal-Catalyzed Antibody Carbonylation with an Improved 
Protein Carbonylation Assay 
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INTRODUCTION     
           As previously reviewed in Chapter 1, metal-catalyzed protein carbonylation results in the 
formation of carbonyl species from lysine, arginine, proline, and threonine residues
1
 (Figure 1). 
These carbonylation products could potentially have detrimental effects on mAb product quality. 
Therefore, it is important to understand how the metal-catalyzed carbonylation occurs during 
mAb production and storage. However, the current understanding of mAb carbonylation during 
bioprocess development (e.g., cell culture production) and pharmaceutical development (e.g., 
formulation and storage) is very limited. From the bioprocess development perspective, Purdie et 
al. showed that lowering the content of cysteine and ferric ammonium citrate in cell culture 
media reduced the extent of mAb carbonylation.
2
 However, their study reported only relative 
levels of mAb carbonylation. From the pharmaceutical development perspective, Uehara and 
Rao showed that iron content, buffer type, and storage temperature affected the extent of 
carbonylation of rabbit IgG and other proteins.
3
 Nevertheless, the underlying mechanisms for the 
interaction between iron ions and various formulation excipients to induce mAb carbonylation, 
and the physicochemical consequence of mAb carbonylation during storage remain poorly 
understood.   
            An analytical challenge for investigating mAb carbonylation is that conventional protein 
carbonylation assays have various assay performance issues. For example, the coefficient of 
variation (CV) of the commonly used 2,4-dinitrophenylhydrazine (DNPH) spectrophotometric 
assay exceeded 20%.
4
 The large CV was attributed to the inconsistent removal of excess 
derivatization reagent, DNPH, during the protein precipitation and washing steps.
5-6
 Another 
commonly used assay quantifies the carbonyl content by enzyme-linked immunosorbent assay 
(ELISA) with anti-dinitrophenylhydrazone (DNP) antibodies.
7
 One limitation of the ELISA-
19 
based carbonylation assay is that the assay requires a standard with a known protein 
carbonylation level. Given that it is difficult to know how accurate the predetermined 
carbonylation level was for the assay standard, significant assay error can be introduced, 
particularly when different assay standards are used by different laboratories.
5
  
            To overcome the assay performance issues with the commonly used carbonylation 
assays, we developed a protein Carbonylation Assay using Lucifer Yellow carbohydrazide 
(CALY) as the derivatization reagent. Like DNPH, Lucifer Yellow carbohydrazide (LY CH)
8
 
contains a hydrazide group, which reacts selectively with aldehydes and ketones on proteins.
9
 
Unlike DNPH, LY CH has significantly higher solubility in water,
10
 which supports a simpler 
sample preparation without protein precipitation. To demonstrate the suitability of CALY for use 
in mAb bioprocess and pharmaceutical development, we evaluated the robustness, linearity, 
precision, accuracy, detection and quantitation limits of the assay.  
           After demonstrating suitable assay performance, we applied CALY to investigate mAb 
carbonylation under pharmaceutically relevant production, storage, and stress conditions. In the 
cell culture production study, we investigated the effect of iron concentration in a chemically-
defined background. In the storage study, we investigated the effects of polysorbate 20 and iron 
during long-term storage. In the stress study, we investigated the effect of iron and hydrogen 
peroxide, key factors identified to control protein carbonylation.
1
 These studies highlighted 
bioprocess and pharmaceutical conditions during production and storage that could increase 
mAb carbonylation. Finally, we also investigated the relationship between carbonylation and size 
or charge heterogeneity of mAbs. These investigations led to novel insights into the impact of 
metal-catalyzed carbonylation on mAb product quality.  
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Figure 1. Oxidative carbonylation products of arginine (Arg), threonine (Thr), proline (Pro), 
and lysine (Lys). 
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MATERIALS AND METHODS 
Materials 
          All mAbs are IgG1 and were manufactured by Genentech: mAb A was used for CALY 
development, the storage study, and the stress study; mAb B was used for the production study; 
mAbs C and D were used for additional stress studies. Lucifer Yellow carbohydrazide dilithium 
salt (Lucifer Yellow CH or LY CH), ferrous sulfate (FeSO4), hydrogen peroxide solution (30% 
in H2O, w/w), methionine, ethylenediaminetetraacetic acid (EDTA), sodium succinate, succinic 
acid, sodium phosphate (dibasic and monobasic), sodium chloride, sodium acetate, acetic acid, 
sodium hydroxide solution (1M in H2O), 2-(N-morpholino)ethanesulfonic acid (MES), lithium 
hydroxide, reduced Triton X-100, and Polysorbate 20 (PS20) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Amicon Ultra-15 30 kDa filter units were purchased from EMD 
Millipore (Billerica, MA, USA). The TSK G3000 SWXL (7.8x300mm) size exclusion column 
was purchased from Tosoh Bioscience (King of Prussia, PA, USA). The ProPac WCX 10 
column was purchased from Dionex (Sunnyvale, CA, USA). The OxiSelect
TM 
protein carbonyl 
assay kit was purchased from Cell Biolabs (San Diego, CA, USA). Carboxypeptidase B (CpB) 
was purchased from Roche Diagnostics (Mannheim, Germany). 
Preparation of mAb Samples for the Development of CALY   
           For the development of CALY, two batches of a highly oxidized mAb A (batch 1 and 
batch 2) were prepared using the condition described previously.
11
 Briefly, mAb A was mixed 
with ferrous sulfate and hydrogen peroxide to a final concentration of 5 mg/mL, 2 mM, and 10 
mM, respectively, in 50 mM sodium succinate, pH 6.5. The reaction mixture was incubated at 
room temperature for 1.5 hours and the reaction subsequently stopped by adding excess 
methionine and EDTA.  
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Determination of Protein Carbonylation Levels by CALY   
          The workflow of CALY is shown in Figure 2. The mAb samples were derivatized by LY 
CH in 50 mM MES, 0.05% reduced Triton X-100, pH 6.0 (titrated with lithium hydroxide). The 
LY CH-to-mAb molar ratio was 8,000:1, where the final mAb concentration was 0.5 mg/mL. 
The derivatization was carried out at 37°C in the dark for 18 hours. After the derivatization, the 
mAb samples (500 µL) were buffer-exchanged three times into a buffer containing 200 mM 
potassium phosphate, 250 mM potassium chloride, pH 6.2, using Amicon Ultra-15 30 kDa filters 
to remove the excess LY CH (with a dilution factor of ~30 for each round of buffer exchange). 
Subsequently, the LY CH-derivatized mAbs were analyzed by size exclusion chromatography 
(SEC), where 25 µL of the mAb material (approximately 25 µg of protein) was injected onto a 
TSK G3000 SWXL (7.8x300 mm) size exclusion column. The mobile phase was 200 mM 
potassium phosphate, 250 mM potassium chloride, pH 6.2. The column temperature was 
controlled at 25°C and the HPLC autosampler temperature was controlled at 8°C. An isocratic 
flow of 0.5 ml/min was employed. The effluent was monitored by UV absorbance at 280 and 428 
nm. Manual integration of all the peaks from approximately 10 to 22 minutes was performed to 
determine the total peak areas at 280 and 428 nm (A280 and A428) for the LY CH-derivatized 
mAb sample as shown in Figure 3. 
          To quantify carbonylation levels, mAb (not derivatized by LY CH) and LY CH were used 
as the standards. The mAb standard curves were prepared by SEC analysis of 25 µL of a mAb 
standard at various protein concentrations (0.25, 0.5, 1, 2, and 3 mg/mL), as shown in Figures 4-
A and 4-B. The LY CH standard curves were prepared similarly by SEC analysis of 25 µL of LY 
CH at various concentrations (1, 5, 10, 15, and 20 uM), as shown in Figures 4-C and 4-D. 
Carbonylation levels (z/x) were determined by solving the two-variable (x and z) linear 
23 
equations: A280=m1x+b1+m3z+b3 and A428=m2x+b2+m4z+b4, where x is the protein 
concentration (mg/mL) and z is the molar concentration (µM = nmol/mL) of carbonyl groups; 
A280 is the integrated peak area of the LY CH-derived mAb at 280 nm (Figure 3A); A428 is the 
integrated peak area of the LY CH-derived mAb at 428 nm (Figure 3B); m1 to m4 and b1 to b4 
are constants obtained from linear regression fitting of the standard curves (Figure 4).  
       The carbonylation level of a mAb sample was reported in nmol/mg as a ratio of the molar 
concentration of carbonyl groups (z) to the protein concentration (x), and can be determined 
using the following equations (derived by solving the two-variable linear equations):  
    x= [m4*A280- m3*A428- m4*(b1+b3) + m3*(b2+b4)] / (m4*m1-m2*m3) 
    z= [m2*A280- m1*A428- m2*(b1+b3) + m1*(b2+b4)] / (m2*m3-m1*m4) 
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Figure 2. Illustration of the workflow of CALY, which includes derivatization, buffer exchange, 
and size exclusion chromatography analysis.   
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Figure 3. Typical size exclusion chromatograms, with absorbance at 280 nm (A) and 428 nm 
(B), of a derivatized and buffer-exchanged mAb sample. Peak integration is illustrated with the 
dashed lines. 
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Figure 4. Standard curves for the CALY reagents:  mAb and LY CH at 280 nm and 428 nm. A: 
Standard curve 1 (mAb at 280 nm): y1=m1x+b1; B: Standard curve 2 (mAb at 428 nm): 
y2=m2x+b2; C: Standard curve 3 (LY CH at 280 nm): y3=m3z+b3; D: Standard curve 4 (LY 
CH at 428 nm): y4=m4z+b4; x is the mAb protein concentration (mg/mL) and z is the molar 
concentration (µM = nmol/mL) of carbonyl groups. Carbonylation level (z/x) is determined by 
solving the two-variable (x and z) linear equations: A280=m1x+b1+m3z+b3; 
A428=m2x+b2+m4z+b4. 
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Determination of Protein Carbonylation Levels by DNPH Spectrophotometric Assay 
         The carbonylation levels of some mAb samples were quantified by the DNPH assay using 
the OxiSelect
TM
 Protein Carbonyl Spectrophotometric Assay Kit (Cell Biolabs, Inc., San Diego, 
CA). Briefly, 1 mL of DNPH solution (2 mg/mL) was mixed with 250 µL mAb solution (5 
mg/mL). The mixture was incubated at room temperature in the dark for 45 minutes. After the 
derivatization, the mAb samples were precipitated. The pellets were washed 5 times to remove 
the excess DNPH. The mAb samples were subsequently re-solubilized. The carbonyl 
concentration was then determined by measuring the absorbance at 375 nm and using the DNPH 
extinction coefficient (22,000 M
-1
 cm
-1
). The protein concentration was determined by the 
bicinchoninic acid assay (BCA). The protein carbonylation level of a mAb was reported in 
nmol/mg as a ratio of the carbonyl concentration (uM) to the protein concentration (mg/mL).   
Cell Culture Study           
         The study used two Chinese hamster ovary (CHO) cell lines derived from a CHO-K1 host, 
that were stably transfected to produce mAb B, and are referred to as cell lines 1 and 2. The 
cryogenically frozen ampoules of these recombinant cell lines were first thawed and expanded 
before starting the cell culture experiment. To start the study, production cultures for cell lines 1 
and 2 were inoculated at ~10
6
 viable cells/mL in 250-mL shake flasks. For each cell line, 6 
production cultures were initiated in the same chemically-defined basal media but were 
supplemented with different initial concentrations of iron (10, 25, 50, 100, 150, and 200 µM 
ferrous sulfate). The 12 production cultures were agitated (150 rpm, 25 mm throw) in Multitron 
incubation shakers (INFORS USA Inc) with a 5% CO2 overlay. The cultures were maintained at 
37°C for the first 3 days, and at 33°C thereafter. On days 3, 6, and 9, the production cultures 
were supplemented with the same chemically-defined concentrated nutrient feed at 1:10 (v/v). 
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On day 12, the production cultures were harvested by centrifugation and filtration. Protein A 
chromatography was then used to purify mAb B from the harvested cell cultured fluid for the 
subsequent characterization.   
          In the cell culture study, several parameters reflecting cell growth and metabolism were 
monitored. The viable cell concentration and viability were analyzed by Vi-Cell XR Cell 
Counter (Beckman Coulter, Brea, CA). Glucose, lactate, ammonium, and culture pH were 
measured using a Bioprofile 400 (Nova Biomedical, Waltham, MA). On days 0, 7, 10, and 12, 
the cell culture fluid was sampled to measure iron concentration by inductively coupled plasma 
mass spectrometry (ICP-MS) using a Thermo Electron X series II instrument (Thermo Scientific, 
Waltham, MA). In addition, mAb B product titer was measured by protein A chromatography for 
cell culture fluid samples on days 7, 10, and 12. 
Storage Study 
         Antibody samples were prepared by mixing mAb A (5 mg/mL, final concentration) with 
ferrous sulfate (Low: 0.1 µM or High: 0.8 µM, final concentration) and PS20 (Low: 0.02%, w/v 
or High: 0.16%, w/v, final concentration) in 50 mM sodium succinate (pH 6.0), as shown in 
Table 1. A 5 mg/mL mAb A in 50 mM sodium succinate (pH 6.0) was used as the control. These 
samples were stored at room temperature in the dark for 4, 8, and 16 weeks. At each time point, 
methionine and EDTA were added to the samples to a final concentration of 1 mM and 50 µM, 
respectively, to quench carbonylation reactions. Subsequently, these samples were stored at -
80°C until further analysis.  
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Sample Label mAb A Concentration Ferrous Sulfate Concentration PS20 Concentration
Control 0 µM 0% (w/v)
Fe (Low)/ PS20 (Low)
0.1 µM 0.02% (w/v)
Fe (Low)/ PS20 (High)
0.1 µM 0.16% (w/v)
Fe (High)/ PS20 (Low) 0.8 µM 0.02% (w/v)
Fe (High)/ PS20 (High) 0.8 µM 0.16% (w/v)
5 mg/mL
 
Table 1. The iron and PS20 concentrations for the storage study. 
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Stress Study 
           Antibody samples were prepared by mixing mAb A (5 mg/mL, final concentration) with 
ferrous sulfate (4, 20, 100, or 500 µM) and hydrogen peroxide (8, 40, 200, or 1000 µM) in 50 
mM sodium succinate (pH 6.5), as shown in Table 2. These samples were incubated at room 
temperature in the dark for 2 hours. Subsequently, excess methionine and EDTA were added to 
these samples to quench carbonylation reactions. Additionally, mAb B and mAb C (5 mg/mL, 
final concentration) were mixed with ferrous sulfate (4, 20, 100, or 500 µM) and hydrogen 
peroxide (1000 µM) in 50 mM sodium succinate (pH 6.5). These samples were incubated at 
room temperature in the dark for 2 hours. Subsequently, excess methionine and EDTA were 
added to the samples to quench carbonylation reactions.  
Size Heterogeneity Analysis 
          The size heterogeneity of the mAb samples was evaluated by size exclusion 
chromatography (SEC) using a TSK G3000 SWXL (7.8x300 mm) size exclusion column with 
the same chromatography conditions as used for CALY, except that the effluent was only 
monitored at 280 nm. Integration of the High Molecular Weight Species (HMWS), Main Peak, 
and Low Molecular Weight Species (LMWS) for each sample was performed manually. 
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Sample Label mAb A Concentration Ferrous Sulfate Concentration Hydrogen Peroxide Concentration
A1 1000 µM
A2 200 µM
A3 40 µM
A4 8 µM
A5 1000 µM
A6 200 µM
A7 40 µM
A8 8 µM
A9 1000 µM
A10 200 µM
A11 40 µM
A12 8 µM
A13 1000 µM
A14 200 µM
A15 40 µM
A16 8 µM
5 mg/mL
500 µM
100 µM
20 µM
4 µM
 
Table 2. The oxidation conditions used to generate the stressed mAb A samples. 
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Charge Heterogeneity Analysis  
             The charge heterogeneity of mAb samples was evaluated by ion exchange 
chromatography (IEC) or imaged capillary isoelectric focusing (iCIEF), as noted. Before the 
analysis, all of the mAb samples were mixed with carboxypeptidase B (CpB) at an enzyme-to-
mAb ratio of 1 to 100 (weight to weight). These mixtures were incubated at 37ºC for 30 minutes, 
which reduces the basic charge heterogeneity of mAb samples by removing the heavy chain C-
terminal lysine residues.  
             For the IEC analysis, the CpB-treated mAb samples were injected onto a Dionex ProPac 
WCX 10 column (4x250 mm) using an Agilent HPLC system. Mobile phase A was 25 mM 
sodium phosphate, pH 6.6. Mobile phase B was 0.2 M sodium chloride in mobile phase A. The 
mAb charge variants were separated by applying a linear gradient of 0% to 45% B in 52 minutes. 
The column temperature was controlled at 40°C and the autosampler temperature was controlled 
at 8°C. The flow rate was 0.5 mL/min. The column effluent was monitored at 280 nm. 
Integration of the acidic, main, and basic charge variants for each sample was performed 
manually.  
            For the iCIEF analysis, the CpB-treated mAb samples were diluted to 0.5 mg/mL and 
added to the ampholyte mixture containing the carrier ampholytes and pI markers. The mixtures 
were briefly vortexed and centrifuged before the analysis. The mAb samples were then focused 
inside the capillary for 1 minute at 1,500 volts and then for 6 minutes at 3,000 volts using an 
iCE280 Analyzer (Protein Simple, San Jose, CA, USA). The separation of the acidic, main, and 
basic charge variants was monitored by UV absorbance at 280 nm. 
Site-Specific Carbonylation Analysis 
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              The site-specific reactivity of LY CH against mAb carbonylation was indirectly assessed 
using a mass spectrometry (MS)-based approach,
11
 where we looked for residual carbonylation 
sites that can be derivatized by Girard’s reagent T, after the sample has been first derivatized by 
LY CH. The highly oxidized mAb A (batch 2) was used as a model mAb. This model mAb 
sample was incubated with LY CH under the derivatization condition of CALY; a control sample 
was prepared under the same condition but without LY CH treatment. After the incubation, the 
two samples were buffer-exchanged into 50 mM sodium acetate buffer (pH 4.5), derivatized by 
Girard’s reagent T, reduced by sodium borohydride, digested by trypsin, and analyzed by MS as 
described previously.
11
 Subsequently, mAb carbonylation sites for the two samples were 
evaluated by database search using the Proteome Discover software (Waltham, MA, USA) and 
manual investigation of the MS data. 
RESULTS 
Optimization of the Derivatization Condition for CALY 
            In this work, we developed an improved protein carbonylation assay, CALY, for 
quantifying mAb carbonylation (Figure 2). To establish an optimal derivatization condition for 
CALY, we first focused on identifying a suitable buffer system. Using the highly oxidized mAb 
A (batch 1) as the test sample, we evaluated several buffers in the pH range of 4.0 to 6.5. At or 
below pH 5.0, we observed some degree of sample precipitation during the derivatization. We 
then selected pH 6.0 as the derivatization pH because no precipitation was observed at pH values 
greater than 5.0 and the derivatization becomes significantly slower at pH values greater than 
7.0. Based on the same consideration, we selected MES, which has a pKa of 6.13, as the buffer. 
To further reduce the risk of sample precipitation during the derivatization procedure, we 
included reduced Triton X-100, a surfactant that does not have any significant UV absorbance at 
34 
280 or 428 nm, in the buffer. In all the subsequent analyses, no sample precipitation was 
observed using 50 mM lithium MES, 0.05% (w/v) reduced Triton X-100, pH 6.0, as the 
derivatization buffer.  
          For the derivatization reaction, we evaluated LY CH-to-mAb molar ratios from 100:1 to 
10,000:1 with a reaction time of 18 hours. Based on the corresponding carbonylation levels 
(Figure 5A) of the highly oxidized mAb A (batch 1), the derivatization started to reach a plateau 
at a molar ratio of 6000:1. To ensure a robust derivatization condition, we selected 8000:1 as the 
appropriate reagent-to-mAb molar ratio for CALY. The derivatization time was optimized using 
a similar approach, and a reaction time of 18 hours was selected (Figure 5B).  
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Figure 5. (A) Optimization of the LY CH-to-mAb molar ratio for the CALY derivatization 
reaction; (B) optimization of the reaction time for the CALY derivatization reaction. 
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Site-Specific Reactivity of LY CH 
           LY CH contains a hydrazide group, a type of derivative that reacts specifically with 
carbonyls.
8-9
 In the literature, LY CH has been used as the derivatization reagent to quantify 
antibody glycan aldehydes generated by periodate oxidation.
12-13
 To demonstrate site-specific 
reactivity of LY CH against carbonyls generated by metal-catalyzed oxidation, we applied a 
mass spectrometry (MS) based approach (Supplemental Methods). In this approach, we 
derivatized an oxidized mAb sample first with LY CH and then with Girard's Reagent T (GRT), 
while a control sample was generated by derivatizing the oxidized mAb sample only with GRT. 
This derivatization scheme was employed to overcome a challenge with detecting LY CH-
derivatized carbonyl peptide ions by MS (sulfate groups on LY CH suppress ionization, data not 
shown). GRT, a hydrazide reagent that contains a permanently-charged quaternary ammonium 
group, was used to allow sensitive detection of carbonyl peptides by MS.
11
 Therefore, 
investigating the presence of any GRT-derivatized carbonyl peptides (after the mAb sample has 
first been derivatized by LY CH) allows an indirect assessment of specific reactivity and 
derivatization efficiency of LY CH. This assessment revealed that no carbonyl peptide was 
observed from the mAb sample (pre-treated with LY CH), while 22 carbonyl peptides were 
observed from the control sample (not pre-treated with LY CH). These MS data indirectly 
demonstrated selective reactivity of LY CH with mAb carbonyls, generated by metal-catalyzed 
oxidation.  
CALY Performance Assessment  
           The robustness of CALY was evaluated by assessing the effect of various assay 
conditions, such as mAb concentration for the derivation (0.45, 0.50, and 0.55 mg/mL), LY CH-
to-mAb molar ratio (7000:1, 8000:1, and 9000:1), derivatization buffer pH (5.9, 6.0, and 6.1), 
37 
number of buffer exchange steps (2, 3, and 4), injection volume (20, 25, and 30 µL),  number of 
freeze/thaw cycles (0 and 1), and time in the HPLC autosampler (1 to 15 hours at 8ºC) on 
quantification. The highly oxidized mAb A (batch 1) was used as the test sample. As shown in 
Figures 6 and 7, very little variation in the measured carbonylation level was observed for most 
of the assay conditions. In particular, the measured carbonylation levels were similar with two, 
three, and four rounds of buffer exchange; this finding demonstrates that CALY is robust against 
variable amounts of unconsumed LY CH (ranging from ~0.033 µM to ~30 µM) in the samples, 
and supports that exhaustive removal of LY CH is not required. The greatest variation was 
observed for the different derivatization pHs (with a CV of 5.1%); this suggests that a tight 
control of the derivatization buffer pH may be necessary for optimal robustness. Overall, a total 
of 25 measurements from the robustness assessment showed an average carbonylation level of 
13.0 nmol/mg with an overall CV of 2.4%.  CV values for each individual robustness experiment 
did not exceed 5.1%. The relatively small CV from these assessments supports that CALY is 
robust.  
           The linearity and precision of CALY was evaluated by measuring the carbonylation levels 
of serially-diluted samples, which were prepared by mixing the highly oxidized mAb A (batch 2) 
with the unstressed mAb A at 0-to-100, 25-to-75, 50-to-50, 75-to-25, and 100-to-0 (weight-to-
weight) ratios. These samples were analyzed by two analysts, on two instruments, with two 
columns. Three independent preparations were made by each analyst on three different days. A 
total of six independent measurements were performed for each sample. As shown in Figure 8, a 
linear relationship was observed between the carbonylation level and the percentage of highly 
oxidized mAb A in the sample mixture, with coefficient of determination (R
2
) of 0.997. The 
38 
coefficient of variation of the measurement for each mixed sample was lower than 15%. These 
results demonstrate the linearity and precision of CALY.  
           The accuracy of CALY was evaluated by comparing the carbonylation levels of the 
serially-diluted samples measured by CALY and by the DNPH spectrophotometric assay, which 
is considered to be a standard assay for quantifying protein carbonylation. As shown in Figure 9, 
the difference between the mean carbonylation levels determined by CALY and by the DNPH 
assay was within the coefficient of variation of the DNPH assay (illustrated by the error bars in 
Figure 9), except for the highly oxidized mAb A. These results support that CALY and the 
DNPH assay provide similar quantitation of mAb carbonylation with levels up to 7 nmol/mg.                       
            The limit of detection (LOD) and limit of quantitation (LOQ) were calculated as 3 times 
and 10 times of the standard deviation of the carbonylation levels of the negative control, 
respectively. Using the unstressed mAb A as the negative control, which was not derivatized by 
LY CH, we performed 30 independent measurements by CALY and the standard deviation from 
these measurements was 0.03 nmol/mg (Table 3). The LOD and LOQ of CALY were then 
determined to be 0.1 and 0.3 nmol/mg, respectively.  
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Figure 6. Robustness assessment for CALY: mAb concentration for the derivatization reaction; 
molar ratio for the derivatization reaction; pH for the derivatization reaction; number of buffer 
exchange steps; injection volume; and sample stability against freeze/thaw. 
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Figure 7. Robustness assessment for CALY: stability of the LY CH-derived mAb A sample in 
the HPLC autosampler at 8°C. 
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Figure 8. Carbonylation levels of the mixed mAb A samples as determined by CALY (six 
independent measurements for each sample). Error bars represent the standard deviation of the 
independent measurements.  
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Figure 9. Carbonylation levels of the unstressed, the 1-to-1 mixed, and the highly oxidized mAb 
A samples as determined by CALY (six independent measurements for each sample) and the 
DNPH method (three independent measurements for each sample). Error bars represent the 
standard deviation of the independent measurements.  
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No. Carbonylation (nmol/mg)
1 0.18
2 0.10
3 0.20
4 0.13
5 0.19
6 0.17
7 0.17
8 0.10
9 0.18
10 0.13
11 0.17
12 0.16
13 0.14
14 0.12
15 0.15
16 0.14
17 0.16
18 0.15
19 0.11
20 0.16
21 0.17
22 0.16
23 0.17
24 0.12
25 0.14
26 0.15
27 0.15
28 0.17
29 0.15
30 0.14  
Table 3. The carbonylation levels of the negative control (i.e., mAb A that was not derivatized 
by LY CH or exposed to stress conditions). These data were generated from 30 independenat 
measurements. The standard deviation (SD) from these data, 0.03 nmol/mg, was used to 
determine the LOD and LOQ of CALY.      
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Cell Culture Study  
           Iron is a required nutrient in cell culture media for mAb production.
14-15
 However, iron 
can also catalyze the formation of carbonyl groups on proteins.
16
 To understand the effect of iron 
on mAb carbonylation during cell culture production, we used chemically defined cell culture 
media supplemented with 6 different levels of iron (10, 25, 50, 100, 150, and 200 µM). These 
levels were based on the iron concentrations commonly used for mAb production.
14-15, 17
 We 
observed that, as the initial iron concentration increased from 10 to 200 µM, the carbonylation 
level of mAb B increased from 1.0 to 1.8 nmol/mg with cell line 1 and from 0.9 to 2.2 nmol/mg 
with cell line 2 (Figure 10). This observation demonstrates that iron in cell culture media 
critically influences mAb carbonylation during cell culture production. 
            The relationship between mAb B carbonylation level and the initial iron concentration 
was not linear: the carbonylation level increased more rapidly as the initial iron concentration 
increased from 10 to 50 µM than from 100 to 200 µM. Considering that the extracellular iron 
concentration is expected to decrease due to the consumption of iron by CHO cells, we 
investigated the relationship between mAb B carbonylation level and the iron concentration in 
the extracellular cell culture fluid at days 0, 7, 10, and 12. As shown in Figure 11, the 
extracellular iron concentration decreased almost linearly over time. When plotting mAb B 
carbonylation levels against the respective extracellular iron concentrations at day 0, 7, 10, or 12, 
we observed similar non-linear relationships (figures not shown). The lack of a linear 
relationship between mAb B carbonylation level and the extracellular iron concentration 
suggests that iron is likely not the only factor that influences mAb carbonylation during cell 
culture production. We next investigated cell culture growth (Figure 12), metabolism (Figures 13 
45 
and 14), and mAb production (Figure 15) profiles, but did not observe any trends or relationships 
that could explain the non-linear increase in mAb B carbonylation.  
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Figure 10. Carbonylation levels of mAb B produced under different initial iron concentrations in 
the cell culture study (error bars represent the standard deviation of three independent 
measurements). 
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Figure 11. Extracellular iron concentration for (A) cell line 1 and (B) cell line 2.   
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Figure 12. Culture viability and viable cell concentration profiles for the cell culture study using 
chemically-defined media supplemented with different iron concentrations. The viable cell 
concentration increased as the initial iron concentration increased, while the culture viability (%) 
essentially remained the same. 
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Figure 13. Glucose (upper panel) and offline pH (lower panel) profiles for the cell culture study 
using chemically-defined media supplemented with different iron concentrations. For cell line 2, 
a faster glucose consumption and lower culture pH were observed as the initial iron 
concentration increased. However, for cell line 1, these trends were less clear. 
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Figure 14. Ammonium (upper panel) and lactate (lower panel) profiles for the cell culture study 
using chemically-defined media supplemented with different iron concentrations. For both cell 
lines, no clear trend was observed in the ammonium and lactate profiles as the initial iron 
concentration increased. 
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Figure 15. Relationship between the initial iron concentration in chemically-defined media and 
(A) mAb B titer at day 12; (B) mAb B titer at days 7, 10, and 12. 
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Storage Study  
            The mAbs produced and purified after bioprocessing would subsequently be stored. 
During storage, the mAbs can be exposed to low levels of iron ions leached from stainless steel 
surfaces or container closure materials.
18-20
 Polysorbate 20 (PS20), a surfactant in mAb 
formulations commonly used to minimize aggregation during storage,
21
 is known to contain 
peroxides.
22
 Therefore, the peroxides from PS20 could react with iron ions to induce mAb 
carbonylation during storage. To understand this potential route of mAb carbonylation, we 
prepared mAb A samples in 50 mM sodium succinate buffer (pH 6.0) with a combination of low 
or high levels of iron and PS20 (Table 1). An unstressed mAb A with a relatively low level of 
carbonylation, 1.1 nmol/mg, was used as the control. The iron concentrations (0.1 µM and 0.8 
µM) were based on the concentrations of the leached iron ions reported by Zhou et al.
18
 The 
PS20 concentrations (0.02% and 0.16%, w/v) were based on the PS20 concentrations reported in 
mAb formulations.
23
 Considering that mAb carbonylation could be a slow process in such a 
storage study, we measured mAb A carbonylation level at 4, 8, and 16 weeks.  
        As shown in Figure 16, compared to mAb A control, whose carbonylation level essentially 
stayed unchanged at 1.1 nmol/mg during storage, all four mAb A samples showed increased 
levels of carbonylation, which ranged from 1.3 to 2.1 nmol/mg. This observation demonstrates 
that mAbs in PS20 formulations are indeed susceptible to metal-catalyzed carbonylation during 
storage when low levels of iron ions are present. Interestingly, the carbonylation levels of the 
mAb A samples formulated with the high level of PS20 (0.16%, w/v) were consistently higher 
than those with the low level of PS20 (0.02%, w/v) at 4, 8, and 16 weeks, regardless of the iron 
concentrations. In addition, mAb A carbonylation products were not stable: a decrease in the 
53 
carbonylation level was observed between week 8 and week 16 for the two samples formulated 
with the high level of PS20 (0.16%, w/v). 
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Figure 16. Carbonylation levels of mAb A samples stored at room temperature in the dark for 4, 
8, and 16 weeks in the storage study (error bars represent the standard deviation of three 
independent measurements). 
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Stress Study  
           In light of the findings from the cell culture and storage studies, we hypothesized that 
peroxides could also be a critical factor that influences mAb carbonylation. To understand the 
effect of iron and peroxides on mAb carbonylation, we performed a stress study using various 
concentrations of iron (4 µM, 20 µM, 100 µM, or 500 µM) and hydrogen peroxide (8 µM, 40 
µM, 200 µM, or 1000 µM), as shown in Table 2. These concentrations were based on the 
reported values from cell culture studies.
15, 24-25
  
            The carbonylation levels of the stressed mAb A samples varied from 2.5 to 13.0 nmol/mg 
(Figure 17). These data showed that a wide range of carbonylation levels can be generated when 
mAbs are exposed to iron and hydrogen peroxide at the pharmaceutically relevant 
concentrations. More importantly, these data showed that hydrogen peroxide critically influenced 
mAb A carbonylation. For example, with 500 µM iron, an increase in hydrogen peroxide 
concentration from 8 to 1000 µM resulted in an increase of the carbonylation level from 4.3 to 
13.0 nmol/mg. Additionally, these data showed that iron and hydrogen peroxide had different 
impacts on mAb A carbonylation. Iron appeared to be a more dominant factor as mAb A 
carbonylation levels did not further increase when excess hydrogen peroxide (in relationship to 
iron) was present. Taken together, the stress study demonstrated a complex dependence of mAb 
carbonylation on both iron and hydrogen peroxide, which could provide a potential mechanism 
for the observed mAb carbonylation during production and storage.  
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Figure 17. Carbonylation levels of mAb A samples stressed with different iron and hydrogen 
peroxide concentrations (error bars represent the standard deviation of three independent 
measurements). 
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Product Quality Correlations 
            Metal-catalyzed carbonylation has been linked to the formation of antibody aggregates.
3, 
19
 To gain a more comprehensive understanding of the effect of metal-catalyzed carbonylation on 
mAb product quality, we investigated the relationship between carbonylation and mAb product 
quality on size and charge variants. In the cell culture study, no apparent correlation was 
observed between the levels of high molecular weight species (HMWS), low molecular weight 
species (LMWS), or basic variants and the levels of mAb B carbonylation (Figure 18). In 
contrast, a positive correlation was observed between the levels of acidic variants and the levels 
of mAb B carbonylation (R
2
 =0.96 for both cell lines, Figure 18).     
             In the storage study, we investigated the relationship between the rate of formation of the 
size or charge variants and mAb A carbonylation. As shown in Figures 19 and 20, formation of 
the size and charge variants appeared to largely follow zero-order kinetics. The rates of 
formation were therefore determined by linear regression analysis of the respective size and 
charge data (Figure 21). Since mAb A carbonylation profiles were quite complex over the 
storage time course (Figure 16), for simplicity, we used the average carbonylation levels at 4, 8, 
and 16 weeks to represent the overall extent of carbonylation during storage. As shown in Figure 
22, positive correlations were observed between the average carbonylation levels and the rates of 
formation of HMWS (R
2
=0.97), LMWS (R
2
=0.97), and acidic variants (R
2
=0.88), but not basic 
variants (R
2
=0.17).           
             In the stress study, positive correlations were observed (Figure 23) between the levels of 
carbonylation and size variants (R
2
=0.85 for both HMWS and LMWS). Positive correlations 
were also observed between the levels of carbonylation and charge variants (R
2
=0.97 for acidic 
charge variants; R
2
=0.96 for basic charge variants). To understand if a positive correlation may 
58 
generally exist between metal-catalyzed carbonylation and acidic charge heterogeneity for 
mAbs, we further evaluated two more mAbs (mAb C and mAb D), which share only 76% 
sequence similarity, with a subset of the stress conditions. As shown in Figure 24, a positive 
correlation (R
2
>0.99) was observed between the levels of carbonylation and acidic variants for 
both mAbs. In contrast, while a positive correlation between the levels of carbonylation and 
basic variants was observed for mAb D (R
2 
=0.97), no such correlation was observed for mAb C 
(Figure 24), as is the case for mAb B in the cell culture study (Figure 18) and mAb A in the 
storage study (Figure 22). The consistent correlations between the level of carbonylation and the 
level of acidic variants for all four mAbs support that a general degradation mechanism may 
exist that links metal-catalyzed oxidation with formation of acidic charge variants. It should be 
also pointed out that the linear regression slopes of these correlations differ, which suggests that 
the degradation mechanism may be sequence- or molecule-specific in response to metal-
catalyzed oxidation.   
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Figure 18. (A) the relationship between the levels of carbonylation and size variants, i.e., High 
Molecular Weight Species (HMWS) and Low Molecular Weight Species (LMWS) of mAb B 
samples from the cell culture study; (B) the relationship between the levels of carbonylation and 
charge variants, i.e., acidic and basic species of mAb B samples from the cell culture study. 
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Figure 19. (A) The levels of HMWS; (B) the levels of LMWS of the mAb A samples from the 
storage study.       
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Figure 20. (A) The levels of acidic variants; (B) the levels of basic variant of the mAb A 
samples from the storage study.      
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Figure 21. (A) The rate of formation of size variants; (B) the rate of formation of charge variants 
of the mAb A samples from the storage study.     
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Figure 22. (A) The relationship between the average level of carbonylation at 4, 8, and 16 weeks 
and the rate of formation of the size variants (i.e., HMWS and LMWS) of mAb A samples from 
the storage study; (B) the relationship between the average level of carbonylation at 4, 8, and 16 
weeks and the rate of formation of the charge variants (i.e., acidic or basic variants) of mAb A 
samples from the storage study.  
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Figure 23. (A) The relationship between the levels of carbonylation and size variants, i.e., High 
Molecular Weight Species (HMWS) and Low Molecular Weight Species (LMWS) of mAb A 
samples from the stress study; (B) the relationship between the levels of carbonylation and 
charge variants, i.e., acidic and basic species of mAb A samples from the stress study. 
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Figure 24. (A) The relationship between the levels of carbonylation and acidic variants of the 
stressed mAb C and mAb D samples; (B) the relationship between the levels of carbonylation 
and basic variants of the stressed mAb C and mAb D samples. 
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DISCUSSION 
            To develop a robust and precise assay for the investigation of mAb carbonylation, we 
selected LY CH as the derivatization reagent based on the following considerations. First, LY 
CH reacts specifically with carbonyls via the hydrazide group. This type of derivatization 
reaction is widely adopted in many different carbonylation assays.
9
 In addition, the site-specific 
reactivity of LY CH against metal-catalyzed carbonylation was confirmed in our study by an 
MS-based approach. Second, LY CH has relatively high solubility in water.
10
 Taking advantage 
of the high solubility of LY CH, we designed a workflow that does not require protein 
precipitation (Figure 2). Third, LY CH strongly absorbs at 428 nm,
8
 which differs from the 
maximum absorbance wavelength (~280 nm) of an mAb. This difference in wavelength allows 
us to apply the absorbance-based quantitation strategy that has been adopted to determine drug-
to-antibody ratios (DARs) for many antibody drug conjugates (ADCs).
26
 Namely, the 
quantitation with CALY is based on the absorbance at 280 nm and 428 nm of an LY CH-
derivatized mAb sample (Figure 3), where the individual concentrations of mAb and LY CH can 
be determined by solving the two equations that account for the absorbance at 280 and 428 nm.  
            We demonstrated that CALY is more robust and precise than the conventional DNPH 
assay. A key feature contributing to the improved performance is that LY CH-derivatized mAb 
species are baseline separated from the unconsumed LY CH on SEC (Figure 3). Therefore, the 
quantitation does not require exhaustive and reproducible removal of LY CH, which was 
supported by the robustness assessment data from 2-4 rounds of buffer exchange. By contrast, 
the commonly used DNPH assay requires protein precipitation, which is believed to cause the 
observed larger CV of the measurement.
4
  
67 
              In the accuracy assessment, we observed that the DNPH assay generated a lower 
carbonylation level for the highly oxidized mAb A than CALY. A similar observation was 
reported by Soglia et al.,
27
 where the DNPH assay generated lower carbonylation levels for 
oxidized muscle and meat proteins than a modified DNPH assay. Protein unfolding and 
solubilization were suggested to be the cause.
27
 While future studies will be needed to 
understand if protein unfolding and solubilization contributed to the under-quantification by the 
DNPH assay for the highly oxidized mAb A in our case, CALY and the DNPH assay provided 
similar quantitation of mAb carbonylation at levels up to 7 nmol/mg, which covers the 
carbonylation levels observed in our cell culture and storage studies, as well as a majority of the 
reported protein carbonylation levels from other studies.
3, 5, 19, 28-30
 
              We established the LOD and LOQ for CALY as 0.1 nmol/mg and 0.3 nmol/mg, 
respectively. The LOQ of 0.3 nmol/mg, equivalent to only 0.05 mole carbonyls per mole of a 
150 KDa mAb, is approximately 6-10 times lower than the reported normal level of plasma 
protein carbonylation of 2-3 nmol/mg.
5
 The LOQ of CALY is higher than that of a recently 
modified ELISA-based method, which was established as 0.2 nmol/mg.
3
 This is not surprising 
since ELISA is inherently more sensitive than spectrophotometric methods. Nevertheless, 
compared to the ELISA-based carbonylation method, CALY has a simpler sample preparation 
procedure and is, therefore, less tedious/labor-intensive than the ELISA method. In addition, the 
ELISA assay requires a protein standard with a known carbonylation level for its use in different 
laboratories,
5
 while CALY does not require such a protein carbonylation standard. 
              The benefit of improved assay robustness and precision with CALY is readily reflected 
in our cell culture, storage, and stress studies, where less precision with the DNPH assay would 
make it more difficult to identify the trends and relationships as clearly. The cell culture study 
68 
established a link between iron levels in cell culture media and mAb carbonylation. In the 
literature, a similar iron titration experiment has been performed by Bai et al. 
15
 However, 
carbonylation levels were not provided for the produced mAbs in their study. Recently, Purdie et 
al. provided relative levels of carbonylation for mAbs produced in two chemically defined media 
and showed relative reduction in mAb carbonylation with the media containing less cysteine and 
ferric ammonium citrate.
2
 Compared to the study by Purdie et al., our results provided a direct 
and more complete understanding of the effect of iron on mAb carbonylation, where we showed 
that the relationship between the iron concentration and mAb B carbonylation was not linear. 
Additionally, we showed that the commonly observed cell culture parameters did not seem to be 
useful indicators for mAb carbonylation. These findings identified iron as a critical factor, but 
also suggested that it may be necessary to understand additional factors, such as hydrogen 
peroxide level in cell cultures
25
 and/or cell line-specific defense mechanisms against reactive 
oxygen species
31
, to enable a robust control of mAb carbonylation in cell culture. 
             The storage study showed that PS20 and iron, at pharmaceutically relevant 
concentrations, induced mAb carbonylation during storage. The peroxides from PS20 were likely 
a critical factor for mAb carbonylation during storage. Thus, mAb A samples containing 0.16% 
PS20, which should contain more peroxides because of the higher PS20 concentration, showed 
consistently higher levels of carbonylation. With longer storage times, we observed decreases in 
the carbonylation levels. While this observation has not been previously reported for mAbs, a 
decrease in the carbonylation levels was observed for myofibrillar proteins during 10-day 
incubation with iron (III) and hydrogen peroxide.
32
 For myofibrilar proteins, the so-called 
decarbonylation was attributed to the formation of Schiff-bases between aldehydes and lysine 
residues.
32
 Such a decarbonylation process could occur in our storage study, since Schiff-bases 
69 
are formed at mildly acidic pHs,
33
 such as pH 6.0 of the storage buffer. In addition, other 
processes, such as formation of insoluble aggregates or formation of carboxylic acids from 
further oxidation of aldehydes, could also contribute to the observed decreases in mAb 
carbonylation during storage.  
             The stress study demonstrated a complex effect of iron and hydrogen peroxide on mAb 
carbonylation, where the existing knowledge is limited. For example, in the report by Uehara and 
Rao,
3
 the effects of iron content, buffer type, and storage temperature on protein carbonylation 
were studied at a fixed hydrogen peroxide concentration. In another report by Kryndushkin and 
Rao,
34
 the oxidation reactions were carried out with excess amounts of hydrogen peroxide. Using 
the 16 stress conditions over a wide range of iron and hydrogen peroxide concentrations, our 
study more extensively mimicked the oxidative environment that mAbs may be exposed to 
during cell culture. It should be pointed out that Fenton and Fenton-like reactions are expected to 
occur under these stress conditions. In the Fenton reactions, ferrous ion is oxidized by hydrogen 
peroxide to form ferric ion, while hydrogen peroxide decomposes to form a hydroxyl radical and 
a hydroxyl ion. The hydroxyl radical is highly reactive and can abstract a hydrogen atom from an 
adjacent carbon-hydrogen bond to form a carbon-centered radical, which initiates the 
carbonylation process and ultimately leads to the carbonyls detected by CALY. In this sense, 
formation of these carbonyl products appears to be primarily catalyzed by ferrous ion but not 
ferric ion. However, in the Fenton-like reactions, ferric ion can react, although at a much slower 
rate
35
, with hydrogen peroxide to generate ferrous ion, hydroperoxyl radical, and proton. The 
regenerated ferrous ion can then participate in protein carbonylation. Therefore, considering the 
cyclic nature of these reactions, we focused on the total iron concentration instead of the 
respective concentration of ferrous or ferric ion. As shown in Figure 17, the observed effect of 
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iron and hydrogen peroxide is consistent with the proposed mechanism for protein 
carbonylation,
1
 where ferrous ion (which can be regenerated from ferric ion) acts as a catalyst 
and hydrogen peroxide is consumed in the process. Importantly, the stress study showed that 
hydrogen peroxide also plays a critical role in mAb carbonylation, which has not been 
emphasized in the literature. Furthermore, the stress study lends support to our hypotheses and 
proposed mechanisms that implicate peroxides in the cell culture and storage studies.  
               From the storage and stress studies, we observed positive correlations between metal-
catalyzed carbonylation and the formation of HMWS and LMWS. While correlation does not 
imply causation, the observed correlation with the HMWS in our studies adds to the growing 
evidence in the literature supporting that carbonylation may promote the formation of protein 
aggregates,
3, 19, 36-37
 where the cause-effect relationship has been largely attributed to the 
increased protein hydrophobicity.
36
 For the observed correlation with the LMWS, it is unlikely 
that metal-catalyzed carbonylation directly generated the LMWS. Instead, the carbonylation 
levels likely parallel the extent of metal-catalyzed mAb fragmentation, probably caused by 
protein backbone radicals, generated via Fenton reaction (the Fenton reaction cannot only lead to 
carbonylation but also other radical-mediated processes).
38
 From the cell culture studies, 
surprisingly no correlation was observed between carbonylation and the formation of HMWS or 
LMWS in mAb B samples. This result suggests that carbonylation cannot be used as a general 
indicator for mAb aggregation or fragmentation propensity. It is possible that mechanisms 
39-40
 
not related to metal-catalyzed reactions contributed to the formation of HMWS and LMWS 
under the cell culture conditions.    
              Our studies revealed a positive correlation between metal-catalyzed carbonylation and 
formation of acidic variants in mAbs. To the best of our knowledge, this correlation has not been 
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previously reported for mAbs. The consistent correlations in all of our studies suggests that 
metal-catalyzed oxidation may represent a degradation pathway for inducing acidic charge 
heterogeneity of mAbs. This highlights a new direction for investigating acidic charge 
heterogeneity of mAbs during production and storage. It should be noted that the observed 
product quality correlations in our studies cannot be satisfactorily explained by deamidation or 
glycation, two common degradation pathways for inducing acidic variants during production
41
 or 
storage.
42
 For example, in the stability study, different mAb A samples should essentially 
deamidate at the same rate as suggested by the deamidation mechanism,
43-44
 since these samples 
were exposed to the same buffer and temperature. In the cell culture study, the glucose or the 
offline pH profiles (Figure 13) differed only slightly or were in an opposite trend compared to 
those of the acidic charge variants.  
           Carbonylation of lysine and arginine residues directly forms acidic charge species due to 
the loss of the positive charge on their side chains, and therefore a cause-effect relationship can 
at least be partially established to explain the correlations. It is possible that, other than lysine 
and arginine carbonylation, formation of Schiff bases (between aldehydes and primary amines) 
or carboxylic acids (by further oxidation of aldehyde groups), could contribute to acidic charge 
heterogeneity, although formation of these products results in a decrease in mAb carbonylation 
level. In the stability study, formation of Schiff bases or carboxylic acids could potentially 
explain why the decrease in carbonylation level from 8 to 16 weeks in some samples did not 
cause a decrease in the level of acidic variants. Further characterization, such as by peptide 
mapping analysis of enriched acidic fractions, will be performed in the future to elucidate these 
acidic charge species.     
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            In summary, this work presents an improved protein carbonylation assay, CALY, which 
addressed several key analytical challenges with commonly used protein carbonylation assays. 
The method performance of CALY was extensively evaluated and the utility of CALY was 
demonstrated by several case studies under cell culture, storage, and stress conditions. More 
importantly, through the use of CALY, we acquired new insights into both the mechanism and 
the effects of metal-catalyzed carbonylation of mAbs. These insights place us in a better position 
to address product quality risks associated with metal-catalyzed carbonylation during mAb 
production and storage.  
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Chapter 3 
Characterization of Acidic Charge Heterogeneity Induced by Metal-Catalyzed 
Oxidation in a Recombinant Monoclonal Antibody 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
INTRODUCTION 
       Recombinant monoclonal antibodies (mAbs) are an important class of therapeutic drugs
1
 
and have broad applications in many disease areas.
2-3
 Compared to small molecule drugs, mAb 
drugs are immensely more complex not only because mAbs have a much larger molecule weight 
(~150kDa) but also because a large variety of mAb product variants can be generated during 
mAb manufacturing.
4-6
 These product variants could potentially impact mAb safety and efficacy 
profiles.
7-8
 Therefore, it is necessary to thoroughly characterize mAb product variants during 
mAb development. In fact, health authorities have recently introduced a quality-by-design 
paradigm, which emphasizes building process and product quality understandings into a control 
strategy.
9-10
  
       Charge variants are a common type of mAb product variants.
11-14
 Formation of mAb 
charge variants often involves changes in the isoelectric point or net charge of mAbs.
11
 These 
charge variants are typically monitored by ion exchange chromatography or imaged capillary 
isoelectric focusing in a control system.
15-16
 During mAb development, it is highly desirable to 
have consistent charge heterogeneity profiles that meet product quality acceptance criteria for 
therapeutic use.
17
 To help achieve that goal, significant amount of knowledge has been acquired 
in recent years on the source of mAb charge heterogeneity and the relevant manufacturing 
factors.
5
 For example, a major basic charge variant was identified as C-terminal lysine variant.
18
 
The source of this variant was attributed to the incomplete enzymatic removal of mAb heavy 
chain C-terminal lysine residue, which contains a positive charge from the primary amine group 
on the lysine side chain.
18
 Zinc, a cofactor of the enzyme responsible for the removal of the C-
terminal lysine residues, was identified as a cell culture factor that can help control this basic 
variant in mAb products.
19
 For the acidic charge variants, a commonly observed acidic charge 
81 
variant was asparagine deamidation to aspartate, which contains a negative charge from the 
carboxylic acid group on aspartate side chain.
20
 For the deamidation reaction, multiple factors, 
such as protein sequence, pH, temperature, and higher order structure, have been identified to 
explain the formation of these acidic charge variant in mAbs.
20
 Based on these understandings, 
temperature and pH downshifts were implemented in cell culture processes to lower acidic 
charge variant content in mAbs.
21
 
         Existing literature points out that mAb acidic charge variants are often more heterogeneous 
than basic charge variants.
22
 This is likely because many possible reactions can occur on lysine 
or arginine residues, which leads to the loss of the positive charges on mAbs. Quan et. al. 
reported that glycation, a reaction between lysine and reducing sugars, led to increased acidic 
charge heterogeneity in a model mAb.
23
 This was explained by the formation of a ketoamine 
Amadori product, which removes the positive charge from lysine.
23
 Chumsae et. al. reported that 
arginine residues can react with methylglyoxal, a cell culture metabolite, to form 
dihydroxyimidazolidine and hydroimidazolone products, which removes the positive charge 
from arginine.
24
 Interestingly, methionine oxidation, which does not change the net charge of 
mAbs, was reported in the acidic fractions of an IgG1 mAb.
22
 It was hypothesized that 
conformational changes induced by methionine oxidation promoted the formation of 
deamidation products, which co-localized with methionine oxidation in the acidic fractions.
22
 
This may also be explained by methionine oxidation-induced unfolding,
25
 which could change 
pKa values of various residues on proteins.
26
   
          We previously reported that metal-catalyzed oxidation can induce the formation of acidic 
charge variants in mAbs.
27
 However, to date, the induced acidic charge variants have not been 
characterized. Several degradation pathways are likely involved in the formation of these acidic 
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variants. First, metal-catalyzed oxidation can generate protein carbonyls (such as aldehydes and 
ketones) on lysine, arginine, threonine, and proline residues.
28
 When lysine and arginine are 
converted to their respective aldehyde product (adipic semialdehyde and glutamic 
semialdehyde), the positive charge on the side chain is lost. While our previous study has 
confirmed the presence of these two aldehyde products in mAbs after metal-catalyzed 
oxidation,
29
 it is not known if the aldehyde products constitute a major component of the 
oxidation-induced acidic variants. Second, the aldehyde products can be further oxidized to 
carboxylic acid (adipic acid or glutamic acid) or react with primary amines on mAbs to form a 
Schiff base. These additional degradation products can contribute to the acidic charge 
heterogeneity due to addition of a negative charge (from carboxylic acid) or removal of a 
positive charge (from primary amine). Third, metal-catalyzed oxidation has been known to 
convert additional neutral or basic residues to acidic species in proteins.
30
 For example, cysteine 
can be oxidized to cysteic acid; histidine can be oxidized to aspartate; proline can be oxidized to 
glutamate.
30
 For mAbs, it has been reported that cysteine residues in the hinge region can be 
oxidized to cysteic acid after metal-catalyzed oxidation.
31
 However, very little is known about 
the location and relative abundance of the other acidic oxidation products (if they exist) in mAbs. 
Considering that these various types of acidic variants may have different impacts on mAb 
product quality, it is critical to provide a detailed characterization of mAb acidic variants induced 
by metal-catalyzed oxidation.    
              This study reports a comprehensive characterization of the acidic variants of a model 
IgG1 mAb after metal-catalyzed oxidation. The acidic and main peak fractions from the 
unstressed and highly stressed mAb A were collected to high purity by ion exchange 
chromatography. Subsequently, these fractions were characterized by a wide range of analytical 
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methods, such as size exclusion chromatography, intact/reduced molecular mass analysis, 
peptide mapping, and hydrogen-deuterium exchange mass spectrometry.
32-35
 It was found that 
conventional peptide mapping provided only limited information on the product variants, in 
particular, the protein carbonyls. To facilitate the characterization of these carbonylation 
products, an existing site-specific carbonylation peptide mapping method was optimized to for 
relative quantitation of site-specific carbonyls in mAb A fractions. We showed that, contrary to 
the common belief, threonine carbonylation products, but not lysine or arginine carbonylation 
products, are a major component in the acidic fractions. Additionally, we identified a large 
number of acidic degradation products. Many of these acidic degradation products are reported 
in mAbs for the first time. The detailed characterization provides a better understanding on how 
metal-catalyzed oxidation induces acidic charge variants on mAbs. The characterization of these 
degradation products better informs mAb product quality assessment, which aligns with 
expectations from health authorities on implementing quality-by-design to ensure the safety and 
efficacy of mAb products.  
MATERIALS AND METHODS 
Materials 
        The recombinant monoclonal antibody, mAb A, was manufactured at Genentech (South San 
Francisco, CA). Lucifer Yellow carbohydride dilithium salt (Lucifer Yellow CH), ferrous 
sulfate, hydrogen peroxide solution (30% in H2O, w/w), methionine, ethylenediaminetetraacetic 
acid (EDTA), sodium succinate, succinic acid, sodium phosphate (dibasic and monobasic), 
sodium chloride, sodium acetate, acetic acid, sodium hydroxide solution (1M in H2O), 2-(N-
morpholino)ethanesulfonic acid (MES), lithium hydroxide, reduced Triton X-100, TCEP (tris(2-
carboxyethyl)phosphine), (Carboxymethyl)trimethylammonium chloride hydrazide (Girard’s 
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Reagent T, GRT), dithiothreitol (DTT), formic acid, iodoacetic acid (IAA), calcium chloride, 
tris(hydroxymethyl) aminomethane (Tris), deuterium water, urea, and trifluoroacetic acid (TFA) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). TSK G3000 SWXL (7.8x300mm) 
size exclusion column was purchased from Tosoh Bioscience (King of Prussia, PA, USA). 
ProPac WCX 10 column was purchase from Thermo Fisher Scientific (Waltham, MA, USA). 
Carboxypeptidase B was purchased from Roche Diagnostics (Mannheim, Germany). Acetonitrile 
(ACN) was purchased from Burdick & Jackson (Muskegon, MI, USA). Sequencing-grade 
trypsin was purchased from Promega (Madison, WI, USA). ACQUITY UPLC Peptide CSH C18 
Column (130 Å, 1.7 µm, 2.1x150 mm), Waters ACQUITY BEH C18 VanGuard Pre-column 
(2.1x5 mm), BEH C18 column (1.0 × 50 mm), and BEH C18 (300 Å, 1.7 um, 2.1x150mm) 
column were purchased from Waters (Milford, MA, USA). An immobilized protease XIII/pepsin 
column (2.0 × 30 mm) was purchased from NovaBioAssays (Woburn, MA, USA).  
Metal-catalyzed oxidation of mAb A  
        The oxidized mAb A sample was prepared by metal-catalyzed oxidation, where mAb A was 
mixed with ferrous sulfate and hydrogen peroxide to a final concentration of 5 mg/mL, 2 mM, 
and 2 mM, respectively. The oxidation reaction was carried out at the room temperature in 50 
mM sodium succinate buffer (pH 6.5) for 2 hours, and was subsequently stopped by addition of 
excess amounts of methionine and EDTA.   
Charge Heterogeneity Analysis 
       The mAb A samples were analyzed by ion exchange chromatography (IEC) using a Dionex 
ProPac WCX 10 column (4x250 mm). Before the analysis, the mAb A samples were mixed with 
Carboxypeptidase B at an enzyme-to-substrate ratio of 1:100 (weight to weight). These samples 
were then incubated at 37ºC for 30 minutes to remove heavy chain C-terminal lysine on mAb A. 
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For the IEC analysis, the mobile phase A was 20 mM MES, pH 6.50 ± 0.05. The mobile phase B 
was 100 mM sodium chloride in mobile phase A. A linear gradient of 0% solvent B to 100% 
solvent B in 50 minutes was applied to separate mAb A charge variants. The column temperature 
was controlled at 40°C and the autosampler temperature was controlled at 8°C. The flow rate 
was 0.5 mL/min. The column effluent was monitored by UV absorbance at 280 nm. Integration 
of the acidic, main peak, and basic regions was performed manually using Agilent Chemstation 
software. 
Size Heterogeneity Analysis  
        The mAb A samples were analyzed by size exclusion chromatography (SEC) using a TSK 
G3000 SWXL (7.8x300 mm) size exclusion column. For the SEC analysis, the mobile phase was 
200 mM potassium phosphate, 250 mM potassium chloride, pH 6.2. The column temperature 
was controlled at 25°C and the HPLC autosampler temperature was controlled at 8°C. An 
isocratic flow of 0.5 ml/min was employed. The effluent was monitored by UV absorbance at 
280 nm. Integration of the High Molecular Weight Species (HMWS), Main Peak, and Low 
Molecular Weight Species (LMWS) was performed manually using Agilent Chemstation 
software. 
Total Protein Carbonylation Analysis  
        Total protein carbonylation levels of mAb A samples were measured using Lucifer Yellow 
CH as the derivatization reagent. As previously described in Chapter 2, for the analysis, mAb A 
samples (to a final concentration of 0.2 mg/mL) were mixed with Lucifer Yellow CH at a 
Lucifer Yellow CH-to-mAb molar ratio of 8,000:1. The derivatization reaction was carried out in 
50 mM lithium MES buffer, 1% Triton X-100, pH 6.0, at 37°C for 16 hours. After the 
derivatization, these samples (500 µL) were buffer-exchanged three times into the SEC buffer 
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using 15mL Amicon Ultra-15 30 kDa filters. Subsequently, the total protein carbonylation levels 
was determined by the peak areas from 280 and 428 nm absorbance of the Lucifer Yellow CH-
derived mAb A on the size exclusion chromatograms.  
Peptide Mapping 
         The mAb A samples were analyzed by the conventional tryptic peptide mapping method, 
where the samples were denatured, reduced, and S-carboxymethylated before being digested by 
trypsin. For the tryptic digestion, the trypsin-to-substrate ratio was 1:50 (weight to weight), and 
the digestion was carried out in 25 mM Tris-HCl, 2 mM CaCl2, pH 8.2, at 37°C for 5 hours. 
Subsequently, the digestion was stopped by addition of TFA to a final concentration of 0.3% 
(v/v). The digested samples were separated on a CSH C18 column (130 Å, 1.7 µm, 2.1x150 
mm). Solvent A was 0.1% formic acid in water. Solvent B was 0.1% formic acid in acetonitrile. 
For the separation, a step gradient was used as follows: 1-13% B in 5 minutes and then 13-35% 
B in 35 minutes. Flow rate was 0.2 ml/min.  Column temperature was controlled at 55°C. The 
eluted peptides were introduced to an OrbiTrap Velos for mass spectrometry analysis. 
      Additionally, the mAb A samples were analyzed by a site-specific carbonylation peptide 
mapping method as previously described.
29
 Briefly, the carbonyls were derivatized by Girard's 
Reagent T (GRT). The hydrozones formed after the derivatization were then reduced by sodium 
borohydride (to a final concentration of 100 µM). Subsequently, the samples were reduced (by 
DTT), S-carboxymethylated, and digested with trypsin at a trypsin-to-substrate ratio of 1:50 
(weight to weight). The digestion was carried out in 25 mM Tris-HCl, 2 mM CaCl2, pH 8.2, at 
37°C for 4 hours, and was stopped by addition of TFA to a final concentration of 0.3% (v/v). The 
digested samples were separated on a BEH C18 column (300 Å, 1.7 µm, 2.1x150 mm). Solvent 
A was 0.1% TFA in water. Solvent B was 0.09% TFA in acetonitrile. For the separation, a step 
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gradient was used as follows: 1-20% B in 16 minutes, 20-40% B in 35 minutes, and then 40-57% 
B in 15 minutes. Flow rate was 0.3 ml/min. Column temperature was controlled at 60°C. The 
eluted peptides were introduced to an OrbiTrap Velos for mass spectrometry analysis. 
           The mass spectrometry analysis was performed in positive mode with an electrospray 
voltage of 4.0 kV and a capillary temperature of 250°C. The MS data acquisition was in a data-
dependent mode, where a full MS survey scan was followed by MS2 scans of the 9 most intense 
ions in the full MS spectrum. To acquire MS
2
 spectra, the normalized collision energy was 35 
with an activation time of 10 milliseconds. To identify oxidation products, the mass spectrometry 
data were analyzed by database searching using the Proteome Discover software. The search 
results were then manually investigated to confirm the identification of the oxidation products. 
The relative quantification of these oxidation products was performed by extracted ion 
chromatography as previously described.       
Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS) 
          Samples were prepared in 20 mM histidine acetate buffer, pH 6.2 ± 0.2, at a concentration 
of 3 mg/mL. HDX-MS experiments were performed with a fully automated LEAP RTC system 
(Leap Technologies, Carr, NC) coupled with an Orbitrap Elite mass spectrometer (Thermo 
Fisher Scientific, San Jose, CA). For deuterium labeling, three samples were incubated in 
deuterium buffer (20 mM histidine acetate buffer in D2O, pH 6.2 ± 0.2) at 20°C. For blank 
control, each sample was diluted into H2O buffer instead of D2O. Duplicate data points were 
taken after 0.5, 1, 10, 60, 240 minutes of deuterium incubation. The exchange reaction was 
quenched by reducing the pH to 2.2 with 8 M urea and 1 M TCEP·HCl. Each quenched sample 
was immediately injected onto an immobilized protease XIII/pepsin column (2.0 × 30 mm) for 
on-line digestion in 0.1 % formic acid and 0.04 % TFA in H2O (pH 2.3) at 100 µL/min. Then, 
88 
the digested peptides were desalted on a trapping column (Waters ACQUITY BEH C18 
VanGuard Pre-column 2.1x5 mm) and further separated on an analytical column (BEH C18 
column 1.0 × 50 mm). A separation gradient from 5% to 50% B (A: 0.1 % formic acid and 0.04 
% TFA in H2O; B: 0.1 % formic acid, 0.04 % TFA in acetonitrile) over 12 minutes was provided 
by a Thermo Ultimate 3000 HPLC (Thermo Fisher Scientific, San Jose, CA). On-line digestion 
and separation were performed at 0°C to minimize back-exchange. The eluate was introduced 
into an Orbitrap Elite for measurement. Mass spectra were collected over a range of m/z 300 ~ 
1800 at a resolving power setting of 60,000 at m/z 400. Peptides identifications were based on 
accurate masses together with MS/MS fragmentation by Mascot search.
36
 Deuterium 
incorporation was determined by use of EXMS.
37
 Averaged deuterium uptake difference 
(ARDD) was calculated by a modified python script
38
 and mapped onto homologous crystal 
structures to visualize overall HDX results. No back-exchange corrections were made. All 
deuterium uptake levels are reported in relative values.        
RESULTS 
Charge Heterogeneity of the Unstressed and Oxidized mAb A Samples 
         The unstressed and oxidized mAb A samples were analyzed by ion exchange 
chromatography to evaluate the impact of metal-catalyzed oxidation on the charge heterogeneity 
profile. As shown in Figure 1 and Table 1, compared to the unstressed mAb A, the oxidized mAb 
A showed increased acidic and basic variants and a decreased main peak. The decrease in the 
main peak (by ~40%) in the oxidized mAb A appeared to be largely due to the increase in the 
acidic variants. Interestingly, despite the large change in the relative distribution, the overall 
charge profiles of the two mAb A samples are similar. No distinctive new peak was observed in 
the oxidized mAb A. To characterize the oxidation-induced acidic charge variants in the oxidized 
89 
mAb A, we collected the acidic and main peak fractions from the unstressed and the oxidized 
mAb A samples. Subsequently, the collected fractions were re-analyzed by ion exchange 
chromatography and shown to be highly purified (Figure 2). 
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Figure 1. Ion exchange chromatograms of the unstressed and the oxidized mAb A samples 
 
mAb A Acidic (%) 
Main Peak 
(%) 
Basic (%) 
Unstressed 18.2 77.6 4.2 
Oxidized 51.3 39.8 8.9 
 
Table 1. Charge distribution of the unstressed and the oxidized mAb A samples 
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Figure 2. Ion exchange chromatogram of the acidic and main peak fractions from (A) the 
unstressed and (B) the oxidized mAb A samples. 
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Size Heterogeneity of mAb A Fractions 
           Metal-catalyzed oxidation is known to generate size variants, such as low- and high- 
molecular weight species (LMWS and HMWS), on mAbs.
39-42
 These size variants could affect 
antibody charge heterogeneity since their charge and/or hydrophobicity characteristics may be 
different from those of the main peak species. We therefore characterized the collected mAb A 
fractions by SEC (Figures 3 and 4). For the LMWS, a higher level of LMWS was observed in the 
acidic fraction than in the main peak fraction, for both the unstressed and the oxidized mAb A, 
which suggests a preferential enrichment of LMWS in the acidic region. Interestingly, one of the 
LMWS (the shoulder peak eluted at ~16 minutes) was more abundant in the acidic fraction of the 
oxidized mAb A than in the acidic fraction of the unstressed mAb A. This LMWS was likely 
des-Fab (an antibody form that contains Fc and one Fab),
43
 which could come from metal-
catalyzed antibody fragmentation.
42
 For the HMWS, a similar level of HMWS was observed in 
the acidic and the main peak fractions of the unstressed mAb A. By contrast, a lower level of 
HMWS was observed in the acidic fraction than in the main peak fraction of the oxidized mAb 
A. The distribution pattern of the HMWS suggests that the oxidation-induced HMWS is unlikely 
a source of the increased acidic charge heterogeneity.  
             Quantitatively, as shown in Figure 4, for the oxidized mAb A, the increase in the level of 
LMWS in the acidic fraction over that in the main peak fraction is relatively small (less than 4%, 
Figure 4), which cannot fully explain the relatively large increase in the level of acidic charge 
variants (greater than 30%, table 1) after metal-catalyzed oxidation. In addition, for the oxidized 
mAb A, the effects of the increased LMWS and decreased HMWS are cancelled out between the 
acidic and main peak fractions, which suggests that the changes in mAb A size heterogeneity 
93 
after metal-catalyzed oxidation are not a major factor for the increased acidic charge 
heterogeneity.    
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Figure 3. Size exclusion chromatograms of the acidic and main peak fractions of the oxidized 
and the unstressed mAb A samples 
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Figure 4. Relative peak areas of the HMWS and LMWS in the acidic and main peak fractions of 
the oxidized and the unstressed mAb A samples 
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Molecular Mass of mAb A Fractions 
          The collected fractions were characterized by intact/reduced molecular mass analysis to 
identify species that may explain the increased acidic charge heterogeneity. In the deconvoluted 
mass spectra of intact mAb A samples (Figure 5), the unstressed mAb A fractions have four 
major species, corresponding to masses of 145,743, 145,905, 146,066, and 146,225 Da, 
respectively, which are consistent with the theoretical masses of various glycan forms (G0/G0, 
G0/G1, G1/G1 or G0/G2, and G1/G2, respectively) of intact mAb A. It is worth noting that, 
compared to the mass spectrum of the unstressed main peak fraction, the mass spectrum of the 
unstressed acidic fraction showed an elevated baseline, where a large unstructured peak appears 
to be present. This indicates that more species may be present in low abundance. For the 
oxidized acidic and main peak fractions, the four major species became much less prominent. In 
particular, for the oxidized acidic fraction, it appears that only the unstructured baseline peak was 
present. It is possible that some of the species observed in the oxidized acidic fraction may also 
be present in the unstressed acidic fraction. However, it is difficult to accurately determine the 
masses of these species due to poor MS resolution.   
        In the deconvoluted mass spectra of reduced mAb A samples (Figure 6), the unstressed 
mAb A fractions have three major mass species, 22400, 50486, 50648, and 50809 Da, which are 
consistent with the theoretical masses of the reduced light chain and heavy chain (in three glycan 
forms, G0, G1, and G2) of mAb A. It should be noted that while the three heavy chain glycan 
forms could theoretically lead to six combinations of glycan forms for the intact mAb A, only 
four of the glycan forms are the major species observed in the intact mAb A (Figure 5). The 
oxidized mAb A fractions contain additional species with one or multiple additions of +16 Da to 
the light chain or heavy chain, suggesting that various oxidation products may be present. 
97 
However, these additional species appear to be present in similar relative intensities in the acidic 
and main peak fractions of the oxidized mAb A (Figure 6).          
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Figure 5. Deconvoluted mass spectra of the intact mAb A fractions 
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Figure 6. Deconvoluted mass spectra of the reduced light chain (A) and heavy chain (B) of mAb 
A fractions 
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Peptide Mapping of Reduced and S-Carboxymethylated mAb A Fractions 
           To identify the chemical modifications or degradation products that contributed to the 
increased acidic charge heterogeneity, mAb A fractions were analyzed by conventional tryptic 
peptide mapping. The peptide map UV profiles of the acidic fraction from the oxidized mAb A 
and the main peak fraction from the unstressed mAb A (as a control) were compared. As shown 
in Figure 7 and Table 2, a total of 21 peaks showed different absorbance intensity between the 
two peptide maps. The peaks that showed decreased peak intensity in the acidic fraction are 
identified as peptide fragments or digest artifacts, which are unlikely the source of the increased 
acidic charge heterogeneity. The peaks that showed increased peak intensity in the acidic fraction 
are identified as oxidation products of methionine (HC M256 and HC M432), tryptophan (HC 
W53), and threonine (HC T28) residues, or digest artifacts, as summarized in Table 2. 
Identification of the HC T28 threonine carbonylation product, a ketone, was based a 
characteristic mass shift of -2 Da at HC T28, where a consistent loss of 2 Da was observed in the 
y ions starting from y4 and in the b ions starting from b11 in the MS
2
 spectrum (Figure 8).   
           The levels of the identified methionine, tryptophan, and threonine oxidation products in 
the respective mAb A fractions were subsequently quantified by using the extracted ion 
chromatograms As shown in Figure 9, relatively small increases were observed in M256 or 
M432 oxidation levels between the acidic and main peak fractions of the unstressed or the 
oxidized mAb A. By contrast, relatively large increases were observed in Trp53 oxidation (+16 
Da and +4 Da products) levels between the acidic and main peak fractions of the unstressed or 
the oxidized mAb A (Figure 10). For example, the level of oxindolyalanine product (+16 Da) is 
almost five-fold higher in the acidic fraction than in the main peak fraction of the oxidized mAb 
A. A similar distribution pattern was observed for HC T28 carbonylation, where a higher level 
101 
was found in the acidic fraction than in the main peak fraction of oxidized mAb A (Figure 11). 
While these oxidation products showed various degrees of enrichment in the acidic fraction, 
these oxidation products do not provide satisfactory explanation for the oxidation-induced acidic 
charge heterogeneity, since these oxidation products are neutral in charge and are not expected to 
change the net charge of mAbs.   
           Several types of degradation products from metal-catalyzed oxidation, such as aspartic 
acid from the oxidation of histidine and cysteic acid from the oxidation of cysteine, can introduce 
negative charges into mAbs. These degradation products were investigated for their presence in 
mAb A acidic fractions. Based on tryptic peptide mapping, we found a Cys-to-Cysteic acid 
product at Cys230 in the hinge region and three His-to-Asp products in the Fc region (Table 3). 
Identification of the His-to-Asp products was based on a characteristic mass shift of -22 Da at the 
respective histidine residues. For example, for the HC H289-to-Asp product, a consistent loss of 
22 Da was observed in the y ions starting from y4 and in the b ions starting from b11 in the MS
2
 
spectrum (Figure 12). These unique changes in the fragmentation ion masses allow unambiguous 
identification of the His-to-Asp product, considering also that no other histidine modification 
produces a mass shift of -22 Da. Identification of the C230-to-Cysteic acid product was based on 
a characteristic mass shift of +48 Da, which started from y23 ion in the MS
2
 spectrum (Figure 
13). After identification of these acidic degradation products, we quantified the relative level of 
these products in the acidic and main peak fractions by using the extracted ion chromatograms. 
As shown in Table 3, we found that these acidic products were preferentially localized in the 
acidic fraction of the oxidized mAb A. However, these levels were considerably lower than those 
of the methionine, tryptophan, and threonine oxidation products. 
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Figure 7. Comparison of the tryptic peptide maps of the oxidized acidic fraction and the 
unstressed main peak fraction (as a control). (A) 0 to 25 minutes; (B) 25 to 50 minutes.   
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No. Retention Time (min) Observed Mass (m/z) Theoretical Mass (m/z) Peptide ID Comment
1 3.90 656.3842 656.3838 K.AKGQPR.E Missed Cleavage (HC K344/HC G345)
2 12.80 586.3308 586.3307 R.PGGSLR.L Tryptic Cleavage before Proline
3 18.14 851.4291 851.4291 K.DTLM(ox)ISR.T HC M256 Oxidation
4 19.29 1357.7057 1357.7070 EVQLVQSGGGVER.P Tryptic Cleavage before Proline
5 21.41 952.9763 952.9748 R.EPQVYTLPPSREEMTK.N Missed Cleavage
6 22.31 655.8461 655.8462 L.TVLHQDWLNGK.E Nonspecific cleavage (HC L310/HC T311)
7 22.76 1409.6274 1409.6267 R.WQQGNVFSCSVM(ox)HEALHNHYTQK.S HC M432 Oxidation
8 22.93 1094.9992 1094.9988 N.VFSCSVMHEALHNHYTQK.S Nonspecific cleavage (HC N425/HC V426)
9 26.42 1146.1162 1146.1164 K.PGQAPVLVIYGANNRPSGIPDR.F Tryptic Cleavage before Proline
10 27.70 682.8174 682.8171 K.FNWYVDGVEVH.N Nonspecific cleavage (HC H289/HC N290)
11 28.99 1164.0507 1164.0534 K.GLEWVSGINW(ox)QGGSTGYADSVK.G HC W53 Oxidation (+16 Da)
12 29.56 1158.0519 1158.0509 K.GLEWVSGINW(ox)QGGSTGYADSVK.G HC W53 Oxidation (+4 Da)
13 32.15 1302.1509 1302.1501 R.SYYASWYQQKPGQAPVLVIYGAN.N Nonspecific cleavage (LC N50/LC N51)
14 34.03 1019.9672 1019.9661 K.THTCPPCPAPELLGGPSVF.L Nonspecific cleavage (HC F245/HC L246)
15 36.99 829.9015 829.9011 K.TTPPVLDSDGSFFLY.S Nonspecific cleavage (HC Y411/HC S412)
16 37.44 1669.3005 1669.3007 K.SCDKTHTCPPCPAPELLGGPSVFLFPPKPK.D Missed Cleavage (HC K226/HC T227)
16 37.48 1091.9667 1091.9646 R.LSCAASGFT(-2H)FDDYAMSWVR.Q HC T28 Carbonylation (-2 Da) 
17 38.65 1423.7168 1423.7164 K.THTCPPCPAPELLGGPSVFLFPPKPK.D Hinge Tryptic Peptide
18 39.66 1651.1672 1651.1643 H.TFPAVLQSSGL------ICNVNHKPSNTK.V Nonspecific cleavage (HC H172/HC T173)
19 41.08 1760.5548 1760.5558 N.SGA------ICNVNHKPSNTK.V Nonspecific cleavage (HC N163/HC S164)
20 47.32 1547.5137 1547.5125 K.DYFPE------VNHK.P Tryptic Cleavage before Proline
21 51.33 N/A N/A N/A Poor MS data  
Table 2. Assignment of the peaks identified on the tryptic peptide maps of the acidic and main 
peak fractions (as shown in Figure 6). 
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Figure 8. MS2 spectra of (A) a threonine containing peptide and (B) its oxidation product and 
assignment of the fragment ions 
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Figure 9. (A) Methionine and its oxidation product (methionine sulfoxide); (B) relative levels of 
methionine oxidation products in mAb A fractions based on the extracted ion chromatograms  
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Figure 10. (A) Tryptophan and its oxidation products; (B) relative levels of tryptophan oxidation 
products in mAb A fractions based on the extracted ion chromatograms (note: +32Da oxidation 
products were not detected)  
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Figure 11. Relative levels of threonine oxidation product (-2Da, ketone) in mAb A fractions 
based on the extracted ion chromatograms  
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Figure 12. (A) Histidine and one of its oxidation products (aspartic acid); (B) MS2 spectrum of a 
His containing peptide (HC His289); (C) MS2 spectrum of the oxidized peptide containing a 
His-to-Asp (-22Da) modification and assignment of the fragment ions  
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Figure 13. (A) Cysteine and one of its oxidation products (cysteic acid); (B) MS2 spectrum of a 
Cys containing peptide (HC Cys230); (C) MS2 spectrum of the oxidized peptide containing a 
Cys-to-Cysteic Acid (+48Da) modification and assignment of the fragment ions  
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Oxidation Products Level (%) in 
the Unstressed 
(Main Peak) 
Level (%) in the 
Unstressed 
(Acidic) 
Level (%) in 
the Oxidized  
(Main Peak) 
Level (%) in 
the Oxidized 
(Acidic) 
HC C230-to- 
Cysteic Acid 
0.0 0.0 0.4 1.1 
HC H228-to-D 0.0 0.0 0.1 0.2 
HC H289-to-D 0.0 0.0 0.2 0.8 
HC H437-to-D 0.4 0.4 0.4 1.7 
 
Table 3. Relative levels of histidine-to-aspartic acid oxidation in the collected fractions by 
peptide map (based on extracted ion chromatograms)  
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Total Protein Carbonylation Level of mAb A Fractions 
           Enrichment of HC T28 carbonylation product, a ketone, in the acidic fraction of the 
oxidized mAb A suggests that protein carbonylation could be a source of the oxidation-induced 
acidic charge heterogeneity. We therefore measured the protein carbonylation content of mAb A 
fractions using a total protein carbonylation assay (CALY).
27
 As shown in Figure 14, the protein 
carbonylation level is consistently higher in the acidic fraction than in the main peak fraction for 
both the unstressed and the oxidized mAb A. This observation supports that metal-catalyzed 
carbonylation contributes to the oxidation-induced acidic charge heterogeneity. Interestingly, 
compared to the unstressed mAb A, oxidized mAb A showed highly increased protein 
carbonylation content in both the acidic and the main peak fractions, whose levels greatly 
exceeded that of HC T28 carbonylation product quantified by peptide mapping. This observation 
suggests that carbonylation products formed at other residues may be present, and that these 
products may not be readily detected by the conventional tryptic peptide mapping analysis. 
Therefore, efforts aimed at optimization of a peptide map for relative quantitation of site-specific 
carbonylation is described in the following sections.        
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Figure 14. Protein carbonylation level of the acidic and main peak fractions from the unstressed 
and the oxidized mAb A samples (error bars represent the standard deviation from three 
measurements) 
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Optimization of a Peptide Mapping Method for Relative Quantitation of Site-Specific 
Carbonylation  
            A peptide mapping method was previously developed to identify site-specific 
carbonylation on mAbs.
29
 In this method (Figure 15), Girard’s Reagent T (GRT), a hydrazide 
that contains a permanently charged quaternary ammonium, was used to derivatize carbonyl 
groups (aldehydes and ketones) and to enhance the detection and identification of carbonyl 
peptides.
29
 However, it is not known if the method condition is optimal for relative quantitation 
purposes. We therefore investigated several method conditions that could affect relative 
quantitation of site-specific carbonylation.  
          We first investigated peptide mapping digestion pH and digestion time since the potential 
hydrolysis of the quaternary ammonium group of GRT (to form a tertiary amine) at pH 8.2
44
 
during enzymatic digestion can lead to under-quantification of site-specific carbonylation. The 
concern over the quaternary ammonium hydrolysis is based on the observed pH-rate profiles of 
several quaternary ammonium salts amines in basic solutions.
44
 Therefore, two digestion buffers, 
25 mM Tris-HCl, 2 mM CaCl2, pH 8.2 and 20 mM MOPS buffer, pH 7.0, were evaluated. The 
digestion was carried out at 37ºC for 2, 4, and 17 hours, respectively, in both buffers. A highly 
oxidized mAb A was used as a test sample, and six carbonylation sites were evaluated for their 
relative carbonylation levels against the different digestion times and pHs.   
            As shown in Figure 16, for each buffer, very minor differences were observed in the 
relative level of carbonylation for all six peptides after 2, 4, and 17 hours of digestion, 
respectively. This suggests that the quaternary ammonium of GRT is relatively stable in the 
digestion buffers at 37ºC for up to 17 hours. With different digestion buffers (pH 8.2 vs pH 7.0), 
very minor differences were observed in the relative levels of carbonylation, respectively, for 
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five of the peptides. However, higher levels of carbonylation were observed for carbonylation 
peptide LC K157 with Tris buffer (pH 8.2) than with MOPS buffer (pH 7.0) for all digestion 
times. This observation is not consistent with quaternary ammonium hydrolysis since the 
hydrolysis rate is usually greater with higher pHs.
44
 Therefore, it is unlikely that quaternary 
ammonium hydrolysis led to the observed differences in LC K157 carbonylation level between 
pH 8.2 and pH 7.0. Overall, relative quantitation of site-specific carbonylation appeared to be 
minimally affected by the suspected hydrolysis of the quaternary ammonium of GRT. We 
subsequently selected 25 mM Tris-HCl, 2 mM CaCl2 (pH 8.2) as the digestion buffer and 4 hours 
as the digestion time.      
            We next investigated the sodium borohydride reduction conditions. This investigation is 
based on two considerations. First, the hydrazides formed after GRT derivatization are not stable 
under the chromatographic condition (low pH and high temperature) of peptide mapping. 
Second, sodium borohydride reduction is a necessary step that converts hydrazides to amines 
(more stable than hydrazides). Incomplete reduction of the hydrazides by sodium borohydride 
can therefore lead to under-quantification of site-specific carbonylation. In the method that we 
previously developed,
29
 the optimal sodium borohydride concentration for reduction is not 
known. In this investigation, in order to identify an optimal sodium borohydride concentration, 
we evaluated 0, 10, 40, 100, and 150 µM sodium borohydride for their effect on the relative 
carbonylation level at the six carbonylation sites.       
           As shown in Figure 17, the sodium borohydride concentrations used in the reduction step 
critically affected relative quantitation of site-specific carbonylation. The relative level of 
carbonylation at HC R19 appeared to plateau as the sodium borohydride concentration reached 
10 µM; for the other five carbonylation sites, their relative levels appeared to plateau as the 
 115 
sodium borohydride concentration reached 100 µM. Therefore, we selected 100 µM sodium 
borohydride as a final condition for the reduction of hydrazides formed after GRT derivatization.   
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Figure 15. The workflow for characterizing site-specific carbonylation by peptide mapping  
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Figure 16. Effects of digestion pH and time on relative quantitation of carbonylation  
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Figure 17. Effect of sodium borohydride reduction on the relative quantitation of carbonylation  
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Characterization of Site-Specific Carbonylation Products 
         Using the optimized carbonylation peptide mapping method, we identified the 
carbonylation sites on mAb A by database searching and manual interpretation of the MS data. 
For example, database searching indicated that HC K98 was a carbonylation site. The full MS of 
the observed carbonylation peptide showed an increase of +114 Da in mass compared to that of 
the unmodified peptide. The mass shift of +114 Da is consistent with GRT derivatization at HC 
K98, which also results in a trypsin miscleavage site. Additionally, the MS
2
 data (Figure 18) 
showed a mass shift of +114 Da in the y ions starting from y9, while no such mass shift was 
observed in y4, y5, and y6. Based on the MS
2
 data, the +114 Da modification can only occur at 
HC C96, HC A97, or HC K98. Given that there is no known +114 Da modification of Cys 
(carboxymethylated) or Ala residue, HC K98 was therefore assigned as a carbonylation site. As 
shown in Table 4, a total of 16 carbonylation sites were identified on mAb A, which include 4 
arginine sites, 3 lysine sites, 8 threonine sites, and 1 proline site. Arginine and lysine 
carbonylation result in loss of positive charges on their side chains, which can be a source for the 
oxidation-induced acidic charge variants.       
          We investigated the distribution of site-specific carbonylation products in mAb A fractions 
by extracted ion chromatography. As shown in Table 4, for the oxidized mAb A, all of the site-
specific carbonylation products showed a higher level in the acidic fraction than in the main peak 
fraction. The enrichment of the carbonylation products in the acidic fraction does not seem to 
depend on the type (aldehyde vs. ketone) or the location of these products on mAb A. 
Surprisingly, threonine carbonylation is the predominant carbonylation product enriched in the 
acidic fractions, while arginine and lysine carbonylation products are significantly less abundant. 
In the acidic fraction of oxidized mAb A, the total level of lysine and arginine carbonylation 
 120 
products is ~ 2%, while the total level of threonine carbonylation products is 39%. This 
distribution pattern for the different carbonylation products indicates that threonine carbonylation 
is a major source of the induced acidic charge heterogeneity after metal-catalyzed oxidation.  
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Figure 18. MS
2
 spectrum of a GRT-derivatized carbonylation peptide (HC K98) and assignment 
of the fragment ions  
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Identified 
Carbonylation 
Site 
Carbonylation 
level (%) in 
the 
Unstressed 
(Main Peak) 
Carbonylation 
level (%) in 
the 
Unstressed 
(Acidic) 
Carbonylation 
level (%) in 
the Oxidized  
(Main Peak) 
Carbonylation 
level (%) in 
the Oxidized  
(Acidic) 
HC R13 0.0 0.0 0.0 0.2 
HC R19 0.0 0.0 0.0 0.1 
HC T28 0.0 0.1 11.8 18.7 
HC T58 0.0 0.0 2.2 2.7 
HC K65 0.0 0.0 0.0 0.1 
HC R87 0.0 0.0 0.0 0.3 
HC K98 0.0 0.1 0.1 0.7 
HC R104 0.0 0.0 0.0 0.1 
HC T115 0.1 0.3 5.3 6.4 
HC T139 0.0 0.2 0.6 2.5 
HC T227 0.0 0.0 1.7 3.7 
LC T4 0.0 0.0 1.2 1.7 
LC P7 0.0 0.0 0.1 0.2  
LC T117 0.0 0.0 1.0 2.0 
LC T132 0.0 0.0 1.0 1.3 
LC K157 0.0 0.0 0.0 0.2 
 
Table 4. Relative levels of site-specific carbonylation in mAb A fractions by peptide map (based 
on extracted ion chromatograms) 
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Characterization of Additional Oxidation Products  
           Aldehydes generated by metal-catalyzed oxidation can be further oxidized to carboxylic 
acids. For example, glutamic semialdehyde (proline- and arginine-derived carbonyl product) can 
be oxidized to glutamic acid;
45
 adipic semialdehyde (lysine-derived carbonyl product) can be 
oxidized to adipic acid.
45
 Formation of these carboxylic acids can increase acidic charge 
heterogeneity of proteins. Therefore, we further characterized mAb A fractions to understand if 
these carboxylic acid products could be a source of the induced acidic charge heterogeneity. 
           From peptide mapping of the reduced and S-carboxymethylated mAb A fractions, we 
observed formation of glutamic acid but not adipic acid (Table 5). Identification of an arginine-
to-glutamic acid product at HC R13 was based on the MS
2
 spectrum of a doubly charged peptide 
ion of m/z 949.4828, which showed a mass shift of -27 Da (to that of the unmodified peptide) in 
the y ions starting from y7 and in the b ions starting from b13 (Figure 19). The unique mass 
shifts allow us to pinpoint the arginine-to-glutamic acid modification at HC R13. Similarly, 
identification of a proline-to-glutamic acid product at LC P7 was based on the MS
2
 spectrum of a 
doubly charged ion of m/z 951.9915, where a mass shift of +32 Da (in comparison to those from 
the unmodified peptide) was observed in the y ions starting from y11 (Figure 20), allowing us to 
pinpoint the proline-to-glutamic acid at LC P7. 
          Interestingly, multiple proline-to-pyroglutamic acid (but not proline-to-glutamic acid) 
products were observed on mAb A hinge peptide, THTCPPCPAPELLGGPSVFLFPPKPK 
(proline-to-pyroglutamic acid sites are underlined/bold). Identification of these oxidation 
products was supported by their MS
2
 spectra (Figure 21), which have the same y ions from y5 to 
y14. In addition, a terminal or penultimate y ion (from the N-terminal side) was present in the 
MS
2
 mass spectra, which allows the assignment of the mass shift/modification to the proline 
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residue at the N-termini of these peptides (Figure 21). Formation of these proline-to-
pyroglutamic acid products requires cleavage of the hinge peptide (between the proline residue 
and its preceding residue). Given that the preceding residues (Cys230, Pro231, Cys233, and 
Ala235, respectively) are not lysine or arginine, it was likely that these products were generated 
by metal-catalyzed oxidation. It should be pointed out that the proline-to-pyroglutamic acid 
modification does not introduce a change in the net charge at the modification site. However, the 
oxidation-induced cleavage introduces a C-terminal carboxylic acid to the preceding residue, 
which is expected to increase acidic charge heterogeneity of mAb A.     
          Relative quantitation by using the extracted ion chromatogram shows that the glutamic 
acid products are not a major source of the induced acidic charge heterogeneity (Table 5), as 
their levels are not more than 0.1% in the main peak or the acidic fractions of unstressed and 
oxidized mAb A. By contrast, up to 0.7% proline-to-pyroglutamic acid product was observed in 
the acidic fraction of the oxidized mAb A. Furthermore, for the oxidized mAb A, higher levels of 
proline-to-pyroglutamic acid products were consistently observed in the acidic fraction than in 
the main peak fraction (Table 5).  
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Figure 19. (A) Arginine and one of its oxidation products (glutamic acid); (B) MS
2
 spectrum of 
an Arg containing peptide (HC R13); (C) MS
2
 spectrum of the oxidized peptide containing an 
Arg-to-Glu (-27 Da) modification and assignment of the fragment ions 
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Figure 20. (A) Proline and one of its oxidation products (glutamic acid); (B) MS
2
 spectrum of a 
Pro containing peptide (LC P7); (C) MS
2
 spectrum of the oxidized peptide containing a Pro-to-
Glu (+32 Da) modification and assignment of the fragment ions 
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Figure 21. MS
2
 spectra of hinge region peptides that contain a P-to-pE oxidation product (A: HC 
P231; B: HC P232) and assignment of the fragment ions  
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Figure 21. MS
2
 spectra of hinge region peptides that contain a P-to-pE oxidation product (C: HC 
P234; D: HC P236) and assignment of the fragment ions  
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Oxidation 
Products 
Level (%) in 
the 
Unstressed 
(Main Peak) 
Level (%) in 
the 
Unstressed 
(Acidic) 
Level (%) in 
the 
Oxidized 
(Main Peak) 
Level (%) 
in the 
Oxidized 
(Acidic) 
HC R13-to-E 0.0 0.0 0.0 0.1 
HC R104-to-E 0.1 0.1 0.0 0.1 
HC P231-to-pE 0.0 0.0 0.2 0.4 
HC P232-to-pE 0.0 0.0 0.3 0.5 
HC P234-to-pE 0.0 0.0 0.2 0.4 
HC P236-to-pE 0.0 0.0 0.5 0.7 
LC P7-to-E 0.0 0.0 0.1 0.1 
 
Table 5. Relative level of additional oxidation products in mAb A fractions by peptide map 
(based on extracted ion chromatograms)  
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Analysis of Conformational Dynamics of mAb A Fractions by HDX-MS  
           We investigated the conformational dynamics of the mAb fractions by H/D exchange 
experiments. As shown in Figure 22, minor differences were observed in deuterium uptakes near 
the HC M256 site, i.e., HC245-255 and HC248-255. Both peptides displayed increased dynamics 
in the acidic fraction of the stressed mAb A than the main peak fraction of the unstressed mAb A 
(as a control). However, no significant conformational difference was detected for peptides near 
HC T28, HC W53, HC T115, HC N319 (deamidation site located within an NG motif), HC 
N388 (deamidation site located within an NG motif), and HC M432. Therefore, our data indicate 
that it is unlikely that conformational factors play a major role in the oxidation-induced acidic 
charge heterogeneity.  
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Figure 22. Plots of deuterium uptake as a function of time for the unstressed main peak fraction 
(Black, as the control) versus the stressed acidic fraction of mAb A (Green), for near the 
following sites HC T28, HC W53, HC T115, HC M256, HC N319 (NG motif), HC N388 (NG 
motif) and HC M432.  
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DISCUSSION 
           This study applied a large array of analytical characterization methods to gain an in-depth 
understanding of the acidic charge heterogeneity induced by metal-catalyzed oxidation on a 
model IgG1 mAb. During the characterization, we found that the commonly used analytical 
characterization methods, such as molecular mass analysis, size exclusion chromatography, and 
peptide mapping after reduction and S-carboxymethylation, provided limited information on the 
oxidation-induced acidic charge variants. For example, from the molecular mass analysis, the 
deconvoluted mass spectra of the acidic and main peak fractions are almost identical (Figures 5 
and 6), making it difficult to link/attribute the oxidation-induced acidic charge heterogeneity to a 
particular species. From size exclusion chromatography, the increase in the LMWS levels and 
the decrease in the HMWS levels essentially cancelled out, which suggests that these changes in 
the size variants cannot be a major source for the oxidation-induced acidic charge heterogeneity. 
Based on conventional tryptic peptide mapping, two of the predominant degradation products 
enriched in the acidic fractions were identified as Fc methionine sulfoxide and oxidized 
tryptophan in the CDR. Since methionine and tryptophan oxidation products are not expected to 
affect the net charge of mAbs, these oxidation products do not provide a satisfactory explanation 
for the oxidation-induced acidic charge heterogeneity. Specifically, for the Fc methionine 
oxidation products, conflicting observations have been reported on their distribution in mAb 
charge variant fractions. Chumsae et al. showed that Fc methionine oxidation products induced 
by tert-butyl hydroperoxide (tBHP) localized to the basic fraction.
46
 By contrast, Ponniah et al. 
reported higher levels of Fc methionine oxidation products in the enriched acidic fraction 
47
 
Hintersteiner et al. hypothesized that conformational changes could affect interactions between 
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the column and the charge residues/species adjacent to these oxidation products.
48
 However, to 
date, no conformational data are available to support this hypothesis.  
             To gain a better understanding of the nature of the oxidation-induced acidic charge 
variants, we took a targeted approach and investigated acidic degradation products
45
 from metal-
catalyzed oxidation that could be present in the acidic fraction. A cysteine-to-cysteic acid 
product (HC C230) and a histidine-to-aspartic acid product (HC H228) were identified in the 
hinge region, which are consistent with the degradation products reported in a human IgG1 under 
similar oxidation conditions.
31
 Two additional histidine-to-aspartic acid products were identified 
in the CH2 (HC H289) and CH3 (HC H437) domains. These two histidine oxidation sites were 
previously reported in a human IgG1 under light stress conditions, where +32 Da oxidation 
products were observed.
49
 Interestingly, no histidine-to-aspartic acid product was reported under 
the light stress condition.
49
 Additionally, while HC H289 was found to be the predominant 
oxidation (+32 Da) site under light stress,
49
 our study showed that HC H437 was the 
predominant histidine-to-aspartic acid degradation site. Our observation indicates that metal-
catalyzed oxidation shows different site preferences than light stress for histidine oxidation. It 
should be noted that cysteine-to-cysteic acid and the histidine-to-aspartic acid products are 
located in the conserved regions of IgG1. Formation of these products, therefore, may represent a 
general degradation pathway for the increased acidic charge heterogeneity of mAbs observed 
after metal-catalyzed oxidation.  
             Oxidative carbonylation is another degradation pathway that is expected to contribute to 
the acidic charge heterogeneity after metal-catalyzed oxidation, as formation of lysine- and 
arginine-derived carbonylation products (2-aminoadipic semialdehyde and glutamic 
semialdehyde) result in a loss of the positive charge on lysine and arginine side chains. On the 
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other hand, formation of threonine- and proline-derived carbonylation products (2-amino-3-
ketobutyrate and glutamic semialdehyde) should not change the net charge of a protein, and, 
therefore, these carbonylation products are not expected to be enriched in the acidic charge 
variants of mAbs. However, to date, no study has investigated the distribution of these carbonyl 
products in mAb charge variants.  
             It should be pointed out that the conventional peptide mapping analysis can readily 
detect the threonine carbonylation product (2-amino-3-ketobutyrate) but not the 
lysine/argining/proline carbonylation products (aminoadipic semialdehyde and glutamic 
semialdehyde). It is possible that these aldehyde products may not be as stable as the ketone 
product under the peptide mapping conditions. Thus, as previously discussed,
29
 identification of 
site-specific protein carbonyls (especially aldehyde products) often requires the derivatization of 
the carbonyl groups before the enzyme digestion. The commonly used derivation reagents are 
hydrazides, which react with carbonyls on proteins. The derivatization products are further 
stabilized by sodium borohydride reduction to form amines. However, for relative quantitation of 
site-specific carbonyls, an analytical challenge that has not been previously noted in the literature 
is the efficiency of the sodium borohyride reduction. As illustrated by this study, incomplete 
reduction of hydrazides resulted in underestimation of the relative levels, which is not ideal for 
characterizing the distribution of the carbonylation products in mAb A fractions. We therefore 
improved the sodium borohyride reduction condition to enable a consistent reduction of the 
hydrazides after the GRT derivatization. With the optimized reduction condition, the relative 
levels of threonine-derived carbonylation products obtained from the conventional peptide 
mapping and the GRT-derivitization peptide mapping methods were found to be similar (data not 
shown).     
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             By measuring the extent of mAb A carbonylation in the acidic and main peak fractions, 
we found that carbonylation products are enriched in the acidic fractions (Figure 14 and Table 4). 
The total protein carbonylation level correlated well with the sum of site-specific carbonylation 
levels (Figure 23). The orthogonal measurements further support that metal-catalyzed 
carbonylation contributes to the induced acidic charge heterogeneity. For the distribution of the 
carbonylation products, it is surprising that the predominant carbonylation products localized in 
the acidic fractions are threonine-derived carbonylation products but not lysine- or arginine-
derived carbonylation products, as commonly expected based on the literature.
50-54
 Given that 
threonine carbonylation is not expected to change the net charge of a protein, one hypothesis for 
the observed enrichment of threonine-derived carbonylation products in the acidic region could 
be due to concurrent formation of threonine-derived carbonylation products with lysine- and 
arginine-derived carbonylation products during metal-catalyzed oxidation, and subsequent co-
localization of these carbonyls in the acidic region. This hypothesis is based on the existing 
reports on the distribution pattern of protein carbonylation sites by Lv et.al.,
55
 which showed that 
carbonylation sites tend to cluster together, presumably near metal binding sites. However, not 
all threonine-derived carbonylation sites are close to a lysine- or arginine-derived carbonylation 
site on mAb A. Furthermore, lysine- and arginine-derived carbonylation products constitute only 
a small fraction of the total carbonyls (Table 4). Finally, all eight threonine-derived 
carbonylation products are found to be preferably localized in the acidic fraction regardless of 
their locations on mAb A. Thus, the concurrent formation hypothesis provides only a partial 
explanation. Clearly, further study will be necessary to fully understand the mechanism for the 
preferential enrichment of threonine-derived carbonylation products. Nevertheless, this study 
demonstrates that, at least for mAb A, threnonine-derived carbonylation products are a major 
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component of the oxidation-induced acidic charge heterogeneity after metal-catalyzed oxidation. 
It should be also pointed out that, different from the cysteine and histidine oxidation products, 
only a small portion of the carbonylation products are located in the conserved regions. This 
suggests that formation of these carbonylation products may be a molecule- or sequence- specific 
degradation pathway for the oxidation-induced acidic charge heterogeneity. 
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Figure 23. Correlation between the total protein carbonylation levels and the sum of site-specific 
carbonylation levels of the collected mAb A fractions. 
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            This study detected formation of glutamic acid from arginine and proline residues. The 
arginine- and proline-derived carbonylation products (glutamic semialdehyde) are likely the 
precursors, which are further oxidized to carboxylic acid. This study also detected formation of 
pyroglutamate from proline residues in the mAb A hinge region. To the best of our knowledge, 
these hinge fragmentation products have not been previously described. Surprisingly, no proline-
to-glutamic semialdehyde or proline-to-glutamic acid products were detected at these hinge 
proline sites. Three degradation mechanisms that do not involve oxidative carbonylation were 
therefore proposed, as illustrated in Figures 24-26 to explain the formation of these 
pyroglutamate products, where oxidation of pyrrolidine ring to pyroglutamate (via at least three 
possible oxidation mechanisms) is followed by hydrolysis of the peptide bond between 
pyroglutamate and the preceding residue. Considering that the hinge sequence is conserved for 
IgG1, formation of these pyroglutamate products should represent a general degradation pathway 
for the oxidation-induced acidic charge heterogeneity of mAbs after metal-catalyzed oxidation. It 
should be pointed out that the proposed mechanisms (Figures 24-26) are different from a 
mechanism for oxidative cleavage of prolyl peptides suggested by Uchida et al.,
56
 where a 2-
pyrrolidone product was formed at the C-terminus of a proline residue following the peptide 
bond cleavage (induced by the hydroxyl radical), and no pyroglutamate product was reported.
56
  
           In summary, this study presents for the first time a detailed characterization of the acidic 
charge variants induced by metal-catalyzed oxidation on mAbs. From the perspective of mAb 
product variant characterization, this study identified multiple degradation pathways and related 
degradation products as the source of the oxidation-induced acidic charge heterogeneity. To the 
best of our knowledge, many of the degradation products, such as histidine-to-aspartic acid, 
proline-to- pyroglutamate, and arginine-to-glutamic acid, are reported in mAbs for the first time. 
 139 
More importantly, this study discovered that metal-catalyzed carbonylation directly contributes 
to the formation of acidic charge variants of mAbs. This study also revealed that threonine-
derived carbonylation but not lysine- or arginine-derived carbonylation can be the predominant 
carbonylation product enriched in mAb acidic fractions. Identification and further 
characterization of these degradation products should help address increasing expectations from 
health authorities on physiochemical characterization of mAb product variants. Additionally, the 
findings from this study should help develop a targeted analytical control strategy to ensure the 
safety and efficacy of mAb products. Finally, from a bioprocessing perspective, this study further 
confirms our previous claim that metal-catalyzed oxidation represents a general degradation 
mechanism (like deamidation or glycation) that leads to increased acidic charge heterogeneity of 
mAbs. Therefore, this study points to a new area of product quality investigation/root cause 
analysis to assist mAb bioprocess development, where maintaining consistent mAb charge 
heterogeneity profile is highly desirable. 
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Figure 24. A proposed mechanism (#1) for the formation of proline-to-pyroglutamate product: 
oxidation of proline to pyroglutamate is followed by hydrolysis of the peptide bond between the 
preceding residue and pyroglutamate.  
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Figure 25. A proposed mechanism (#2) for the formation of proline-to-pyroglutamate product: 
oxidation of proline to pyroglutamate is followed by hydrolysis of the peptide bond between the 
preceding residue and pyroglutamate.    
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Figure 26. A proposed mechanism (#3) for the formation of proline-to-pyroglutamate product: 
oxidation of proline to pyroglutamate is followed by hydrolysis of the peptide bond between the 
preceding residue and pyroglutamate.    
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INTRODUCTION 
         During pharmaceutical development of recombinant monoclonal antibody (mAb) drug 
products, a major focus is identification of mAb candidates and formulations that provide 
suitable physical stability characteristics.
1
 In particular, it is necessary to control the formation of 
mAb aggregates in the products, since the aggregates could pose a safety risk to patients.
2-3
 The 
safety risk of mAb aggregates is often attributed to adverse immune responses potentially 
induced by the aggregates.
4
 Both innate and adaptive immune pathways could be involved.
5
 For 
the innate immune response, mAb aggregates may have repetitive structure motifs or patterns, 
which can directly activate B1 cells to generate low-affinity antibodies (such as IgM) against the 
aggregates.
5-6
 For the adaptive immune response, mAb aggregates may be recognized by antigen 
presenting cells and are then internalized, processed, and presented to the major 
histocompatibility complex (MHC).
5, 7
 The peptide epitope presented in the MHC activates naive 
T cells to form antigen-specific helper T cells, which subsequently trigger B cell activation and 
production of antigen-specific antibodies against the aggregates.
7
 To date, the exact factors that 
could lead to an immune response against mAb aggregates are not well understood. For example, 
in a study by Boll et al., mAb particles/aggregates with low levels of chemical modifications 
were not immunogenic in a transgenic mouse model.
8
 These particles/aggregates broke immune 
tolerance when extensive chemical modifications were present.
8
 However, many of these 
modifications are yet to be identified.
8
 It is therefore important to understand the nature and 
underlying mechanism of mAb aggregation, and to correlate the understandings with clinical 
experience or immunogenicity model system data, which will enable better assessment and 
control of the safety risk from mAb aggregates. 
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              Existing studies show that mAb aggregates can be generated by a large variety of stress 
conditions.
9-10
 The resulting aggregates often have different physicochemical properties and 
morphologies. Joubert et al. reported that among the 14 tested stress conditions, harsh 
mechanical stress generated the greatest number of subvisible particles, while thermal stress  
generated the greatest number of visible particles.
9
 From FTIR analysis, almost all aggregates 
displayed a certain degree of changes in secondary structure, where 90ºC treated mAb samples 
showed the greatest perturbation of the folded-β sheet structure.
9
 The 90ºC samples also showed 
the highest degree of change in tertiary structures, indicating that proteins were mostly unfolded 
in the aggregates from the 90ºC stress.
9
 Finally, these aggregates demonstrated different surface 
hydrophobicity and reversibility.
9
 Using similar stress conditions, Telikepalli et al. provided 
additional characterization of IgG1 mAb aggregates, and found that shaking stress generated 
mostly fibrillar particles, while stirring stress generated mostly spherical particles.
11
 
Interestingly, the aggregates generated by shaking and freeze–thaw did not display many 
differences in the biophysical characteristics compared with the unstressed mAb.
11
 The 
aggregates generated by stirring and heating, however, contained non-native disulfide cross-
links, intermolecular beta sheet content, and elevated surface hydrophobicity.
11
 Using a 
transgenic mouse model, Filipe et al. discovered that the different types of aggregates had 
different immunogenic potential.
4
 The aggregates produced by freeze-thaw are not 
immunogenic.
4
 However, the aggregates produced by metal-catalyzed oxidation are most 
immunogenic,
4
 which suggests that oxidative modifications may generate neo-epitopes on mAbs. 
Kijanka et al. reported that submicron size particles of a murine antibody are more immunogenic 
than its soluble oligomers or micron size particles, which shows that mAb aggregate size can 
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affect the immunogenic potential.
12
 These studies highlight the complexity of mAb aggregation 
and the importance to understand the nature of mAb aggregates.  
           Various mechanisms, including mAb self-association, interactions between unfolded or 
partially unfolded intermediates, and chemical degradations/crosslinks, have been proposed to 
explain mAb aggregation.
2, 13-14
 Through these mechanisms, intrinsic and extrinsic factors could 
influence the mAb physical stability profile. For the intrinsic factors, aggregation-prone motifs or 
hot-spots have been identified in mAb variable and constant domains.
15-17
 In particular, the 
complementarity determining regions (CDRs) could contribute to aggregation since the CDRs 
often contain hydrophobic and charged/polarizable residues required for antigen binding.
18
 The 
light chain CDR3 contains a glutamine/asparagine rich motif, that was also found in the 
aggregation prone regions on prion and amyloid proteins.
17
 In the constant domains, CL and CH2  
have conserved sequences (VVCLL and VVSVLTVL) rich in β-branched aliphatic residues 
(valine, leucine, isoleucine), which could contribute to aggregation.
17
 Chemical 
degradation/crosslinks, such as methionine oxidation in the Fc domain, intra- or inter-molecular 
disulfide scrambling, histidine oxidation/co-valent crosslinks, could alter antibody structure and 
thus lead to increased aggregation propensity.
10, 17
 For the extrinsic factors, various mAb 
formulation parameters, such as buffer type, ionic strength, and surfactant type/concentration, 
can influence mAb physical stability profiles.
14, 19
 For example, in an agitation study, with three 
IgG2 mAbs, Fesinmeyer et al. showed that the extent of mAb aggregation increased as the buffer 
anion size increased, while the cation size did not have any effect.
20
 Using several stress 
conditions, Telikepalli et al. showed that presence of sodium chloride in mAb solutions enhanced 
mAb aggregation.
11
 Under a shaking stress condition, Wang et al. showed that the effects of 
surfactants on two IgG1 mAbs depended on the surfactant type/concentration.
21
 At the lower 
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concentrations, these surfactants reduced the extent of mAb aggregation.
21
 However, at the 
higher concentrations, certain surfactants induced structural perturbation and were found to 
destabilize the mAbs.
21
   
            Considering that mAb aggregates generated by metal-catalyzed oxidation could 
potentially pose an immunogenic risk
4
 and that oxidation products themselves could contribute 
to immunogenicity, it is necessary to gain an in-depth understanding of the nature and 
mechanism of metal-catalyzed mAb aggregation. In particular, understanding the effects of 
chemical degradation products from metal-catalyzed oxidation on mAb aggregation could help 
to elucidate and address the potential immunogenicity risks. Among the various degradation 
products, oxidative carbonylation products, which primarily consist of aminoadipic 
semialdehyde (from lysine), glutamic semialdehyde (from arginine/proline), and 2-amino-3-
ketobutyric acid (from threonine),
22
 attracted a lot of interest since oxidative carbonylation 
products themselves can be immunogenic.
23-24
 Zafar et al. reported increased binding of 
carbonylated human serum albumin over unstressed human serum albumin by autoantibodies 
from systemic lupus erythematosus patients, and suggested that oxidative carbonylation could 
trigger autoantibody production.
24
 Oxidative carbonylation products have also been implicated in 
protein/mAb aggregation. Bee et al. reported that protein carbonylation levels in mAb aggregates 
generated on stainless steel microparticle surfaces increased four-fold.
25
 Interestingly, no 
methionine oxidation was observed in the aggregates.
25
 In a storage study, Purdie et al. reported 
a positive correlation between the relative extent of mAb carbonylation and mAb aggregation 
rate.
26
 From a theoretical perspective, Petrov and Zagrovic applied molecular dynamics 
simulations to understand the effect of oxidative carbonylation to protein structure and dynamics, 
and suggested that carbonylation of lysine and arginine residues can significantly increase the 
 156 
protein intrinsic aggregation propensity.
27
 While these studies support that oxidative 
carbonylation can contribute to protein aggregation, to date, a detailed understanding of the 
effects of oxidative carbonylation on mAb physical stability is still lacking.  
            This study investigates the effects of oxidative carbonylation on the physical stability of a 
model IgG1 antibody (mAb A) in several buffers. A commonly used stir stress system
9, 11
 was 
employed to compare the aggregation propensity between the unstressed and the carbonylated 
mAb A, which provided an initial assessment of the effects. The carbonylated mAb A samples 
were further analyzed for the extents of total protein carbonylation and site-specific 
carbonylation in the supernatants, after the mAb solutions were stirred for 1 day and 3 days (and 
subsequently centrifuged). This analysis helps understand if there is any preferential 
aggregation/precipitation of carbonylation products, which could reveal aggregation-prone 
carbonylation spots on mAb A. Other degradation products generated by metal-catalyzed 
oxidation, such as methionine sulfoxide and hydroxytryptophan,
28
 were also analyzed to 
understand their contributions to physical instability of mAb A in relation to oxidative 
carbonylation. From an extrinsic perspective, buffer ion types and ion strength in the mAb A 
solutions were studied to understand if these factors exacerbate or alleviate the effects of 
oxidative carbonylation. Specifically, three different anions, SO4
2-
, I
-
, and Cl
-
, from the 
Hofmeister series,
29
 were used to probe potential interactions between these anions and site-
specific carbonylation that may impact the physical stability of mAb A. Furthermore, the 
unstressed and the carbonylated mAb A were analyzed by differential scanning calorimetry 
(DSC) to identify any correlations between mAb A thermal stability and oxidative carbonylation, 
which provided a more comprehensive view on the effect of oxidative carbonylation. 
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MATERIALS AND METHODS 
Materials 
        The recombinant humanized IgG1 monoclonal antibody, mAb A, was produced at 
Genentech (South San Francisco, CA). Lucifer Yellow carbohydride dilithium salt (Lucifer 
Yellow CH), hydrogen peroxide solution (30% in water, w/w), ferrous sulfate, methionine, 
ethylenediaminetetraacetic acid (EDTA), sodium succinate, sodium borohydride, methanol, 
succinic acid, sodium phosphate (dibasic and monobasic), sodium chloride, sodium acetate, 
sodium sulfate, sodium iodide, acetic acid, sodium hydroxide solution (1 M in water), 2-(N-
morpholino)ethanesulfonic acid (MES), lithium hydroxide, reduced Triton X-100, 
(Carboxymethyl)trimethylammonium chloride hydrazide (Girard’s Reagent T, GRT), 
dithiothreitol (DTT), iodoacetic acid (IAA), calcium chloride, tris(hydroxymethyl) 
aminomethane (Tris), trifluoroacetic acid (TFA), potassium phosphate, and glycine were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). guanidinium hydrochloride (8 M in 
water) was purchased from Thermo Scientific (Waltham, MA, USA). TSK G3000 SWXL 
(7.8x300 mm) size exclusion column was purchased from Tosoh Bioscience (King of Prussia, 
PA, USA). Acetonitrile (ACN) was purchased from Burdick & Jackson (Muskegon, MI, USA). 
Sequencing-grade trypsin was purchased from Promega (Madison, WI, USA). ACQUITY UPLC 
Peptide BEH C18 (300 Å, 1.7 um, 2.1x150mm) column were purchased from Waters (Milford, 
MA, USA).   
Preparation of Carbonylated mAb A by Metal-catalyzed Oxidation  
        The carbonylated mAb A sample was prepared by metal-catalyzed oxidation as previously 
described.
30
 The oxidation reaction mixture consisted of mAb A, ferrous sulfate, and hydrogen 
peroxide at final concentrations of 5 mg/mL, 2 mM, and 10 mM, respectively. The mixture was 
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incubated at room temperature for 2 hours in 50 mM sodium succinate buffer (pH 6.5).  Excess 
amounts of methionine and EDTA were subsequently added to the mixture to stop the oxidation 
reactions. The carbonylated mAb A sample was then buffer exchanged into 10 mM sodium 
acetate (pH 5.0) with a 30 kDa Amicon filter (EMD Millipore, Burlington, MA, USA).   
Aggregation of mAb A by Stirring  
        A commonly used stir stress condition
9, 11
 was employed to generate mAb aggregates. The 
unstressed and carbonylated mAb A were buffer-exchanged into four different buffers: A) 10 
mM sodium acetate, 1 mM EDTA, pH 5.0; B) 150 mM sodium chloride, 10 mM sodium acetate, 
1 mM EDTA, pH 5.0; C) 150 mM sodium sulfate, 10 mM sodium acetate, 1 mM EDTA, pH 5.0; 
D) 150 mM sodium iodide, 10 mM sodium acetate, 1 mM EDTA, pH 5.0. The final mAb protein 
concentration was 2 mg/mL. These mAb solutions were stirred at a speed setting of 7 on a 
Corning stirring plate (Corning, NY, USA) with a magnetic stir bar (10 mm x 6 mm, Fisher 
Scientific, Hampton, NH, USA). After stirring for 1 and 3 days at room temperature, the mAb 
samples were centrifuged at 10,000 rpm for 10 minutes using a Beckman Coulter Centrifuge. For 
each sample, the supernatant was transferred to another tube for subsequent analyses.  
Analysis of mAb A Size Variants by Size Exclusion Chromatography 
        The size variants of mAb A samples were separated on a TSK G3000 SWXL (7.8x300 mm) 
size exclusion column with an isocratic flow of 0.5 mL/min. The SEC mobile phase was 200 
mM potassium phosphate, 250 mM potassium chloride, pH 6.2. The column temperature was set 
at 25°C and the HPLC autosampler temperature was at 8°C. The elution was monitored by UV 
absorbance at 280 nm. Sample injection volume was 40 µL. The relative peak areas as well as 
the total peak area of mAb A size variants were determined by manual integration of the size 
exclusion chromatograms using Agilent Chemstation software. 
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Total Protein Carbonylation Assay  
        Total protein carbonylation levels were determined using a previously described assay.
30
 
Briefly, for the analysis, mAb A samples were derivatized by Lucifer Yellow CH at a Lucifer 
Yellow CH-to-mAb molar ratio of 8,000:1. The derivatization reaction mixture was incubated at 
37°C for 16 hours in 50 mM lithium MES buffer, 1% Triton X-100, pH 6.0. After the 
derivatization, the mAb A samples were buffer-exchanged into 200 mM potassium phosphate, 
250 mM potassium chloride, pH 6.2. Subsequently, the Lucifer Yellow CH-derived mAb A 
samples were analyzed by size exclusion chromatography, and the total protein carbonylation 
levels were determined by the total peak areas from 280 and 428 nm absorbance.  
Differential Scanning Calorimetry (DSC) 
         DSC analysis was performed to assess the overall conformational stability of unstressed 
and stressed mAb A in the four different buffers. The analysis was conducted on a MicroCal VP-
Capillary instrument (Malvern Panalytical, Malvern, UK). A temperature ramp from 20°C to 
100°C with a scan rate of 60°C per hour was used for the scanning. A volume of 300 µl of mAb 
solutions was injected through setting the cell filling volume. A clean cycle step was applied 
between each sample run. DSC data analysis was conducted with Origin 7.0 software, where the 
corresponding buffer signal was subtracted and the thermograms were fitted into a 3-transition 
model with Tm of CH2, CH3, and Fab regions.  
Characterization of Site-Specific Carbonylation  
         The site-specific carbonylation analysis was based on a previously described peptide 
mapping method.
31
 The carbonyls were derivatized by Girard's Reagent T (GRT) at a GRT-to-
protein molar ratio of 20,000:1. After the derivatization, the mAb A samples were buffer-
exchanged to 10 mM sodium acetate, pH 5.0. Subsequently, each mAb A sample (200 µL) was 
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mixed with 1 M sodium borohydride (100 µL, prepared in methanol) and 400 mM sodium 
phosphate buffer (200 µL, pH 8.0) to a final volume of 500 µL. The reduction by sodium 
borohydride was carried out at room temperature for 30 minutes. These samples were then 
reduced (by DTT), S-carboxymethylated (by IAA), and buffer exchanged to 25 mM Tris, 1 mM 
calcium chloride, pH 8.2, for tryptic digestion. The digestion was carried out at 37°C for 4 hours 
with a trypsin-to-substrate ratio of 1:50 (weight to weight), and was stopped by the addition of 
TFA to a final concentration of 0.3% (v/v). The digested mAb A samples were separated on a 
BEH C18 column (300 Å, 1.7 µm, 2.1x150 mm), where solvent A was 0.1% TFA in water and 
solvent B was 0.09% TFA in acetonitrile. A step gradient was employed: 1-20% B in 16 
minutes, 20-40% B in 35 minutes, and 40-57% B in 15 minutes. Column temperature was 60°C. 
Flow rate was 0.3 mL/min. 
          Mass spectrometry analysis was performed on an OrbiTrap Velos in the positive mode 
with an electrospray voltage of 4.0 kV and a capillary temperature of 250°C. A data-dependent 
mode was used to acquire the mass spectrometry data, where the top 9 most intense ions in the 
full MS spectrum were selected for MS
2
 analysis. For the MS
2
 analysis, the normalized collision 
energy was 35%, and the activation time was 10 milliseconds. Identification of carbonylation 
and other oxidation products was based on database searching using the Proteome Discover 
software. The relative quantification of these oxidation products was performed by using 
extracted ion chromatograms as previously described.
31
              
RESULTS 
Formation of Precipitates or Insoluble Aggregates  
          After 1 day and 3 days of stirring, extensive protein precipitation was observed in all mAb 
A samples. The amount of precipitates or insoluble aggregates was indirectly evaluated by the 
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relative total peak areas (normalized to that of the T0 sample) of mAb A supernatants from the 
SEC analysis, where a decrease in the relative total peak area of a supernatant sample reflects an 
increase in the amount of precipitates or insoluble aggregates (based on mass balance). As shown 
in Figure 1, the relative total peak area for all mAb A supernatants decreased over the time 
course of stirring. Interestingly, in each buffer, after 1 day of stirring, no significant difference 
was observed in the relative total peak area between the unstressed and stressed mAb A samples. 
By contrast, after 3 days of stirring, the relative total peak area of the stressed mAb A was lower 
than that of the unstressed mAb A. Chemical or physical changes induced by metal-catalyzed 
oxidation may be responsible for the increased formation of precipitates or insoluble 
aggregation. The effects of the chemical or physical changes induced by metal-catalyzed 
oxidation, however, were not apparent with the first day of stirring. When comparing the effects 
from the four different buffers, we found that buffer type also impacted the formation of 
precipitates or insoluble aggregates. Among the four buffers, buffer A generated the least amount 
of precipitates/insoluble aggregates, respectively, for the unstressed and the stressed mAb A, at 
day 1 and day 3. This observation suggests that the presence of the additional 150 mM sodium 
salts in buffers B, C, and D exacerbated mAb A precipitation/aggregation. Between buffers B, C, 
and D, the extent of precipitation or aggregation follows an order of D>B>C, where the greatest 
amount of precipitates/insoluble aggregates after 3 days of stirring was observed with buffer D. 
Given that the pI of mAb A is 8.2 (and thus mAb A is positively charged in the pH 6.5 buffers), 
the order of D>B>C is consistent with a reversed order of the Hofmeister series for the effects of 
the three anions (I
-
>Cl
-
>SO4
2-
), which is commonly observed for positively charged proteins.
32-33
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Figure 1. Relative total peak area (normalized to that of T0 sample) of mAb A supernatants on 
size exclusion chromatograms. Buffer A is 10 mM sodium acetate, 1 mM EDTA, pH 5.0. Buffer 
B is 150 mM sodium chloride, 10 mM sodium acetate, 1 mM EDTA, pH 5.0. Buffer C is 150 
mM sodium sulfate, 10 mM sodium acetate, 1 mM EDTA, pH 5.0. Buffer D is 150 mM sodium 
iodide, 10 mM sodium acetate, 1 mM EDTA, pH 5.0. 
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Soluble Aggregates  
         The soluble aggregates in mAb A supernatants were characterized by size exclusion 
chromatography. As shown in Figures 2 and 3 and Table 1, for buffer A, B, or C, the levels of 
soluble aggregates in the supernatants of both unstressed and stressed mAb A decreased over the 
time course of stirring. By contrast, for buffer D, the levels of soluble aggregates increased after 
1 day of stirring, and subsequently decreased after 3 days of stirring. In addition, for buffer D, 
the soluble aggregates were more heterogeneous than those from buffer A, B, or C (Figures 2 
and 3). In particular, a peak eluted at ~11 minutes, presumably a very large oligomer of mAb A, 
was present only in mAb A supernatants from buffer D (Figure 3). These differences indicate 
that the effect of buffer D on the formation of soluble aggregates may differ significantly from 
that of buffer A, B, or C. It should also be pointed out that although the highest levels of 
precipitates and soluble aggregates were found in buffer D, the formation of soluble aggregates 
does not correlate with the formation of the precipitates or insoluble aggregates as shown in 
Figure 1.     
           For mAb A supernatant samples, the levels of LMWS (i.e. mAb A fragments, eluted at 
~19.5 minutes) consistently increased over the time course of stirring, for all four buffers. The 
enrichment of LMWS in the supernatants regardless of the buffer type suggests that LMWS may 
not be a major component that drives the formation of the precipitates or insoluble aggregates. 
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Figure 2. Size exclusion chromatograms of the mAb A supernatants after mAb A samples were 
stirred for 0, 1, and 3 days in buffer A (10 mM sodium acetate, 1 mM EDTA, pH 5.0) and buffer 
B (150 mM sodium chloride, 10 mM sodium acetate, 1 mM EDTA, pH 5.0). 
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Figure 3. Size exclusion chromatograms of mAb A supernatants after mAb A samples were 
stirred for 0, 1, and 3 days in buffer C (150 mM sodium sulfate, 10 mM sodium acetate, 1 mM 
EDTA, pH 5.0) and buffer D (150 mM sodium iodide, 10 mM sodium acetate, 1 mM EDTA, pH 
5.0) 
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mAb A  % HMWS % Main Peak % LMWS 
Unstressed  
  
T0 0.3 ± 0.0 98.6 ± 0.0 1.1 ± 0.0 
Stirred for 1 Day in Buffer A 0.3 ± 0.1 97.9 ± 0.3 1.8 ± 0.2 
Stirred for 3 Days in Buffer A 0.2 ± 0.1 97.3 ± 0.7 2.5 ± 0.7 
Stirred for 1 Day in Buffer B 0.2 ± 0.0 98.0 ± 0.0 1.8 ± 0.4 
Stirred for 3 Days in Buffer B 0.1 ± 0.0 96.9 ± 1.0 3.0 ± 1.1 
Stirred for 1 Day in Buffer C 0.1 ± 0.1 98.2 ± 0.1 1.7 ± 0.1 
Stirred for 3 Days in Buffer C 0.2 ± 0.0 97.0 ± 0.7 2.9 ± 0.8 
Stirred for 1 Day in Buffer D 11.8 ± 0.6 86.2 ± 0.9 2.0 ± 0.3 
Stirred for 3 Days in Buffer D 7.1 ± 4.3 87.2 ± 1.0 5.7 ± 5.1 
Stressed  
  
T0 6.9 ± 0.0 90.4 ± 0.0 2.7 ± 0.0 
Stirred for 1 Day in Buffer A 5.8 ± 0.2 90.8 ± 0.2 3.3 ± 0.1 
Stirred for 3 Days in Buffer A 5.2 ± 0.2 89.7 ± 0.4 5.2 ± 0.4 
Stirred for 1 Day in Buffer B 4.6 ± 0.2 92.0 ± 0.1 3.3 ± 0.3 
Stirred for 3 Days in Buffer B 2.6 ± 0.6 90.2 ± 1.8 7.2 ± 2.3 
Stirred for 1 Day in Buffer C 4.4 ± 0.1 92.1 ± 0.1 3.5 ± 0.2 
Stirred for 3 Days in Buffer C 2.2 ± 0.4 91.7 ± 0.6 6.2 ± 1.0 
Stirred for 1 Day in Buffer D 15.3 ± 0.3 78.3 ± 0.4 6.4 ± 0.2 
Stirred for 3 Days in Buffer D 14.3 ± 0.2 76.1 ± 0.3 9.6 ± 0.2 
 
Table 1. Relative levels of HMWS, Main Peak, and LMWS in mAb A supernatants from the 
SEC analysis. The error represents the standard deviation from three independent analyses.   
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Extent of mAb A Carbonylation in the Supernatants  
             To understand the relationship between oxidative carbonylation and the formation of 
mAb A precipitates or insoluble aggregates, we planned to measure the extent of mAb A 
carbonylation in the precipitates and in the supernatants by CALY. However, for the precipitates, 
poor solubility/recovery of the precipitates caused significant sample loss (greater than 90%) at 
the buffer exchange step of CALY, which prevented a reliable measurement of mAb A 
carbonylation. For the supernatants, no sample solubility or recovery issue was observed for 
CALY measurement. We therefore focused on studying the relationship between mAb A 
carbonylation level in the supernatants and the formation of precipitates. It is worth noting that a 
modified DNPH assay which used urea and SDS for sample solubilization was recently 
developed to measure protein and cell wall polysacharide carbonyl content.
34
 In the future, it will 
be interesting to investigate if the modified DNPH assay could provide a reliable measurement of 
the carbonylation content for the precipitates. 
            As shown in Figure 4, for buffers A, B, and C, mAb A carbonylation levels in the 
supernatant followed a similar pattern against time: after 1 day of stirring, the carbonylation level 
decreased by approximately 1.5 nmol/mg; subsequently, the carbonylation level remained 
essentially unchanged. For buffer D, after 1 day of stirring, the carbonylation level decreased by 
approximately 4.3 nmol/mg, almost three times the decrease observed in buffers A, B, and C; 
subsequently, after 3 days of stirring, the carbonylation level further decreased by 0.9 nmol/mg.     
            The relationship between mAb A carbonylation in the supernatants and the amount of 
precipitates/insoluble aggregates appeared to depend on buffer type. For buffers A, B, and C, the 
levels of mAb A carbonylation in the supernatants decreased in almost the same way (Figure 4), 
while the amounts of precipitates/insoluble aggregates were different with the three buffers 
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(Figure 1). In particular, the amount of soluble mAb A in the supernatants continued to decrease 
after 1 day of stirring for all three buffers (Figure 1). However, mAb A carbonylation level in the 
supernatants remained essentially unchanged after 1 day of stirring for all three buffers (Figure 
4). These data indicate that, for buffers A, B, and C, mAb A carbonylation was likely not a major 
factor that led to the formation of mAb A precipitates/insoluble aggregates. By contrast, for 
buffer D, the change in the level of mAb A carbonylation in the supernatants (Figure 4) mirrors 
the change in the amount of the precipitates/insoluble aggregates (Figure 1). These data indicate 
that mAb A carbonylation may have a more prominent effect on the formation of 
precipitates/insoluble aggregates in buffer D than in buffers A, B, and C.   
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Figure 4. Total protein carbonylation levels of mAb A in the supernatants after the oxidized 
mAb A samples were stirred for 0, 1, and 3 days in buffers A, B, C, and D. 
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Characterization of Site-Specific Carbonylation in mAb A Supernatants  
          To further understand the effect of oxidative carbonylation on the formation of 
precipitates/insoluble aggregates, we characterized site-specific carbonylation products in mAb 
A samples by peptide mapping. For the precipitates, similar to the CALY analysis, we observed 
significant sample losses during sample preparation, which prevented reliable analysis of site-
specific carbonylation products in the precipitates. We therefore focused on characterizing site-
specific carbonylation products in the supernatants, and differences in these levels between 0, 1 
and 3 days of stirring. This characterization indirectly reveals the carbonylation products that are 
preferentially localized/enriched in the precipitates under the stir stress condition. Using the 
peptide mapping method previously described
31
 and optimized (Chapter 3) for relative 
quantitation of site-specific carbonylation on mAbs, we identified a total of 15 carbonylation 
products/sites (Table 2) in mAb A supernatants. The relative levels of these carbonylation 
products were subsequently determined by extracted ion chromatograms.  
            Preferential localization or enrichment of a site-specific carbonylation product in the 
precipitates leads to a decrease in the relative level of this product in the supernatants. Therefore, 
we looked for the carbonylation products that decreased in the supernatants over the time course 
of stirring. Interestingly, as shown in Table 2, not all carbonylation products decreased in the 
supernatants over the time course of stirring. In addition, certain carbonylation products 
decreased only in buffer D. To differentiate the various carbonylation products, we categorized 
these carbonylation products to three types based on how their levels changed in the four 
different buffers (Table 3). The carbonylation products that did not decrease significantly in any 
of the buffers were assigned as type 1. The carbonylation products that decreased only in buffer 
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D, but not in buffer A, B, or C, were assigned as type 2. The carbonylation products that 
decreased in all four buffers were assigned as type 3. 
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T0 1 day 3 days 1 day 3 days 1 day 3 days 1 day 3 days
HC K98 1.2±0.1% 1.1±0.2% 1.2±0.1% 1.0±0.1% 1.2±0.4% 1.2±0.2% 1.1±0.2% 1.5±0.2% 1.3±0.2%
HC R13 0.2±0.0% 0.1±0.0% 0.0±0.0% 0.1±0.0% 0.0±0.0% 0.1±0.0% 0.0±0.0% 0.1±0.0% 0.0±0.0%
HC T58 1.9±0.1% 1.9±0.1% 2.0±0.0% 1.9±0.1% 2.0±0.2% 1.9±0.1% 2.0±0.0% 0.0±0.0% 0.0±0.0%
HC R104 1.2±0.1% 1.5±0.1% 1.4±0.1% 1.4±0.1% 1.4±0.2% 1.4±0.0% 1.4±0.2% 1.4±0.1% 1.4±0.1%
HC T115 5.2±0.2% 5.1±0.5% 5.9±0.2% 6.0±0.2% 6.0±0.2% 5.8±0.1% 6.1±0.4% 1.4±0.2% 1.4±0.1%
HC T139 1.9±0.1% 1.9±0.1% 1.9±0.1% 1.8±0.2% 2.0±0.1% 1.9±0.1% 1.7±0.1% 0.0±0.0% 0.0±0.0%
LC T4 1.9±0.1% 1.8±0.1% 1.8±0.1% 1.8±0.2% 1.8±0.3% 1.7±0.1% 1.9±0.2% 1.6±0.2% 1.4±0.1%
LC P7 0.2±0.0% 0.2±0.1% 0.2±0.0% 0.2±0.1% 0.2±0.1% 0.2±0.1% 0.2±0.1% 0.1±0.0% 0.1±0.0%
LC K157 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0%
HC R19 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0%
HC T28 10.3±0.1% 9.9±0.4% 10.3±0.5% 10.1±0.4% 10.2±0.1% 10.2±0.2% 10.4±0.5% 3.7±0.2% 3.2±0.2%
LC T117 1.0±0.0% 1.0±0.1% 1.0±0.1% 0.9±0.1% 0.9±0.1% 0.9±0.1% 1.0±0.1% 0.3±0.0% 0.2±0.0%
LC T132 1.2±0.1% 1.1±0.1% 1.1±0.1% 1.1±0.1% 1.2±0.2% 1.2±0.1% 1.1±0.1% 1.1±0.1% 1.1±0.1%
HC R87 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0% 0.1±0.0%
HC T227 2.1±0.1% 2.1±0.1% 2.1±0.1% 2.1±0.1% 2.1±0.1% 2.3±0.1% 2.2±0.0% 0.0±0.0% 0.0±0.0%
Carbonylation 
Sites
Buffer A Buffer B Buffer C Buffer D
 
 
Table 2. Relative levels (mean ± standard deviation) of site-specific carbonylation products in 
mAb A control and supernatants (determined by extracted ion chromatograms). The mean and 
standard deviation were obtained from three independent measurements. 
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Table 3. The type and location of identified carbonylation products on the stressed mAb A. Over 
the time course of stirring, the product that did not show any significant decrease in the 
supernatants is assigned as Type 1; the product that showed decreased levels in supernatants with 
buffer D but not with the other buffers is assigned as Type 2; the product that showed decreased 
levels in supernatants with all four buffers is assigned as Type 3. 
Carbonylation Site Type Location 
HC K98 1 CH1 
HC R13 3 VH 
HC T58 2 VH 
HC R104 1 CH1 
HC T115 2 CH1 
HC T139 2 CH1 
LC T4 2 VL 
LC P7 1 VL 
LC K157 1 CL 
HC R19 1 VH 
HC T28 2 VH 
LC T117 2 CL 
LC T132 1 CL 
HC R87 1 VH 
HC T227 2 Hinge 
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        An example of type 1 carbonylation product was LC T132 carbonylation. Identification of 
this product was supported by the MS
2
 data. As shown in Figure 5, for the b ions, when 
comparing the LC T132 carbonylation peptide and the unmodified wild type tryptic peptide, we 
observed a mass shift of +113 Da at the b5 ion. The mass shift of +113 Da is consistent with the 
theoretical mass increase introduced by the derivatization of a threonine carbonylation product 
(2-amino-3-ketobutyric acid).
31
 Given that no known modification of +113 Da occurs on alanine, 
leucine, valine, or cysteine of the sequence covered by the b5 ion, the MS
2
 data support the 
assignment of threonine carbonylation on LC T132. Relative levels of LC T132 carbonylation 
were determined by extracted ion chromatograms (Figure 6), which showed very little difference 
between T0, 1-day stir, and 3-day stir supernatant samples, in all four buffers. It should be noted 
that reduction of the hydrazide formed between GRT and the ketone group (2-amino-3-
ketobutyric acid) by sodium borohydride, as a part of the peptide mapping procedure, can 
generate up to 4 chiral centers. These stereoisomers could be separated as two or more peaks on 
the extracted ion chromatograms (as shown in Figure 6). In contrast, no chiral center is generated 
from reduction of the hydrazide formed between GRT and the aldehyde group (glutamic 
semialdehyde and adipic semialdehyde), which leads to a single peak on the extracted ion 
chromatograms.  
            An example of a type 2 carbonylation product was HC T28 carbonylation, a predominant 
carbonylation product of mAb A (Table 2). Identification of this product was supported by the 
MS
2
 data. As shown in Figure 7, when comparing HC T28 carbonylation peptide and the 
unmodified wild type tryptic peptide, we observed a mass shift of +113 Da that started at the y11 
ion (but not at the y10 ion). The unique mass shifts allowed an unambiguous assignment of 
carbonylation on HC T28. On the extracted ion chromatograms (Figure 8), the HC T28 
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carbonylation product was separated into four peaks. As previously explained, the four peaks 
likely came from the four stereoisomers introduced after GRT derivatization and sodium 
borohydride reduction. Importantly, the relative level of HC T28 carbonylation did not change 
significantly in buffers A, B, and C, over the time course of stirring (Table 2). By contrast, the 
relative level of HC T28 carbonylation decreased by more than 50% in buffer D (Figure 8 and 
Table 2). Furthermore, for buffer D, the decrease in the relative level of HC T28 carbonylation 
followed a similar pattern to that observed in the overall mAb A carbonylation level (Figure 4D). 
Interestingly, the same pattern was observed for all type 2 carbonylation products: a larger 
decrease occurred during the first day of stirring than during the second and the third days of 
stirring. These observations suggest that type 2 carbonylation products likely contributed to the 
increased mAb A precipitation/aggregation in buffer D.  
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Figure 5. MS
2
 spectra a GRT-derivatized carbonylation (LC T132) peptide and the 
corresponding wide type peptide, with assignment of the fragment ions.  
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Figure 6. Extracted ion chromatograms of the GRT-derivatized carbonylation (LC T132) peptide 
and the corresponding wide type peptide in mAb A samples: (1) T0 (control); (2) the supernatant 
after 3 days of stirring in buffer A; (3) the supernatant after 1 day of stirring in buffer D; (4) the 
supernatant after 3 days of stirring in buffer D.  
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Figure 7. MS
2
 spectra a GRT-derivatized carbonylation (HC T28) peptide and the corresponding 
wide type peptide, with assignment of the fragment ions.  
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Figure 8. Extracted ion chromatograms of the GRT-derivatized carbonylation (HC T28) peptide 
and the corresponding wide type peptide in mAb A samples: (1) T0 (control); (2) the supernatant 
after 3 days of stirring in buffer A; (3) the supernatant after 1 day of stirring in buffer D; (4) the 
supernatant after 3 days of stirring in buffer D.  
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           An example of type 3 carbonylation product was HC R13 carbonylation. Identification of 
this product was described previously in Chapter 3. The extracted ion chromatograms showed 
that the relative level of HC R13 carbonylation was only 0.2% at T0 (Table 2). Nevertheless, the 
level of HC R13 carbonylation consistently decreased in the supernatants for all buffers over the 
time course of stirring (Figure 9 and Table 2). A small RSD (=0.0%) was observed with three 
independent analyses of all the samples, which supports that the decrease was not due to assay 
error. Since type 1 and type 2 carbonylation products did not decrease significantly in the 
supernatants for buffers A, B, and C, type 3 carbonylation products may be responsible for the 
decrease observed in the overall mAb A carbonylation level for buffers A, B, and C. 
Additionally, compared to type 1 and type 2 carbonylation products, type 3 carbonylation 
products are least abundant. Only two products were identified, and their levels were at 0.3% or 
lower. The low abundance of type 3 products is consistent with the relatively small decrease (i.e., 
a decrease of ~1.5 nmol/mg from 16.5 nmo/mg) in the overall mAb A carbonylation level for 
buffers A, B, and C.    
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Figure 9. Extracted ion chromatograms of the GRT-derivatized carbonylation (HC R13) peptide 
and the corresponding wide type peptide in mAb A samples: (a) T0 (control), the supernatant 
after 1 day, and after 3 days of stirring in buffer A; (b) T0 (control), the supernatant after 1 day, 
and after 3 days of stirring in buffer D. 
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Characterization of Additional Degradation Products in mAb A Supernatants  
              It is worth noting that a decrease in mAb A carbonylation content in the supernatants 
may be due to enrichment of the carbonylation products in the precipitates or due to further 
degradation of the carbonylation products in the supernatants. For example, aldehydes (from 
oxidative carbonylation of Lys, Arg, and Pro residues) may react with primary amines to form 
Schiff bases or may be further oxidized to form carboxylic acids. To better define the effect of 
site-specific carbonylation on the formation of precipitates/insoluble aggregates, it is necessary 
to characterize these further-degraded carbonylation products in mAb A supernatants. For Schiff 
base products, the reactions between aldehydes and primary amines are reversible. During the 
peptide mapping analysis, the Schiff base products are expected to be converted to hydrazides by 
GRT derivatization. This is based on a consideration that the GRT derivatization reaction (while 
also reversible) effectively competes with the Schiff base formation reaction since the hydrazide 
is more stable than a Schiff base.
35
 In addition, excess GRT reagent (with a GRT-to-mAb molar 
ratio of 8000:1) is present during the derivatization reaction, which is expected to further drive 
the dissociation of the Schiff base products. While it may still be necessary to confirm that Schiff 
base products were indeed converted to hydrazides during the peptide mapping analysis, in this 
study, we focused on the carboxylic acid products, which are stable during peptide mapping 
analysis. As shown in Table 4, two carboxylic acid products (HC R13E and LC P7E) were 
identified, whose levels were less than 0.1% in all the supernatant samples. These data showed 
that formation of carboxylic acid products is not a major pathway for the decrease of aldehyde 
products during the time course of stirring. Therefore, the observed decrease of aldehyde 
products in the supernatants is more likely due to the enrichment of these aldehyde products in 
the precipitates.       
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             Besides oxidative carbonylation products, metal-catalyzed oxidation can generate other 
oxidation products, such as methionine sulfoxide or hydroxytryptophan.
22
 To understand if the 
enrichment of carbonylation products in the precipitates may be due to co-precipitation with 
these additional oxidation products, we further characterized methionine, tryptophan, and 
histidine oxidation products in mAb A supernatants. As shown in Table 5, we identified four 
methionine oxidation products, eight tryptophan oxidation products, and two histidine oxidation 
products. These oxidation products behaved similarly to type 1 or type 3 carbonylation products 
(Tables 5 and 6). There are no type 2 Met/Trp/His oxidation products. Interestingly, the type 3 
Met/Trp/His oxidation products are not located in close vicinity to the type 3 carbonylation 
product (HC R13) on mAb A. This distribution pattern suggests that the enrichment of 
carbonylation products in the precipitates was not due to co-precipitation with Met, Trp, or His 
oxidation products. It should also be noted that four oxidation products (on HC W47, HC W106, 
HC W317, and HC H228) increased slightly in the supernatants. The increase may be caused by 
a low degree of oxidation during the stirring experiment or enrichment of these oxidation 
products in the supernatants. 
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T0 1 day 3 days 1 day 3 days 1 day 3 days 1 day 3 days
HC R13E 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0%
LC P7E 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0% 0.0±0.0%
Buffer A Buffer B Buffer C Buffer DCarbonylation 
Degradation 
Products
 
Table 4. Relative levels (mean ± standard deviation) of the further degradation products 
(aldehyde-to-carboxylic acid) in mAb A control and supernatants (determined by extracted ion 
chromatograms). The mean and standard deviation were obtained from three independent 
measurements. 
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T0 1 day 3 days 1 day 3 days 1 day 3 days 1 day 3 days
HC M256 (+16) 46.6±2.0% 46.8±1.4% 45.2±1.1% 45.5±2.8% 42.3±3.2% 44.9±1.3% 45.0±0.6% 43.5±2.0% 42.4±0.5%
HC M432 (+16) 26.2±1.3% 25.3±0.3% 24.8±0.7% 25.2±0.6% 21.8±1.1% 24.2±2.1% 24.9±1.0% 26.0±0.9% 22.0±2.2%
HC M83 (+16) 3.2±0.4% 2.7±0.6% 2.6±0.5% 2.4±0.5% 1.8±0.3% 2.2±0.3% 2.2±0.4% 1.9±0.6% 1.9±0.8%
HC M34 (+16) 61.3±3.4% 60.6±4.8% 60.8±3.4% 56.6±4.0% 54.0±2.5% 56.8±3.7% 55.7±3.6% 53.0±6.0% 53.7±6.4%
LC W149 (+4) 0.3±0.2% 0.1±0.0% 0.2±0.2% 0.2±0.1% 0.2±0.1% 0.2±0.1% 0.1±0.1% 0.2±0.1% 0.1±0.1%
LC W149 (+16) 1.4±0.4% 1.5±0.3% 1.7±0.1% 1.5±0.5% 1.5±0.5% 1.6±0.4% 1.4±0.5% 1.4±0.4% 1.3±0.4%
HC W47 (+16) 15.2±0.4% 16.2±0.3% 18.2±0.6% 16.2±0.2% 18.9±1.0% 15.5±0.2% 17.8±0.2% 18.9±0.3% 20.7±0.5%
HC W281 (+16) 1.6±0.1% 1.8±0.1% 1.5±0.1% 1.7±0.1% 1.7±0.1% 1.7±0.1% 1.6±0.1% 1.8±0.1% 1.7±0.1%
HC W106 (+16) 2.9±0.2% 3.3±0.2% 3.6±0.3% 3.1±0.3% 3.0±0.3% 3.0±0.3% 3.6±0.3% 3.0±0.2% 3.4±0.4%
LC W186 (+16) 1.3±0.1% 1.3±0.1% 1.2±0.1% 1.2±0.1% 1.4±0.1% 1.3±0.1% 1.2±0.1% 1.4±0.2% 1.4±0.1%
HC W317 (+16) 1.6±0.0% 2.0±0.1% 1.7±0.1% 2.0±0.1% 1.7±0.1% 2.0±0.1% 1.7±0.1% 2.1±0.1% 1.9±0.1%
HC W421 (+16) 68.4±3.4% 67.1±0.7% 66.4±0.8% 67.7±0.9% 63.3±1.3% 66.3±2.0% 66.3±0.6% 67.5±1.8% 63.1±3.6%
HC H272 (+16) 1.1±0.1% 1.1±0.1% 1.0±0.1% 1.0±0.1% 1.0±0.0% 1.1±0.0% 1.0±0.1% 0.9±0.0% 0.9±0.1%
HC H228 (+16) 2.6±0.1% 3.0±0.2% 2.9±0.3% 3.1±0.2% 2.8±0.3% 3.1±0.2% 2.8±0.2% 2.4±0.3% 2.5±0.2%
Oxidation Site
Buffer A Buffer B Buffer C Buffer D
 
Table 5. Relative levels (mean ± standard deviation) of site-specific methionine, tryptophan, and 
histidine oxidation products in mAb A control and supernatants (determined by extracted ion 
chromatograms). The standard deviation was obtained from three independent measurements. 
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Table 6. The type and location of identified methionine, tryptophan, and histidine oxidation 
products on the stressed mAb A. Over the time course of stirring, the product that did not show 
any significant decrease in the supernatants is assigned as Type 1; the product that showed 
decreased levels in supernatants with buffer D but not with the other buffers is assigned as Type 
2 (not present in this table); the product that showed decreased levels in supernatants with all 
four buffers is assigned as Type 3; the product that showed increased levels in the supernatants is 
assigned as Type 1’.  
Oxidation Site Type  Location 
HC M256 (+16) 3 CH2 
HC M432 (+16) 3 CH3 
HC M83 (+16) 3 VH 
HC M34 (+16) 3 VH 
LC W149 (+4) 3 CL 
LC W149 (+16) 1 CL 
HC W47 (+16) 1’ VH 
HC W281(+16) 1 CH2 
HC W106 (+16) 1’ CL 
LC W186 (+16) 1 CL 
HC W317 (+16) 1’ CH2 
HC W421 (+16) 3 CH3 
HC H272 (+16) 1 CH2 
HC H228 (+16) 1’ Hinge 
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              Finally, as shown in Figures 10 and 11, we visually compared the total ion 
chromatograms of the digested supernatant samples from buffer D at different time points (T0, 1 
day, and 3 days). Interestingly, several peaks increased over the time course of stirring. The two 
peaks eluted at 17.8 and 19.0 minutes are singly charged ions with m/z of 460.3112 and 
504.3378, respectively. The identity of these two peaks are yet to be determined, since their MS 
data did not match any apparent mAb A peptides. The peak at 27.3 minutes is a doubly charged 
ion with m/z of 1146.1169, which came from a K/P miscleavage by trypsin. Aside from these 
three peaks, we did not identify any additional peptide peaks that decreased significantly during 
the time course of stirring.    
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Figure 10. The total ion chromatograms of the tryptic peptide maps of the stressed mAb A 
samples (0-25 minutes): control (T0), the supernatant after 1 day of stirring in buffer D, and the 
supernatant after 3 days of stirring in buffer D.    
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Figure 11. The total ion chromatograms of the tryptic peptide maps of the stressed mAb A 
samples (25-52 minutes): control (T0), the supernatant after 1 day of stirring in buffer D, and the 
supernatant after 3 days of stirring in buffer D.    
 
 
 
 190 
DSC Analysis 
             DSC analysis was performed to understand the effects of buffer type and oxidation status 
on the thermal stability of mAb A, which could provide additional explanations for the formation 
of precipitates/insoluble aggregates and help us better interpret the effects of oxidative 
carbonylation. As shown in Figure 12, three thermal transitions were observed in the DSC 
thermograms, which likely correspond to transitions in the Fab, CH2, and CH3 domains, as seen 
in typical DSC thermograms of IgG1 antibodies.
36-37
  
             For the unstressed mAb A, as the buffer type changed from A to D, the Fab 
transition/denaturation shifted to lower temperatures in an order of A>B>C>D, where the lowest 
transition temperature was observed with buffer D. This observation shows that buffer type has a 
significant impact on the thermal stability of Fab, where Fab is least stable in buffer D. For CH2 
and CH3, the effect of buffer type appeared to be less prominent. Only minor differences were 
observed in the DSC thermograms: in buffers B, C, and D, the CH2 and CH3 peaks appeared to 
merge with each other, while in buffer A the two peaks were resolved on the thermogram.  
            For the stressed mAb A, as the buffer type changed from A to D, the Fab 
transition/denaturation shifted in the same order as that for the unstressed mAb A. Interestingly, 
for each buffer, very little difference was observed in the Fab transition temperature between the 
unstressed and the stressed mAb A, which showed that the oxidation status has very little impact 
on Fab transition/denaturation temperature. On the other hand, for each buffer, Fab had a lower 
heat capacity (Cp) value for the stressed mAb A than for the unstressed mAb A, which indicates 
that the Fab domain became less ordered or structured after metal-catalyzed oxidation.
38
 For 
CH2 and CH3, the DSC thermogram of the stressed mAb A was very similar to the respective 
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DSC thermogram of the unstressed mAb A. This observation indicates that the thermal stability 
of CH2 and CH3 was not significantly impacted by buffer type or oxidation status. 
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Figure 12. The DSC thermograms of unstressed and stressed mAb A in buffer A, B, C, and D.   
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DISCUSSION 
              This study applied stir stress, a model stress condition, to investigate the effect of 
oxidative carbonylation on the physical stability of a recombinant monoclonal antibody. The stir 
stress condition used in the study was largely the same as the condition used by Joubert et al.
9
 
and Telikepalli et al.
11
 This stir stress condition is considered a harsher condition than many 
other stress conditions,
11
 as the stir stress generates large amounts of insoluble antibody 
aggregates within days. For our investigation, the formation of large amounts of aggregates is 
beneficial in that it could help differentiate subtle changes in the effects induced by the various 
intrinsic and extrinsic factors. The relatively short stress time is also beneficial in that it helps to 
minimize the formation of other degradation products (such as deamidation) during stress 
studies, as degradation products concurrently generated during the study may complicate our 
investigation.  
              This study applied metal-catalyzed oxidation to generate a test sample with a 
moderately high level of oxidative carbonylation (approximately five times the reported normal 
level of plasma protein carbonylation
39
). Due to the complex nature of metal-catalyzed oxidation 
reactions,
22
 various factors, including oxidative carbonylation, could impact mAb stability 
profiles. To distinguish the effect of oxidative carbonylation from those of other factors, in this 
study, we investigated the formation of mAb A precipitates/insoluble aggregates from multiple 
perspectives, with a focus on elucidating the role of oxidative carbonylation in the various 
mechanisms.  
              Taking into consideration several possible aggregation mechanisms, this study first 
evaluated intrinsic aggregation factors of mAb A by including the unstressed mAb A as the 
control, which is important for a more accurate characterization of the effect of oxidative 
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carbonylation. After the first day of stirring, for each buffer, there was essentially no difference 
in the relative amount of soluble mAb A between the unstressed and stressed mAb A samples. 
Clearly, it was the intrinsic aggregation factors but not oxidation-related changes that 
significantly contributed to the formation of precipitates/insoluble aggregates during the first day 
of stirring. By contrast, the effect of oxidation-related changes (including oxidative 
carbonylation) only became evident after additional days of stirring. This observation suggests 
that the effects of oxidation-related changes are not as fast-acting as those of intrinsic factors on 
the formation of precipitates/insoluble aggregates. This study then evaluated if the enrichment of 
certain carbonylation products in the precipitates may be a result of co-precipitation with other 
oxidation products on mAb A, based on a consideration that these oxidation products may be in 
close proximity with each other. By surveying a large variety of oxidation products during site-
specific peptide mapping, this study showed that co-precipitation was unlikely a major 
mechanism, which helped establishing a direct link between oxidative carbonylation and 
formation of precipitates/insoluble aggregates. Finally, this study evaluated thermal stability of 
mAb A samples by DSC analysis. The analysis indicated that metal-catalyzed oxidation caused 
mAb A to become less ordered or structured than the unstressed mAb A, although the 
denaturation temperatures for Fab, CH2, and CH3 did not change significantly. Given that the 
DSC data did not rule out an effect of higher order structure on the formation of 
precipitates/insoluble aggregates, the effect of oxidative carbonylation could be confounded by 
various structural factors.     
             When comparing the protein carbonylation levels with the corresponding soluble mAb A 
levels, we observed an apparent lag between the enrichment of carbonylation products and the 
formation of precipitates (reflected by the relative level of soluble mAb A). As shown in Figure 
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4, the enrichment of carbonylation products occurred primarily within the first day of stirring. 
However, after the first day of stirring, very little difference in the relative level of soluble mAb 
A was observed between the stressed and the unstressed mAb A (Figure 1). While significant 
differences in the relative amount of soluble mAb A were subsequently observed between the 
stressed and the unstressed mAb A after additional days of stirring, the carbonylation levels 
either remained unchanged (presumably reached an equilibrium) or changed slightly. One 
explanation for the apparent lag is that other changes induced by meta-catalyzed oxidation, but 
not oxidative carbonylation, were responsible for the subsequently increased accumulation of 
precipitates (from day 1 to day 3). Another explanation is that carbonyl-containing aggregates 
formed during the first day of stirring may act as nuclei that drive faster formation of larger 
aggregates, which leads to the subsequently increased accumulation of precipitates. In either 
scenario, the direct effect of oxidative carbonylation on the formation of precipitates appeared to 
be limited. It is also interesting to note that majority of the carbonylation content (ranging from 
75 to 90%) remained in the supernatants throughout the time course of stirring (Figure 4). Based 
on this indirect measurement, we deduce that only a small portion of the carbonylation products 
was preferentially enriched in the precipitates.  
              For the carbonylation products that demonstrated preferential enrichment in the 
precipitates, only one arginine carbonylation product (HC R13) can be categorized as 
aggregation-prone carbonylation product, given that only this carbonylation product was 
consistently enriched in the precipitates in all four buffers. This arginine carbonylation site is not 
in the conserved sequence of mAb A, which suggests that there may not be a common 
aggregation-prone carbonylation site on IgG1 mAbs. Seven carbonylation products, all from 
threonine residues, demonstrated preferential enrichment in the precipitates with buffer D but not 
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with buffers A, B, or C. Clearly, the iodide ion present in buffer D has a large impact on the 
effect of these type 2 carbonylation products. It should also be pointed out that this study did not 
survey all possible oxidation products from metal-catalyzed oxidation. It is likely that these other 
oxidation products, in particular, di-Tyr, Tyr-Trp, or di-Trp crosslinks that form covalent 
dimers,
40
 may co-precipitate with adjacent carbonylation products. In the future, these potential 
crosslink products will need to be investigated by mass spectrometry and fluorescence 
spectroscopy, which could further distinguish the roles/effects of oxidative carbonylation from 
other chemical modifications on mAb aggregation. 
              In the anionic Hofmeister series, iodide ion ranks lower than chloride and sulfate ions 
based on their ability to “salt out” negatively charged proteins.
32
 For positively charged proteins, 
the order is usually reversed, where iodide ion has a stronger “salt out” effect than chloride and 
sulfate ions (as is the case in this study).
33
 The mechanism for the Hofmeister effect has not been 
fully understood yet.
29, 33
 Nevertheless, it is generally believed that specific ion 
interaction/pairing with positively charged side chains or hydrophilic regions on protein surfaces 
may explain the reversed Hofmeister effect.
29, 32-33
 Considering that the threonine carbonylation 
product is neutral in charge and is more hydrophobic than threonine, and that the formation of 
the threonine carbonylation product (2-Amino-3-Ketobutyric Acid, Figure 13) removes a 
potential hydrogen bond donor, it is unlikely that the reversed Hofmeister effect observed in this 
study came from interactions between Hofmeister ions and threonine carbonylation product. We 
hypothesiz that positively charged residues adjacent to the threonine carbonylation sites may be 
involved in the aggregation characteristics of the type 2 threonine carbonylation products, where 
these positively charged residues could have specific ion interactions with the Hofmeister ions. 
We further hypothesize that the local surface areas near these positively charged residues could 
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be less prone to aggregation due to electrostatic repulsion from the positively charged residues. 
For the three Hofmeister ions evaluated in this study, iodide ion could have a stronger interaction 
with these positively charged residues than chloride and sulfate ions, which could result in more 
effective shielding of these adjacent positive charges. Consequently, the reduced electrostatic 
repulsion would allow the threonine carbonylation product to participate in the aggregation 
process (due to hydrophobic interactions and/or reduced hydrogen-bonding), which may lead to 
the observed preferential enrichment of type 2 carbonylation products.   
              To evaluate the proposed hypothesis, we investigated the presence of positively charged 
residues near type 2 carbonylation products. Using a model IgG structure (1HZH), we examined 
the two carbonylation sites, HC T115 and HC T139, that are located in the conserved regions of 
mAb A. As shown in Figure 14, we found two lysine residues (HC K113 and HC K209) near HC 
T115, and one lysine residue (HC K137) near HC T139. The presence of positively charged 
residues near the type 2 carbonylation products is consistent with our proposed hypothesis. 
However, a mutagenesis study (on the adjacent lysine residues) will be needed in the future to 
confirm this hypothesis. It should also be pointed out that the presence of positively charged 
residues does not necessarily lead to preferential enrichment of an adjacent carbonylation 
product. For example, LC T132 is a type 1 carbonylation product, even though an adjacent 
lysine, LC K130, is present. It is possible that additional factors, such as orientation of the 
positive charge, steric constrains, and local flexibility, can also influence the aggregation 
propensity of carbonylation products.              
           The DSC analysis results of the stressed and unstressed mAb A showed that metal-
catalyzed oxidation did not introduce significant structural changes in mAb A. The DSC results 
are consistent with the H/D exchange analysis results from our previous study in Chapter 3. On 
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the other hand, the DSC analysis results showed that the Hofmeiser ions did affect thermal or 
conformational stability of mAb A. This effect is consistent with existing literature reports.
41-43
 A 
study by Majumdar et. al found that chloride ion decreased local flexibility in VL, CH1, and 
CH3 domains; sulfate ion increased local flexibility in CH1 and VL domains; thiocyanate ion 
increased local flexibility in the CH2 domain of an IgG1 antibody.
41
 For our study, it will be 
interesting to understand in the future how chloride, sulfate, and iodide ions change the local 
flexibility of mAb A, which can provide additional explanations for the effects of carbonylation 
products.  
            In summary, this study demonstrated that the effect of oxidative carbonylation on the 
physical stability of mAbs is much more complicated than suggested in the existing literature.
25-
27
  Using a model IgG1 mAb, this study showed that the effect of oxidative carbonylation on the 
physical stability of mAbs can be site- and buffer-specific, which has not been previously 
reported. For example, using molecular dynamics simulations, Petrov and Zagrovic reported that 
lysine and arginine carbonylation significantly increases protein aggregation propensity via 
hydrophobic effects.
27
 However, their study did not evaluate any buffer effect.  In addition, their 
study did not reveal any site-specific effects for lysine and arginine carbonylation, while our 
study showed that not all lysine and arginine carbonylation products contribute to the formation 
of mAb aggregates. Similarly, in several reported mAb stability case studies,
25-26, 30
 no site-
specific carbonylation information was provided. Notably, this study revealed the effect of 
threonine carbonylation products, which has not been pointed out in the literature. To explain the 
buffer-dependent aggregation of type 2 carbonylation products, we provided several new 
potential mechanisms, which should be tested further in future investigations. Finally, this study 
provides new aspects of product quality evaluation of oxidative carbonylation, which can help to 
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identify critical carbonylation products and the development of future mAb candidates with 
improved physical stability.  
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Figure 13. Threonine residue and its carbonylation product (2-Amino-3-Ketobutyric Acid)   
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A 
HC T115 HC T115
HC K113
HC K109
 
 
B 
HC T139
HC T139
HC K137
 
 
Figure 14. (A) Location of HC T115 (left) on an IgG1(PDB:1HZH) and electrostatic potential 
(red area: negatively charged; blue area: positively charged) distribution on the surface (right). 
(B) Location of HC T139 (left) on an IgG1(PDB:1HZH) and electrostatic potential (red area: 
negatively charged; blue area: positively charged) distribution on the surface (right). 
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Characterization of Protein Crosslinks in a Recombinant Monoclonal 
Antibody After Metal-Catalyzed Oxidation 
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INTRODUCTION 
       Metal-catalyzed oxidation is a commonly observed protein degradation pathway during 
manufacturing of recombinant monoclonal antibody (mAb) therapeutics.
1,2,3
 This type of protein 
degradation can negatively impact mAb product quality. First, metal-catalyzed oxidation of 
methionine or tryptophan residues in the complementarity-determining regions could decrease 
target binding of mAbs.
4
 Second, metal-catalyzed oxidation of methionine residues in the Fc 
region could change pharmacokinetic properties of mAbs.
5
 Third, certain degradation products 
generated by metal-catalyzed oxidation can be potentially immunogenic. For example, formation 
of protein carbonyls (such as 2-aminoadipic semialdehyde, glutamic semialdehyde, and 2-amino-
3-butyrate) by metal-catalyzed oxidation of lysine, arginine, threonine, and proline residues in 
proteins, could represent a danger signal to the immune system and induce production of 
autoantibodies against the carbonyl-modified proteins.
6
 Additionally, metal-catalyzed oxidation 
can drive formation of mAb aggregates,
2
 which often pose an immunogenicity risk.
7-9
 For 
example, a study by Filipe et al. showed that mAb aggregates generated by metal-catalyzed 
oxidation were more immunogenic than those generated by shaking, pH, or heat stress conditions 
in transgenic mice.
7
 To date, the chemical source of the immunogenicity for aggregates 
generated after metal-catalyzed oxidation remains poorly understood.       
        Protein crosslinks, referring to covalent bonds that link amino acidic residues, could 
contribute to the formation of immunogenic aggregates.
10
 The commonly observed crosslinks are 
inter-peptide crosslinks (type 2 crosslinks), intra-peptide crosslinks (type 1 crosslinks), and  
dead-end links (type 0 crosslinks).
11
 Since inter-peptide crosslinks could directly lead to protein 
dimerization or oligomerization, characterization of this type of crosslinks is often a major focus 
in the investigation of immunogenic aggregates.
12
 For metal-catalyzed oxidation, several inter-
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peptide crosslinks have been discovered by Torosantucci et al. in human insulin.
13
 These 
crosslinks occurred between amino acids with nucleophilic properties (such as lysine, histidine, 
phenylalanine) and tyrosine oxidation products via 1,4- or 1,6-type addition.
13
 In another study, 
Torosantucci et al. identified similar types of crosslinks in human interferon beta-1a after 
oxidation with copper and ascorbate, where primary amines formed covalent bonds with 
oxidation products of tyrosine and phenylalanine via 1,4- or 1,6-type addition.
12
 Interestingly, at 
the active site of a cytochrome c oxidase, a covalent bond was found between tyrosine and 
histidine near the ligated copper ion,
14
 likely via a similar mechanism reported by Torosantucci 
et al.
12-13
 Another tyrosine-related crosslink identified in various proteins after oxidation with 
copper and hydrogen peroxide is di-tyrosine.
15-17
 This crosslink is formed by interactions 
between two tyrosine radicals, often via ortho-ortho coupling.
18
 Di-tyrosine has a unique 
fluorescence with an excitation wavelength of 320 nm and an emission maximum wavelength of 
410 nm, which is often an initial indicator of di-tyrosine crosslinks.
17
      
    In addition to tyrosine- and phenylalanine-related crosslinks, metal-catalyzed oxidation 
could generate Schiff base crosslinks, which are reversible imine bonds formed between 
aldehydes and primary amines.
18-19
 In a study by Bardshaw et al., the presence of Schiff base 
crosslinks in oxidized slug proteins was first suggested by the lack of reactivity towards protein 
carbonyls under native conditions.
20
 The decreased amount of soluble proteins after sodium 
borohydride treatment, which reduces the Schiff base to a more stable amine bond and lowers the 
solubility of protein complexes, is also consistent with the formation of a Schiff base. 
Additionally, the majority of primary amines were not accessible to acid anhydrides, which 
further supports the presence of Schiff base crosslinks in these proteins after metal-catalyzed 
oxidation.
20
 In another study by Rysman et al., the formation of Schiff base crosslinks was 
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suggested in oxidized myofibrillar proteins, based on the increased fluorescence (Em 420 nm/Ex 
350 nm) that may be related to Schiff base structures.
21
 However, the increased fluorescence may 
not be specifically from Schiff base structures, since the maximum emission wavelength is close 
to that of di-tyrosine (Em 410 nm/Ex 325nm).
22
 Interestingly, to date, there is no direct mass 
spectrometry analysis data that identify Schiff base crosslinks in proteins after metal-catalyzed 
oxidation. By contrast, Schiff base crosslink formation catalyzed by lysyl oxidase
23
 was 
identified in collagen
24
 and elastin
25
 by mass spectrometry.
26-27
  
            For mAbs, very little is known about protein crosslinks formed after metal-catalyzed 
oxidation. Several analytical challenges hinder the effort to characterize protein crosslinks in 
mAbs by peptide mapping. First, crosslinked peptides are often in low abundance,
28
 making it 
difficult to identify/distinguish the crosslinked peptide ions from the non-crosslinked peptide 
ions in a peptide map. Second, MS
2
 fragments of the crosslinked peptides are often very 
complex, making it difficult to assign the peptide sequence and the crosslink structure, 
particularly when the crosslink chemistry is not known. Currently, a commonly used analytical 
strategy for the identification and assignment of crosslinked peptides employs enzymatic O
18
 
labeling during tryptic digestion, where trypsin incorporates two O
18
 or O
16
 (as control) atoms 
into the C-terminus of each tryptic peptide.
29-30
 A unique mass shift of +8 Da observed between 
tryptic peptides generated in O
18
 and O
16
 water can then allow for the detection of crosslinked 
peptide ions, where the non-crosslinked peptide ions show only +4 Da mass shift.
31-32
 The 
limitation of the enzymatic O
18
 labeling is that labeling efficiency may vary for different 
peptides,
33
 which may impact the detection. Furthermore, the +8 Da may be masked by natural 
isotopic distribution,
34
 particularly with large peptides. Finally, the O
18
 labeling approach does 
not address the analytical challenge with interpreting complex MS
2
 data of crosslinked peptide 
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ions. In addition, during MS analysis, formation of clusters in the gas phase can lead to false 
positive detection of crosslinks, as cluster dimers sometimes show a mass difference of +8 Da 
(unpublished data).  
             To facilitate characterization of potential inter-peptide crosslinks in mAbs after metal-
catalyzed oxidation, this study applies an analytical approach to enrich crosslink peptides and 
then characterize these crosslinked peptides by a secondary peptide mapping method using 
thermolysin,
35
 a protease less specific than trypsin. Enrichment of the crosslinked peptides is 
based on the net charge differences between the crosslinked peptides and the non-crosslinked 
peptides at pH 2.7, where crosslinked peptides (with ≥+4 charge) can be separated from the non-
crosslinked peptides (with <=+3 charge, except those containing multiple lysine, arginine, and 
histidine residues) on a strong cation exchange column.
28, 36-37
 After the enrichment, a secondary 
peptide map is used to generate complementary peptide information, which reduces the 
complexity of assigning the peptide sequence and the crosslink structure. To evaluate this 
analytical methodology, a model mAb crosslink sample was generated using an N-
hydroxysuccinimide ester crosslinker, BS3, which crosslinks primary amines of proteins.
38
 After 
demonstrating the feasibility of the new methodology to identify crosslinked peptides using the 
mAb crosslink sample, this approach was employed to investigate crosslinked products in a 
model mAb after copper-catalyzed oxidation. Copper-catalyzed oxidation instead of iron-
catalyzed oxidation was used to prepare the model mAb because copper ion was found to be 
more effective than iron ion in generating oxidative carbonylation on mAbs and other proteins.
39-
40
 Therefore, it is expected that more carbonyls and the related Schiff base crosslink products 
will be generated using copper-catalyzed oxidation, which would facilitate/ease the crosslink 
identification effort. Additionally, mAbs stressed by copper-catalyzed oxidation were shown to 
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be highly immunogenic in a transgenic mouse model.
7
 It will be interesting to understand if 
Schiff base crosslink products formed after copper-catalyzed oxidation may be linked to the 
induced immunogenicity. Finally, it was found that copper-catalyzed oxidation but not iron-
catalyzed oxidation generated dityrosine crosslinks in lens proteins.
41
 In addition to Schiff base 
crosslink products, it will be interesting to characterize dityrosine crosslink products in the model 
mAb, which could also be linked to the induced immunogenicity.  
MATERIALS AND METHODS 
Materials 
        The recombinant monoclonal antibody, mAb A, was manufactured at Genentech (South San 
Francisco, CA). Copper sulfate, hydrogen peroxide solution (30% in H2O, w/w), 
ethylenediaminetetraacetic acid (EDTA), sodium phosphate (dibasic and monobasic), sodium 
chloride, sodium acetate, acetic acid, urea, dithiothreitol (DTT), iodoacetamide (IAM), calcium 
chloride, tris(hydroxymethyl) aminomethane (Tris), hydrochloric acid, formic acid (FA), and 
trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Guanidine hydrochloride solution (8 M in H2O) and BS3 (bis(sulfosuccinimidyl)suberate) were 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). A synthetic peptide, acetylated-
ALRLLIKYASQSISGVPSR, was purchased from AnaSpec (Fremont, CA, USA). The TSK 
G3000 SWXL (7.8x300mm) size exclusion column was purchased from Tosoh Bioscience (King 
of Prussia, PA, USA). Acetonitrile (ACN) was purchased from Burdick & Jackson (Muskegon, 
MI, USA). Thermolysin and sequencing-grade trypsin was purchased from Promega (Madison, 
WI, USA). The PolySULFOETHYL A column (4.6x204 mm, 5 µm) was purchased from 
PolyLC (Columbia, MD, USA). Zorbax Eclipse XDB-C18 Column (2.1x150 mm, 3.5 µm) was 
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purchased from Agilent (Milford, MA, USA). The 30-kDa Amicon centrifugal filter units were 
purchased from MilliporeSigma (Burlington, MA, USA).   
Preparation of Crosslinked mAb A with BS3 
         The mAb A sample was extensively buffer exchanged into 100 mM sodium phosphate 
buffer, pH 7.4, which removes primary amines in mAb A storage buffer to prevent interference 
with the BS3 crosslink reaction. For the crosslink reaction, the BS3 stock solution (50 mM BS3 
in water, prepared immediately before the crosslink reaction) was added to an mAb A solution (5 
mg/mL mAb A in 100 mM sodium phosphate, pH 7.4), where the final concentration of BS3 was 
2 mM. The reaction mixture was vortexed briefly and then incubated at room temperature for 40 
minutes. Subsequently, Tris hydrochloride buffer (1M, pH 8.2) was added to the reaction 
mixture to a final concentration of 50 mM. The mixture was vortexed briefly and then incubated 
at room temperature for an additional 15 minutes to quench the BS3 crosslink reaction.  
Copper-catalyzed Oxidation of mAb A 
           Copper-catalyzed oxidation of mAb A was performed in 10 mM sodium acetate buffer, 
pH 5.0. The final concentration of mAb A, copper sulfate, and hydrogen peroxide was 10 
mg/mL, 10 mM, and 20 mM, respectively, in the reaction mixture. The reaction was carried out 
at room temperature for 24 hours, and was stopped by addition of EDTA (to a final concentration 
of 15 mM). Subsequently, the oxidized mAb A was stored at -80°C until further analysis.  
Digestion of mAb A Samples by Trypsin 
           The unstressed, BS3-crosslinked, and oxidized mAb A samples were diluted with 8M 
guanidine hydrochloride to a final mAb A concentration of 2 mg/mL and a final concentration of 
guanidine hydrochloride of 6 M. To reduce the disulfide bonds, 15 µL of 1M DTT was added to 
1 mL of these mAb A sample solutions. The samples were then incubated at 37°C for 1 hour. 
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Subsequently, 90 uL of IAM (0.5 M in water) was added to the samples, and the mixtures were 
incubated at room temperature in the dark for 15 minutes to alkylate free thiols. After the 
incubation, 15 uL of 1 M DTT were added to the samples to quench the alkylation reaction.  
          Different from the unstressed and BS3-crosslinked mAb A samples, the oxidized mAb A 
sample was treated with sodium borohydride prior to the DTT reduction step. The sodium 
borohydride treatment is necessary to stabilize any potential Schiff base products, which reduces 
a Schiff base to an amine. For the sodium borohydride reduction reaction, 250 µL sodium 
borohydride solution (1 M in 100% ethanol) and 50 µL 2M sodium phosphate buffer, pH 8.0 
were added to 1 mL of the mAb A sample solution (that was prepared with 8 M guanidine 
hydrochloride). This mixture was incubated at room temperature for 2 hours. Subsequently, the 
sample was reduced by DTT and alkylated by IAM as described above. 
         The reduced and alkylated mAb A samples were then buffer exchanged (three times) to 6M 
urea, 60 mM hydroxylamine, pH 7.0, using a 30 kDa Amicon filter, where mAb A samples were 
concentrated to approximately 20 mg/mL after the third round of buffer exchange. These 
samples were then diluted to 0.3 mg/mL with 25 mM Tris, 5 mM calcium chloride, pH 8.2. To 
these samples, trypsin was added at an enzyme-to-substrate ratio (weight-to-weight) of 1:50. The 
digestion mixture was incubated at 37°C for 6 hours, and subsequently stopped by addition of 
TFA to a final concentration of 0.3% (v/v).     
Strong Cation Exchange (SCX) Analysis of mAb A Tryptic Digests  
            The mAb A tryptic digests were separated on a PolySulfoethyl A strong cation column. 
Solvent A was 30 mM sodium phosphate, 30% acetonitrile in water, pH 2.7; solvent B was 30 
mM sodium phosphate, 500 mM sodium chloride, 30% acetonitrile in water, pH 2.7. The column 
temperature was controlled at 40°C and the HPLC autosampler temperature was controlled at 
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8°C. The flow rate was 0.4 ml/min. The effluent was monitored by UV absorbance at 214 and 
280 nm. A linear gradient of 0% to 95% B in 33 minutes was applied to separate mAb A tryptic 
peptides. On the strong cation exchange chromatograms, the two regions that contain peptides 
with +4 and +5 charges were fraction collected for further analysis. 
LC-MS/MS analysis of the SCX Fractions 
            The collected SCX fractions were injected onto an Eclipse XDB-C18 Column (2.1x150 
mm, 3.5 µm). Solvent A was 0.1% TFA in water (v/v). Solvent B was 0.09% TFA in 90% 
acetonitrile and 10% water (v/v). The column temperature was controlled at 55ºC, and the flow 
rate was 0.25 mL/min. A two-step gradient was used, where solvent B was first increased from 
5% to 19% in 7 minutes, and then increased to 62% in 53 minutes. The eluent was monitored by 
absorbance at 214 nm, and was introduced to an Orbitrap Elite mass spectrometer. The mass 
spectrometry analysis was performed in the positive mode with an electrospray voltage of 4.0 kV 
and a capillary temperature of 250°C. The MS data acquisition was in a data-dependent mode, 
where top 5 most intense ions in the full MS spectrum was selected for MS
2
 data acquisition by 
collision induced fragmentation. The normalized collision energy was 35% with an activation 
time of 10 milliseconds. 
Tandem Peptide Mapping (Enzymatic MS
2
) by Thermolysin 
           After the LC-MS/MS analysis of the SCX fractions, the peptides separated on the Eclipse 
XDB-C18 column were collected for tandem peptide mapping or enzymatic MS
2 
(eMS
2
). 
Different from the conventional MS
2
 based on collision-induced dissociation in an MS 
experiment, the eMS
2
 process uses non-specific proteases (such as chymotrypsin, elastase, 
pepsin, or thermolysin) to generate peptide fragments from parent tryptic (or Lys-C) peptides. 
Subsequently, these peptide fragments are analyzed by LC-MS/MS. In this study, we used 
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thermolysin to generate eMS
2 
data on the tryptic peptides of the SCX fractions. For the 
thermolysin digestion, the collected peptide fractions were diluted 8-fold with 25 mM sodium 
phosphate buffer, pH 7.8 to adjust the pH and reduce the concentration of acetonitrile. 
Subsequently, 0.1 µg of thermolysin were added to the peptide sample. The mixture was 
incubated at 50°C for 1 hour. The thermolysin digestion was stopped by addition of formic acid 
to a final concentration of 0.3% (v/v). Subsequently, the themolysin digest was analyzed by LC-
MS/MS using the same conditions as described for the analysis of the SCX fractions. 
Identification of Crosslinked Peptides 
           The eMS
2
 data from theromlysin peptide mapping analysis were analyzed by database 
search against the mAb A sequence using the Proteome Discover software (Waltham, MA, 
USA). For database searching, the full MS mass tolerance was 5 ppm; the CID-MS
2
 mass 
tolerance was 0.6 Da; enzyme specificity was set as none; cysteine modification was set as 
carbamidomethyl (+57Da), and no other post-translational modification was included. The 
search results were manually investigated to identify crosslinked peptide candidates, where these 
peptides show partial tryptic sequence coverage in the search results.  
          After identification of the peptide candidates that may be crosslinked, reporter/signature 
fragment ions were manually selected based on the relative intensity of these fragment ions in 
the respective parent tryptic peptides. Typically, these reporter/signature fragment ions are the 
predominant b or y ions from terminal sequences, which can be also present in the CID-MS
2
 
spectra of the related crosslinked peptides. Additionally, since these b or y ions are from terminal 
sequences of the peptide candidates, their masses (m/z) do not change with different crosslink 
types/modifications. Subsequently, the MS
2
 data from the LC-MS/MS analysis of the SCX 
fractions were extracted for any MS
2
 spectrum that contains the reporter/signature fragment ions. 
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These extracted MS
2
 spectra and related full MS spectra were evaluated for identification of 
crosslinked peptides.    
RESULTS 
Analytical Methodology for Identification of Crosslinked Peptides  
          As shown in Figure 1, a new analytical methodology using Strong cation exchange 
Enrichment and Enzymatic MS
2
 (SEEMS
2
) was developed to identify crosslinked peptides. 
Sample preparation, chromatography conditions, and the identification process were designed to 
address the commonly encountered analytical challenges during analysis of crosslinked peptides.  
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Figure 1. Workflow of the Strong cation exchange Enrichment and Enzymatic MS
2
 (SEEMS
2
) 
approach for identification of crosslinked peptides.  
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           For sample preparation, mAb A samples were reduced and alkylated in 6 M guanidine 
hydrochloride to dissolve the aggregates formed from BS3 crosslink reaction or metal-catalyzed 
oxidation. The solubilization of mAb A samples in 6 M guanidine hydrochloride helps improve 
recovery of crosslinked mAb species. Subsequently, these samples were buffer-exchanged to 6 
M urea instead of the tryptic digestion buffer (25 mM Tris, 5 mM calcium chloride, pH 8.2). 
This was based on a concern that crosslinked mAb species are hydrophobic and could precipitate 
in the tryptic digestion buffer during buffer exchange. Urea was thus used since 6 M urea is an 
effective chaotropic reagent
42
 that can keep the mAb A samples in solution during buffer 
exchange. Another consideration is that, upon dilution (to less than 1 M, after buffer exchange), 
urea does not interfere with trypsin digestion.
43
 One drawback with digestion of proteins in urea 
solution is that urea can form isocyanic acid, which readily reacts with N-termini of peptides or 
Lys/Arg side chains to cause protein/peptide carbamylation.
44
 To address the protein/peptide 
carbamylation issue, hydroxylamine was included in the urea solution;
45
 subsequently, we did 
not detect significant carbamylation in the peptide map data (not shown) for all mAb A samples. 
Finally, urea is a non-ionic solute, which does not interfere with the subsequent strong cation 
exchange chromatography for the enrichment of crosslinked peptides.   
         The strong cation exchange chromatography condition was largely based on the condition 
described by Tinnefeld et al.
28
 The mobile phase pH was 2.7, at which the N-terminus and the 
side chains of histidine, lysine, and arginine residues are positively charged; the side chains of 
aspartic acid (pKa=3.7) and glutamic acid (pKa=4.3) are predominantly neutral. Therefore, at pH 
2.7, crosslinked peptides (from two tryptic peptides) have 4 or more positive charges, while non-
crosslinked tryptic peptides have 2 positive charges (except for those that contain histidine or the 
KP/RP mis-cleavage sequence). The charge difference enables separation of the crosslinked 
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peptides from the non-crosslinked peptides on a strong cation exchange column. In this study, we 
increased the acetonitrile concentration in the mobile phase from 20% (as used by Tinnefeld et 
al.
28
) to 30%, which helps to improve the recovery of hydrophobic peptides.
46
 After establishing 
the chromatography conditions, we used the tryptic digest of unstressed mAb A and a synthetic 
model peptide (which contains 3 positive charges at pH 2.7) to determine the regions on the 
strong cation exchange chromatograms for collecting +4 and +5 charged peptides. As shown in 
Figure 2, the synthetic peptide eluted at ~28 minutes on the chromatogram. We therefore 
selected the two groups of peaks (regions A and B) that eluted at between 31 to 33 minutes and 
between 37 to 39 minutes for fraction collection. Considering that region A likely contains +4 
charged peptides and region B likely contains +5 charged peptides, these two regions are 
therefore the primary focus of the crosslink analysis. 
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Figure 2. Strong cation exchange chromatograms of the tryptic peptides from unstressed mAb A 
and a model peptide (+3 charged at pH 2.5). Region A (containing +4 charged peptides) and 
region B (containing +5 charged peptides) were collected for further analysis.  
 
 
 
 
 
 
 
 224 
        For identification of crosslinked peptides, we rely on the information provided by tandem 
peptide mapping (eMS
2
). The rationale is that, after thermolysin digest, the resulting peptides 
that contain crosslink sites are not expected to match any sequence of mAb A (as the 
corresponding mass shifts are not known beforehand for database search); thus, the database 
search result should reveal a gap in the identified peptide sequence as against an expected tryptic 
peptide sequence (that is not crosslinked). The information points to putative peptide candidates 
that may be involved in the crosslinked products. To locate the crosslinked peptides, we rely on 
the assumption that terminal fragment ions that do not cover the crosslink sites are likely also 
present in the CID-MS
2
 spectra of the crosslinked peptides, in particular, for the terminal 
fragment ions with high intensities. Additionally, the masses of these fragment ions do not 
change with different crosslink types or different crosslink counterpart peptides. Therefore, by 
evaluating the CID-MS
2
 spectra of the non-crosslinked counterpart peptides, we can identify 
several signature/reporter MS
2
 ions, whose masses could help us extract/locate crosslinked 
products in the LC-MS/MS data of the collected SCX fractions. Subsequently, from the extracted 
CID-MS
2
 and the corresponding full MS data, crosslinked peptides can be identified by manual 
interpretation.   
Enrichment of BS3-Crosslinked Peptides by SCX 
         To demonstrate the capability of the SEEMS
2
 approach to identify crosslinked peptides, we    
generated a model crosslinked sample using BS3. As shown in Figure 3, BS3 contains two N-
hydroxysulfosuccinimide (NHS) ester groups, which can react with primary amines (such as 
lysine side chains) from two peptides to form crosslinks (Figure 3B). Compared to other 
crosslinking reagents, the BS3 crosslinking reaction is relatively fast and straightforward, and the 
resulting crosslinked products (amide bonds) are stable during subsequent MS analyses, which 
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makes BS3 a popular crosslinking reagent in crosslinking mass spectrometry.
47
 In our study, 
after the BS3 crosslink reaction, we analyzed the unstressed and the BS3-treated mAb A sample 
by size exclusion chromatography, and observed that the relative level of HMWS increased from 
0.8% (for the unstressed mAb A) to 65% (for the BS3-treated mAb A, Figure 4). This 
observation supports that the BS3-treated mAb A sample contains crosslinked species and is, 
thus, suitable for evaluating the capability of the SEEMS
2
 approach to identify crosslinked 
peptides.       
           After tryptic digestion of the BS3-treated mAb A sample, the regions (A’ and B’) that 
likely contain +4 or +5 charged peptides were collected off the strong cation exchange column 
(Figure 5). On the strong cation exchange chromatograms, region B’ looks very similar to region 
B (Figure 2) in terms of overall peak profiles and relative peak intensities. On the other hand, 
region A’ appears to contain more peaks than region A (Figure 2). Furthermore, the percent peak 
area of region A’ is ~7% of the total SCX peak area, while that of region A is ~10%. The low 
percent peak area of region A’ indicates that the BS3-crosslinked peptides are in low abundance. 
Therefore, it is beneficial to enrich these peptides for subsequent analyses. It should be noted that 
the low percent peak area of region A’ does not contradict with the relatively large percent peak 
area of HMWS (~65%) for the BS3-crosslinked mAb A sample on the SEC (Figure 4B), since a 
relatively low level of crosslinks at the peptide level can lead to even 100% crosslinks (i.e. 
containing 100% HMWS) at protein level.         
          LC-MS/MS analysis of the collected region A’ fraction identified two +4 charged tryptic 
peptides. One of them is a CDR peptide, SYYASWYQQKPGQAPVLVIYGANNRPSGIPDR. 
The other one is the hinge peptide, THTCPPCPAPELLGGPSVFLFPPKPK. Since only these 
two tryptic peptides (based on a complete tryptic digestion) are +4 charged for mAb A, the SCX 
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condition is considered properly established for enrichment of the crosslinked peptides, and 
region A’ should contain BS3-crosslinked peptides with +4 charges. 
            Analysis of the LC-MS/MS data by conventional database search against mAb A 
sequence showed that a large number of peptides in region A’ (Figure 6) do not match any 
apparent sequence of mAb A, even after considering mis-cleavage caused by BS3 side chain 
modifications (i.e., the functional group at the other end of BS3, N-hydroxysulfosuccinimide 
ester, reacts with water and undergoes hydrolysis to form a carboxylic acid and a leaving 
product, N-hydroxysulfosuccinimide). These unmatched peptides could be BS3-crosslinked 
peptides. However, given that there are more than 600 possible mAb A crosslinks from the BS3 
crosslinking reactions, it is difficult to survey all possible crosslink masses and identify 
crosslinked peptides directly from the LC-MS/MS data. The collected region A’ was therefore 
further analyzed by the eMS
2
 approach.  
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Figure 3. (A) Chemical structure of BS3 (bis(sulfosuccinimidyl)suberate). (B) Illustration of a 
crosslinked peptide product generated by the BS3 treatment. 
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Figure 4. (A) size exclusion chromatogram of mAb A. (B) size exclusion chromatogram of the 
crosslinked mAb A (generated by the BS3 treatment). 
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Figure 5. Strong cation exchange chromatogram of the tryptic peptides from BS3-crosslinked 
mAb A. Region A’ (containing +4 charged peptides) and region B’ (containing +5 charged 
peptides) were collected for further analysis. 
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Figure 6. Analysis of the collected region A’ fraction by reversed phase high performance liquid 
chromatography (RP-HPLC). 
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Identification of Crosslinked Peptides in Region A’ by Tandem Peptide Mapping (eMS
2
) 
          The peptide peaks (Figure 6) that do not match any apparent sequence of mAb A were 
collected and digested with thermolysin (tandem peptide mapping). The thermolysin digests 
were then analyzed by LC-MS/MS and database search. The database search results revealed 
several missing sequences in the corresponding tryptic peptides. For example, a peptide, 
LYLQMNSLR, was identified by the database search. However, against its corresponding tryptic 
peptide sequence, NSLYLQMNSLR, the two N-terminal residues, “NS”, were not detected in 
the thermolysin map. After investigating the adjacent sequences, XXXR-DNAK-
NSLYLQMNSLR-XXX, we speculated that the lysine residue next to the “NS” is a putative 
crosslink site. This speculation was based on a consideration that if the lysine residue were not 
crosslinked, we should have observed full coverage of the tryptic peptide sequence (that includes 
the “NS” residues). Based on this speculation and that a crosslink at the lysine residue will result 
in a missed cleavage from tryptic digestion, the peptide DNAKNSLYLQMNSLR was assigned 
as a crosslink candidate.         
          Considering that the crosslinked species could produce the same y ions as the peptide 
NSLYLQMNSLR, we investigated the CID-MS
2
 spectrum of peptide NSLYLQMNSLR to look 
for reporter/signature y ions. Importantly, these reporter ions (if present) do not change in mass 
even with different crosslink counterpart peptides. As shown in Figure 7, y3, y5, y6, y7, and y8 
are the dominant y ions in the spectrum. The masses of these fragment ions are not affected by 
any crosslink reaction that occur at the N-terminal sides of the “NS” residues. For simplicity, we 
selected y3, y5, y6, and y7 as the reporter MS
2
 ions. Their masses were then used to extract the 
MS
2
 spectra from region A’ to find any peptide ions that could produce these fragment ions in a 
CID-MS
2
 experiment. As shown in Figure 8, a peptide eluting at ~37.8 minutes was discovered 
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on the extracted MS
2
 ion chromatogram. Subsequently, on the corresponding full MS spectrum, 
we found that the mass species is a +4 charged ion with m/z 1033.79333 (Figure 9A). The 
molecular mass of this species was then calculated as 4*1033.79333-4*1.007825=4131.14202 
Da, which was based on the observed m/z (1033.79333), the charge state (4), and the 
monoisotopic mass of hydrogen (1.007825). Based on the calculated molecular mass of this 
crosslinked species (4131.14202 Da), the molecular mass of peptide DNAKNSLYLQMNSLR 
(1765.87812 Da), and the mass difference (+138.06808 Da) from BS3 crosslink modification, we 
inferred the other peptide in the crosslinked species as VVSVLTVLHQDWLNGKEYK, which 
has a molecular mass of 2227.20010 Da. From the MS
2
 spectrum of the extracted ion (Figure 
9B), we observed a continuous series of y ions (from y3 to y10) from the peptide 
NSLYLQMNSLR, and b13* ion from the peptide VVSVLTVLHQDWLNGKEYK. These 
observations support our assignment of the crosslinked species as shown in Figure 9B. It is worth 
noting that the y ions from NSLYLQMNSLR dominated the MS
2
 spectrum of the crosslinked 
species. It is possible that the C-terminal arginine containing y ions (from NSLYLQMNSLR) 
were more efficient in capturing positive charges than the b ions from 
VVSVLTVLHQDWLNGKEYK during the CID-MS
2
 process.     
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Figure 7. The CID MS
2
 spectrum of a tryptic peptide (NSLYLQMNSLR) that is adjacent to a 
putative BS3 crosslink site. The dominant fragment ions, y3, y5, y6, and y7, were selected for 
extraction of any peptide ions that could produce these fragment ions in a CID experiment. 
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Figure 8. (A) Based on the reporter MS
2
 masses (y3, y5, y6, and y7), the extracted ion 
chromatogram (EIC) leads to discovery of a crosslinked peptide candidate (eluted at ~37.8 
minutes). (B) the corresponding region on the total ion chromatogram (TIC) of the full MS 
spectra.   
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Figure 9. (A) The full MS spectrum of a BS3-crosslinked peptide. (B) The MS
2
 spectrum and 
assignment of a BS3-crosslinked peptide that contains NSLYLQMNSLR. 
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         Using the same approach, another peptide, LVQSGGGVERPGGSLR, was identified by 
database search. Against the corresponding tryptic peptide sequence, 
EVQLVQSGGGVERPGGSLR, three N-terminal residues, “EVQ”, were not detected in the 
thermolysin map. Considering that this peptide is the heavy chain N-terminal tryptic peptide, we 
speculated that the N-terminus is a putative crosslink site. We therefore investigated the CID-
MS
2
 spectrum of the peptide EVQLVQSGGGVERPGGSLR to look for reporter/signature y 
ions. As shown in Figure 10, y6 and y7 are the dominant y ions in the spectrum, and were 
therefore selected as the MS
2
reporter ions for extraction. After the extraction, we found a +2 
charged mass species with an m/z of 1440.78174 (Figure 11A). Based on the observed molecular 
mass of this species (2879.54648 Da) and the mass difference (+138.068080 Da) from the BS3 
crosslink modification, we inferred the other crosslinked peptide in the crosslinked species as 
LTVDKSR, which has a molecular mass of 817.46580 Da. From the MS
2
 spectrum of the 
extracted ion (Figure 11B), we observed y6, y7, y11, and y13 from the peptide 
EVQLVQSGGGVERPGGSLR, and b12
*
 and b18
*
 from the crosslinked species (that contains 
both peptide chains). These observations support our assignment of the crosslinked species as 
shown in Figure 11.       
          Overall, a total of 13 crosslinked species were identified (Table 1). Many of the identified 
ion species are of low intensity. For example, the species eluting at ~37.8 minutes has an 
intensity of 3x10
4
, which is 1/300 of that of the most dominant peptide ion in the total ion 
chromatogram. Identification of these low abundant crosslinked species demonstrates the 
capability of the SEEMS
2
 approach. 
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Figure 10. The CID MS
2
 spectrum of a tryptic peptide (EVQLVQSGGGVERPGGSLR) that 
contains a putative BS3 crosslink site (N-terminus). The dominant fragment ions, y6 and y7, 
were selected for extraction of any peptide ions that could produce these fragment ions in a CID 
experiment. 
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Figure 11. (A) The full MS spectrum of a BS3-crosslinked peptide. (B) The MS
2
 spectrum and 
assignment of a BS3-crosslinked peptide that contains EVQLVQSGGGVERPGGSLR. 
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No. Crosslinked Peptides Observed m/z (charge) Observed Mass (Da) Theoretical Mass (Da) Mass Error (ppm)
1 1033.79333 (+4) 4131.14202 4131.14628 -1.03
2 1440.78174 (+2) 2879.54783 2879.54648 0.47
3 1347.37988 (+3) 4039.11617 4039.11538 0.19
4 1303.32544 (+3) 3906.95314 3906.95278 0.09
5 1007.89099 (+3) 3020.6495 3020.64478 1.50
6 1234.65295 (+2) 2467.29025 2467.29188 -0.66
7 806.46185 (+2) 1610.90805 1610.91048 -1.50
8 1106.56018 (+3) 3316.65706 3316.65898 -0.58
9 877.46893 (+3) 2629.38332 2629.38108 0.85
10 1033.79333 (+4) 4397.13532 4397.13218 0.71
11 1412.69202 (+3) 4235.05258 4235.04298 2.27
12 908.1451517 (+3) 2721.41198 2721.41198 0.00
13 854.11346 (+3) 2559.316905 2559.32278 2.30
 
 
Table 1. Summary of identified crosslinked peptides using the tandem peptide mapping 
approach. 
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Investigation of Potential Crosslinks in mAb A after Copper-catalyzed Oxidation  
            After tryptic digestion of the oxidized mAb A sample, the regions (A’’ and B’’) that 
likely contain +4 or +5 charged peptides were collected off the strong cation exchange column 
(Figure 12). On the strong cation exchange chromatogram, region A’’ and region B’’ represent 
only small percentages of the total peak area (Figure 12), which suggests that potential 
crosslinked species, including those from Schiff base reactions, are in low abundance.   
           LC-MS/MS analysis and database search of the mAb A sequence identified all of the 
major peaks in the chromatograms of the collected region A’’ and region B’ fractions (Figures 
13 and 14; Tables 2 and 3). None of these peptides are inter-peptide crosslinks (type 2 
crosslinks). The unidentified peaks are of very low abundance. Furthermore, even the sum of 
these unidentified peaks represents only a very small percentage of the total peak area. 
Considering that region A’’ and region B’’ are already in a low percentage of the tryptic digests, 
and that not all unidentified peaks are expected to be crosslinked peptides, we concluded that 
Schiff base crosslinks are not a major degradation product after copper-catalyzed 
oxidation/carbonylation. No further fractionation was performed to characterize these 
unidentified peptides by the eMS
2
 analysis.  
         An intra-peptide dityrosine crosslink peptide was tentatively identified on the 
chromatogram of region A’’ (peak 16 on Figure 13). The proposed crosslink occurs between two 
neighboring tyrosine residues, Y29 and Y30, on the mAb A light chain. From the full MS 
spectra, the crosslinked species is a +3 charged ion with an m/z of 1198.60107 (Table 2), whose 
molecular mass is 2 Da lower than that of the corresponding wild type tryptic peptide (peak 15 
on Figure 13). The mass difference of -2 Da is consistent with the formation of dityrosine. From 
the MS
2
 spectra (Figure 15), the crosslinked species showed a mass shift of - 2 Da in the b3, b4, 
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and b5 ions when compared with those ions of the wild type peptide. This observation supports 
that the -2 Da modification is located in the three residues, SYY, from the N-terminus. While 
carbonylation of a serine residue to form aldehyde
48
 can result in a loss of 2 Da, to the best of our 
knowledge, such a carbonylation product is rarely observed or reported under common oxidation 
conditions. Therefore, the -2 Da modification was tentatively assigned to a dityrosine crosslink 
between LC Y29 and LC Y30. In future studies, an MS
3
 experiment will be needed to confirm 
this crosslink product.  
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Figure 12. Strong cation exchange chromatograms of the tryptic peptides from the unstressed 
and oxidized mAb A. Region A’’ (containing +4 charged peptides) and region B’’ (containing 
+5 charged peptides) from the oxidized mAb A were collected for further analysis. 
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Figure 13. Analysis of collected SCX fractions of Region A’’ (oxidized mAb A) by reversed-
phase HPLC. 
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No. Observed m/z (charge) Observed Mass (Da) Theoretical Mass (Da) Mass Error (ppm)  Peptide ID
1 575.34979 (+1) 574.34196 574.33263 16.0 LTVDK
2 586.36523 (+1) 585.35740 585.35984 -4.0 ILGAGR
3 856.38324 (+2) 1710.75083 1710.75191 -0.6 SYSCQVTHEGSTVEK
4 895.33960 (+2) 1788.66355 1788.66111 1.3 SYSCQVTHEGSTVEK (+77.9 Da modification)
5 1266.62842 (+2) 2531.24119 2531.24384 1.0 VPSSSLGTQTYICNVNHKPSNTK (missed cleavage)
6 898.49109 (+2) 1794.96653 1794.97004 -1.9 VQLVQSGGGVERPGGSLR (missed cleavage)
7 963.01270 (+2) 1924.00975 1924.01264 -1.5 EVQLVQSGGGVERPGGSLR
8 963.01300 (+2) 1924.01035 1924.01264 -1.2 EVQLVQSGGGVERPGGSLR (proline isomer)
9 846.89142 (+2) 1691.76719 1691.75799 5.4 FNW(+14)YVDGVEVHN(+1)AK 
10 855.39771 (+2) 1708.77977 1708.78454 -2.8 FNW(+32)YVDGVEVHNAK
11 841.40088 (+2) 1680.78611 1680.78963 -2.0 FNW(+4)YVDGVEVHNAK 
12 839.40515 (+2) 1676.79465 1676.79471 0.0 FNWYVDGVEVHNAK
13 1209.93701 (+3) 3626.78755 3626.79063 -0.8 SYYASW(+32)YQQKPGQAPVLVIYGANNRPSGIPDR 
14 1200.60706 (+3) 3598.79770 3598.79572 0.6 SYYASW(+4)YQQKPGQAPVLVIYGANNRPSGIPDR 
15 1199.27539 (+3) 3594.802695 3594.80080 0.5 SYYASWYQQKPGQAPVLVIYGANNRPSGIPDR
16 1198.60107 (+3) 3592.77973 3592.78515 -1.5 SY(-2)YASWYQQKPGQAPVLVIYGANNRPSGIPDR
17 1422.73169 (+2) 2843.44773 2843.45020 -0.9 THTCPPCPAPELLGGPSVFLFPPKPK
18 904.50677 (+2) 1806.99789 1806.99922 -0.7 VVSVLTVLHQDWLNGK  
Table 2. Summary of the identified peptides in the collected SCX fractions of Region A’’ 
(oxidized mAb A). Peak number is as labeled in Figure 13.    
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Figure 14. Analysis of collected SCX fractions of Region B’’ (oxidized mAb A) by reversed-
phase HPLC. 
 
No. Observed m/z (charge) Observed Mass (Da) Theoretical Mass (Da) Mass Error (ppm)  Peptide ID
1 506.26868 (+2) 1010.52171 1010.52225 -0.54 NRPSGIPDR
2 1409.13550 (+2) 2816.24705 2816.24759 -0.19 WQQGNVFScSVM(-ox)HEALHNHYTQK
3 1401.13684 (+2) 2800.25803 2800.25858 -0.20 WQQGNVFScSVMHEALHNHYTQK
 
Table 3. Summary of the identified peptides in the collected SCX fractions of Region B’’ 
(oxidized mAb A). Peak number is as labeled in Figure 14.    
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Figure 15. (A) Expanded view of the MS
2
 spectrum of a tryptic peptide (wide type) that contains 
a potential intra-peptide dityrosine crosslink site. (B) Expanded view of the MS
2
 spectrum of a 
tryptic peptide that could contain an intra-peptide dityrosine crosslink.  
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DISCUSSION 
         This study established a new analytical methodology, SEEMS
2
, for the analysis of 
crosslinked peptides in complex mAb digest samples. This methodology focused on addressing 
several key challenges that crosslink analysis commonly faces in sample preparation and MS 
data analysis.
49
 First, crosslinked peptides are usually in low abundance. To address this 
challenge, our method adopted an existing analytical strategy to enrich crosslinked peptides by 
strong cation exchange chromatography,
28
 which has been successfully used in capturing 
chemically-crosslinked peptides in nuclear extracts from HeLa cells
37
 and in bovine serum 
albumin and glutathione S-transferase.
28, 36
 A benefit of this strategy is that the majority of the 
non-crosslinked tryptic peptides (+2 and +3 charged) are excluded from fraction collection, 
which reduces the complexity of the peptide samples in subsequent analyses. Second, 
crosslinked peptides are often hydrophobic and thus they can be lost or poorly recovered during 
sample preparation.
50
 To address this challenge, we optimized sample preparation procedures to 
maximize the recovery of hydrophobic peptides. For trypsin digestion, mAb reduction, 
alkylation, and buffer exchange steps were in either 6 M guanidine hydrochloride or 6 M urea, 
which minimized mAb sample precipitation. For strong cation exchange chromatography, 
acetonitrile concentration in the mobile phase was 30%, a 20% increase from what was used by 
Fritzsche et al.,
36
 and a 10% increase from what was used by Tinnefeld et al.
28
 and Buncherd et 
al.
37
 The increased acetonitrile concentration improves the recovery of large and hydrophobic 
peptides during strong cation exchange chromatography analysis, as demonstrated in the work by 
Alpert and Andrews.
46
 The concentration of acetonitrile was not further increased due to a 
concern with the solubility of 500 mM sodium chloride in mobile phase B. It should be pointed 
out that the conventional O
18
 labeling method for crosslink analysis often requires lyophilization 
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of tryptic digests to minimize interference from residual O
16
 water and to ensure a more 
complete incorporation of O
18
 in the digested peptides.
29
 It is not known how efficient 
hydrophobic peptides can be recovered after the lyophilization and reconstitution steps. By 
contrast, our method does not require any lyophilization in sample preparation. Therefore, from 
that perspective, our method should be superior to the O
18
 labeling method.     
          For the MS data analysis of crosslinked peptides, a major challenge is distinguishing the 
crosslinked peptide ions from the more abundant non-crosslinked peptide ions. To address this 
challenge, our method implemented the SEEMS
2
 approach, where peptides of interest are 
fraction-collected and then digested with a non-specific protease (such as thermolysin). 
Subsequently, identification of crosslinked peptides relies on locating putative crosslink sites and 
extracting the MS
2
 ions with reporter/signature masses. Compared to the O
18
 labeling strategy, 
the benefit of this analytical strategy is threefold. First, putative crosslink sites can be readily 
identified by using the commonly available database search software programs (such as 
proteome discover), while the O
18
 labeling method requires specialized software programs
29, 51
 to 
survey full MS spectra in order to identify putative crosslink candidates. Second, this analytical 
strategy inherently generates fewer false positives since the number of non-crosslinked peptides 
is significantly reduced in the collected SCX fractions, while the O
18
 labeling strategy 
considers/surveys all peptide ions in a tryptic digest to identify putative crosslink candidates. 
Third, our analytical strategy provides a simplified process to interpret and decode MS
2
 spectra. 
In particular, the reporter/signature MS
2
 mass information enables a targeted investigation of the 
fragment ions in the MS
2
 spectra, as illustrated by our case examples. By comparison, the O
18
 
labeling strategy does not have such information for the analysis of the MS
2
 spectra.  
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         It should be pointed out that the use of reporter/signature MS
2
 masses to extract/identify 
crosslinked peptide ions is not a novel concept. Iglesias et al. used signature MS
2
 ions from 
lysine side chain rearrangement and the crosslink spacer in a precursor ion scan to identify 
chemically (by disuccinimidyl suberate) crosslinked peptides.
52
 Barysz et al. used small 
fragments from cross-linker backbone and linked residues as signature MS
2
 ions in their analysis 
of chemically crosslinked peptides.
47
  Different from these reported cases, the reporter/signature 
MS
2 
ions in our analytical strategy do not depend on the type of crosslink chemistry. In addition, 
the identification of the reporter/signature MS
2 
masses is a simple process, which depends on the 
identification of a putative counterpart peptide after the digestion with a non-specific protease. 
Finally, our analytical strategy should be applicable to the identification of crosslinked products 
from different crosslinking reactions, as the terminal b or y ions from one or both linear peptide 
components are commonly present in the CID spectra of crosslinked peptides.
53
     
         Compared to many other existing analytical methods for crosslink analysis,
54-58
 a key 
advantage of the SEEMS
2
 approach is that this approach does not require a specialized software 
program for data analysis. The disadvantage of the SEEMS
2
 approach is that this approach is 
labor-intensive. Nevertheless, this new approach should complement the existing analytical 
methods for crosslink analysis well. Future efforts to improve the SEEMS
2
 approach will be 
focusing on using different non-specific proteases for generating more comprehensive peptide 
fragment coverage for the eMS
2
 data. Another area for improvement is introducing HCD and 
ETD for generating reporter ions, which could help reduce false positives. Finally, it should be 
beneficial to use nanospray LC-MS/MS analysis for obtaining eMS
2
 data, given the concern with 
analysis sensitivity and limited sample amount for the collected peptide fractions.   
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         After demonstrating the feasibility of using the SEEMS
2
 approach for crosslink analysis, 
we investigated potential crosslinked products in mAb A after copper-catalyzed oxidation. 
Selection of the copper oxidation condition instead of the iron oxidation conditions (as used in 
previous chapters) for our investigation was based on the following considerations. First, the 
study performed by Filipe et al. reported immunogenicity in an antibody stressed after copper-
catalyzed oxidation.
7
 We were interested in identifying crosslinked products under similar 
conditions to help elucidate potential sources of the immunogenicity. Second, copper-catalyzed 
oxidation was found to be the strongest stress condition among nine different metals evaluated 
for inducing carbonylation and aggregation on IgG and other proteins.
39-40
 Potential crosslinked 
products (including Schiff base crosslinks, if present) are, therefore, expected to be more 
abundant with copper-catalyzed oxidation than with other stress conditions, which is beneficial 
to our investigation. Third, copper/hydrogen peroxide is more effective in causing dityrosine 
formation in lens proteins than iron/hydrogen peroxide.
41
 In addition to investigating Schiff base 
crosslinked products, we were interested in understanding if copper/hydrogen peroxide can 
induce dityrosine crosslinks in mAbs.     
         Our study showed that Schiff base crosslinks are not a major degradation product of mAb 
A even after applying a harsh stress condition with copper ion and hydrogen peroxide. It is 
possible that the aldehyde products (from carbonylation of lysine, arginine, and proline residues) 
are not the major degradation products of mAb A. Additionally, the copper-catalyzed oxidation 
condition, such as copper concentration or incubation time, may not be optimal for the formation 
of Schiff base crosslinks. Nevertheless, our finding indicates that Schiff base crosslinks are 
unlikely a major source for the oxidation-induced acidic charge heterogeneity or aggregation 
propensity as hypothesized in previous chapters, although this will still need to be confirmed in 
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future studies with additional oxidation conditions. Our study tentatively identified a type 1 
dityrosine crosslink product, which is consistent with existing reports in the literature showing 
that tyrosine crosslinks are major crosslink products after copper-catalyzed oxidation. To the best 
of our knowledge, dityrosine crosslink products have not been well characterized in mAbs. In 
future studies, it should be interesting to apply the SEEMS
2
 approach to confirm and investigate 
such dityrosine crosslinked products of mAb A under various oxidation conditions.     
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6.1: Investigation of Antibody Carbonylation during Process Development (Chapter 2) 
         This chapter reviewed the current analytical assays for measuring total protein 
carbonylation levels, and then focused on developing a new protein carbonylation assay, CALY, 
to address the analytical challenges/drawbacks with the conventional protein carbonylation 
assays. After demonstrating that CALY is more robust and precise than the conventional assays, 
we applied CALY to investigate antibody carbonylation under production, storage, and stress 
conditions and showed that iron, hydrogen peroxide, and polysorbate 20 at pharmaceutically 
relevant levels critically influence the extent of mAb carbonylation. In addition, we investigated 
the impact of carbonylation on antibody product quality. We found that carbonylation cannot be 
used as a general indicator for aggregation, even though carbonylation correlates with antibody 
aggregation in several cases. We also found that antibody carbonylation level can decrease 
during storage, which indicates that carbonylation products may not be stable. Finally, we report 
for the first time a positive correlation between carbonylation and acidic charge heterogeneity of 
antibodies that underwent metal-catalyzed oxidation. This finding shows that the impact of 
protein carbonylation on product quality for antibodies is not limited to aggregation but also 
extends to charge heterogeneity. 
         For future study, CALY can be used to investigate additional cell culture factors that 
impact antibody carbonylation and related product quality. For example, recently, 
Vijayasankaran et al. reported the use of hypotaurine, hydrocortisone, peptone, and cysteine as 
cell culture additives to reduce antibody coloration and acidic charge variants.
1
 It will be 
interesting to understand if the reduction in acidic charge variants was actually achieved through 
reduction of antibody carbonylation, and if so, how these cell culture additives interact with iron 
ions or hydrogen peroxide to reduce antibody carbonylation. Specifically, among these additives, 
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hydrocortisone is known to reduce hydrogen peroxide production in cells.
2-3
 It is plausible that 
the hydrocortisone reduces hydrogen peroxide production in CHO cells, which could lead to 
decreased antibody carbonylation. Answering these questions can further elucidate the 
mechanisms of antibody carbonylation in the cell culture environment and help better control 
antibody carbonylation during production. Another cell culture factor worth investigating is the 
effect of ambient light on antibody carbonylation during cell culture production. Mallaney et al. 
reported that antibody acidic variant level increased when the cell culture production was 
exposed to ambient light.
4
 The cause for the increased acidic variants was attributed to light-
induced oxidation, as the antibody showed a similar increase in the acidic variants under ICH 
light stress conditions.
4
 However, since many cell culture medium components are known 
photosensitizers
5
 and can generate hydrogen peroxide upon light exposure, it is possible that 
ambient light promotes antibody carbonylation by increasing hydrogen peroxide levels during 
cell culture production. Clearly, CALY will be a very useful analytical tool to help discern the 
different mechanisms that lead to the increased acidic charge variants during cell culture process 
development.   
6.2: Characterization of Acidic Charge Heterogeneity of Antibodies Induced by Metal-
Catalyzed Oxidation (Chapter 3) 
         Our research findings from Chapter 2 strongly suggest that metal-catalyzed carbonylation 
may represent a general degradation mechanism for inducing acidic charge heterogeneity in 
mAbs. In particular, carbonylation of positive residues, such as lysine and arginine, can lead to 
loss of the positive charge, which should contribute to the increased acidic charge variants. 
However, to date, the induced acidic charge heterogeneity has not been well characterized. This 
chapter therefore focused on studying the mechanism and the related degradation products that 
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account for the induced acidic charge variants after metal-catalyzed oxidation. With a model 
IgG1 antibody, we fraction collected the acidic charge variants generated after metal-catalyzed 
oxidation. We then characterized the collected fractions with a large variety of analytical 
methods, such as SEC, intact/reduced mass analysis, and peptide mapping. Specifically, we 
analyzed antibody carbonylation products at both protein and peptide levels. We showed that the 
commonly observed methionine and tryptophan oxidation products cannot satisfactorily explain 
the formation of oxidation-induced acidic charge variants. On the other hand, carbonylation 
products were found to be enriched in the acidic fractions at both protein and peptide levels. 
Surprisingly, a threonine carbonylation product, but not lysine and arginine carbonylation 
products, was found to be a major component enriched in the acidic fractions. Additionally, our 
characterization identified several novel degradation products that have not been previously 
reported in mAbs. One of these products is the carboxylic acid product formed after further 
oxidation of arginine and proline carbonylation products. Another product is the pyroglutamate 
product from oxidation of proline residues in the hinge region, whose formation also leads to 
hinge fragmentation. Finally, H/D exchange analysis of the acidic and main peak fractions 
showed that metal-catalyzed oxidation did not induce any significant change in mAb 
conformation, which suggests that the induced acidic charge variants is likely not caused by 
conformational factors.   
          For future study, it will be interesting to understand the mechanism(s) for the enrichment 
of threonine carbonylation product (2-amino-3-ketobutyrate), a ketone, in the acidic fraction. 
One hypothesis is the deprotonation of alpha hydrogen in 2-amino-3-ketobutyrate. This 
hypothesis is based on an observation that beta-diketone compounds have unusually acidic alpha 
hydrogens (with a pKa of 9 or lower
6
), where deprotonation of their alpha hydrogens becomes 
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easier due to stabilization of the deprotonated species through multiple resonance structures.
6
 It 
is possible that, in certain protein structures, a similar mechanism may exist, which could 
partially contribute to the enrichment of the threonine carbonylation product in the acidic 
fraction. In the future, we will perform a pH titration study to determine the pKa of threonine 
carbonylation product to understand if this could be the source of the apparent increase in 
antibody acidic charge heterogeneity. Another topic worth investigating is the formation of the 
pyroglutamate product from oxidation of proline residues in the hinge region, which also causes 
hinge fragmentation. To the best of our knowledge, such a hinge fragmentation mechanism has 
not been reported in the literature. To evaluate our proposed mechanism, we will conduct the 
oxidation reaction in O
18
 or O
16
 water and with O
18
 or O
16
 molecular oxygen. This experiment 
will reveal the source of the oxygen introduced to the pyroglutamate product and into the 
carboxylic acid (C-terminus of the other fragment peptide), which can confirm or rule out the 
mechanism we proposed. Finally, based on the relative quantitation of the site-specific 
carbonylation products on mAb 1, we identified a carbonylation hotspot on LC T29, which is 
adjacent to two aspartic acid residues. Considering that aspartic acid could be a metal-binding 
site,
7
 it is possible that the TXDD sequence represents a motif for a carbonylation hotspot. In 
future studies, we will study model peptides, such as XXTDD, XXTXDD, XXTXXDD, 
XXTXXXDD, that have different numbers of residues between the carbonylation site (T) and the 
two DD residues, to understand the role/effect of adjacent aspartic acid residues on metal-
catalyzed carbonylation. This study could help us gain more insight on site-specific 
carbonylation and design mAbs that are more stable against metal-catalyzed carbonylation in the 
future.  
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6.4:  Physical Instability of Antibody induced by Metal-Catalyzed Carbonylation 
(Chapter 4) 
         Existing experimental observations suggested that metal-catalyzed carbonylation may drive 
formation of protein aggregates.
8-10
 A theoretical study using molecular dynamics simulations 
also indicated that lysine and arginine carbonylation can significantly increase intrinsic 
aggregation propensity of proteins, and that the formation of these carbonylation products is 
equivalent of introducing charge-neutral hydrophobic residues on proteins.
11
 To gain a better 
understanding on how metal-catalyzed carbonylation impacts mAb physical stability, this 
chapter studied the aggregation/precipitation of a carbonylated IgG1 antibody in buffers 
containing various Hofmeister anions.
12
 A commonly used stir stress condition was applied to 
generate the mAb aggregates/precipitates. The extent of mAb carbonylation in the supernatants 
was then studied at both protein and peptide levels to assess the effect of carbonylation on the 
induced physical instability. We showed that mAb intrinsic aggregation propensity plays a more 
dominant role than carbonylation (even at a relatively high level) in the formation of mAb 
aggregates/precipitates. More critically, for the first time, we showed that the effect of 
carbonylation on physical instability of mAbs depends on the type of the carbonyls, the location 
of the carbonyls on antibodies, and the type of Hofmeister anion. In particular, for type 2 
carbonylation products, their effect on mAb aggregation/precipitation appeared to depend on 
specific ion-pairing interactions between the Hofmeister anions and the positively charged 
residues that are adjacent to the carbonylation site.    
          For future study, it will be interesting to apply similar buffer/stress conditions to additional 
antibodies or other proteins (such as BSA). These investigations will help us understand if the 
effects of carbonylation that we discovered from the model IgG1 antibody are generally 
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applicable to other proteins. Additionally, for the type 2 carbonylation products, it will be 
interesting to test our hypothesis regarding the effect of the adjacent positively charged residues 
by performing site-directed mutagenesis. If our hypothesis is confirmed, it could provide a new 
approach to designing mAbs with improved stability against metal-catalyzed oxidation. Finally, 
The stability of mAb carbonylation in biological systems may differ significantly from that in 
buffers. For example, intracellularly, mildly carbonylated proteins are targeted for turn-over by 
proteolysis, while extensively carbonylated proteins may escape proteolysis by forming high 
molecular weight species.
13
 In addition, a thiol-dependent decarbonylation mechanism was 
reported in biological systems.
14
 Therefore, it will be interesting to study chemical and physical 
consequences of carbonylated mAbs in additional in vitro (such as plasma) and in vivo systems. 
In particular, it will be interesting to understand if any decarbonylation process may exist when 
relevant biological factors are present. For an initial assessment, a time course study by 
incubating carbonylated mAbs in plasma and PBS will be performed to characterize specific 
physiochemical changes to mAb carbonylation, which can provide insights into the consequence 
of mAb carbonylation under in vivo conditions. 
6.5:  Investigation of Antibody Crosslinks after Metal-Catalyzed Oxidation 
(Chapter 5) 
       Our research findings in Chapters 3 and 4 suggest that formation of Schiff base crosslinks 
could contribute to the formation of acidic charge variants and aggregates. To help investigate if 
Schiff base crosslinks represent a major factor for the induced chemical and physical instability 
of mAbs after metal-catalyzed oxidation, this chapter developed a new analytical method, 
SEEMS
2
, for enriching and identifying crosslinked peptides. Compared to the existing methods, 
our method significantly reduces the difficulties with interpreting the MS
2
 spectra of crosslink 
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peptides and our method does not require any specialized software program to identify 
crosslinked peptides. To demonstrate the feasibility of the SEEMS
2 
approach, we successfully 
identified more than a dozen crosslinked peptides from a BS3-crosslinked mAb. We 
subsequently applied this approach to investigate mAb crosslinks after copper-catalyzed 
oxidation. Our data showed that, even under a harsh oxidation condition, no significant Schiff 
base crosslink was observed in the tested mAb sample. This finding suggests that Schiff base 
crosslinks are not a major factor for the induced chemical and physical instability of mAbs after 
metal-catalyzed oxidation, at least for the tested mAb sample under the copper-catalyzed 
oxidation condition. Interestingly, we tentatively identified a di-tyrosine intra-peptide crosslink 
in the tested mAb sample, which is consistent with the crosslink products that occurred on other 
proteins after copper-catalyzed oxidation.
15-16
    
            For future study, it will be interesting to further confirm that Schiff base crosslinks are not 
a significant degradation product by evaluating additional metal-catalyzed oxidation conditions. 
It will be also interesting to apply the SEEMS
2
 approach to study mAb crosslinks after light 
stress or Maillard reactions. Finally, the SEEMS
2
 method provides a new tool for chemical 
crosslinking mass spectrometry.
17-20
 It will be interesting to apply the SEEMS
2 
method to 
structural and functional analysis of proteins in the future.       
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